STI & HIV 2019
WORLD CONGRESS
Joint Meeting of the
23rd ISSTDR & 20th IUSTI

JULY 14 - 17, 2019 VANCOUVER, CANADA

The Evolving Landscape of STI and HIV Elimination

www.stihiv2019vancouver.com
One clinician- or patient-collected vaginal swab provides results for the three most common causes of vaginitis – bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and *Trichomonas vaginalis* (TV). In addition, BD MAX Vaginal Panel utilizes the CDC-recommended diagnostic technology for *T. vaginalis* detection and provides three results for microorganisms responsible for yeast infections:

- **Candida group**, including *C. albicans*, *C. parapsilosis*, *C. tropicalis*, and *C. dubliniensis*
- Differentiates fungal species – *C. glabrata* and *C. krusei* – associated with antimicrobial resistance.

BD MAX Vaginal Panel detects DNA from the following BV markers:

- **Lactobacillus spp.**
  - *L. jensenii*
  - *L. crispatus*
- **G. vaginalis**
- **A. vaginae**
- **BVAB-2**
- **Megasphaera-1**
- **Anaerobic spp.**

The BD MAX™ Women’s Health and STI portfolio is focused on providing accurate, reliable results that enable clinicians and labs to elevate patient care.

- BD MAX™ Vaginal Panel
- BD MAX™ CT/GC/TV
- BD MAX™ GBS

Reference
1. BD MAX Vaginal Panel Package Insert
STI & HIV 2019 would like to thank the following companies for their generous support:

**SPONSORS**

**PLATINUM LEVEL**

- HOLOGIC®
- Roche

**GOLD LEVEL**

- Abbott

**SILVER LEVEL**

- BD

**BRONZE LEVEL**

- Cepheid
- SD BIOSSENSOR

**OTHER SUPPORTERS**

[Logos of various organizations]
<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>WELCOME ADDRESS</td>
</tr>
<tr>
<td>6</td>
<td>COMMITTEES</td>
</tr>
<tr>
<td>11</td>
<td>ABOUT</td>
</tr>
<tr>
<td>12</td>
<td>ISSTD B ORD LISTING</td>
</tr>
<tr>
<td>13</td>
<td>IUSTI EXECUTIVE COMMITTEE LISTING</td>
</tr>
<tr>
<td>15</td>
<td>KEYNOTE, PLENARY &amp; DEBATE SPEAKERS</td>
</tr>
<tr>
<td>23</td>
<td>SCHOLARSHIPS</td>
</tr>
<tr>
<td>24</td>
<td>ABSTRACT REVIEWERS</td>
</tr>
<tr>
<td>26</td>
<td>PROGRAM AT A GLANCE</td>
</tr>
<tr>
<td>29</td>
<td>SCIENTIFIC PROGRAM</td>
</tr>
<tr>
<td></td>
<td>• Sunday, July 14</td>
</tr>
<tr>
<td></td>
<td>• Monday, July 15</td>
</tr>
<tr>
<td></td>
<td>• Tuesday, July 16</td>
</tr>
<tr>
<td></td>
<td>• Wednesday, July 17</td>
</tr>
<tr>
<td></td>
<td>• Posters</td>
</tr>
<tr>
<td>80</td>
<td>INDUSTRY-SUPPORTED SYMPOSIA</td>
</tr>
<tr>
<td>82</td>
<td>BOARD &amp; SIDE MEETINGS</td>
</tr>
<tr>
<td>84</td>
<td>NETWORKING EVENTS</td>
</tr>
<tr>
<td>85</td>
<td>GENERAL INFORMATION</td>
</tr>
<tr>
<td>89</td>
<td>VENUE FLOOR PLAN</td>
</tr>
<tr>
<td>90</td>
<td>EXHIBIT FLOOR PLAN</td>
</tr>
<tr>
<td>92</td>
<td>EXHIBITOR BIOGRAPHIES</td>
</tr>
</tbody>
</table>
Dear Friends and Colleagues,

On behalf of the Organizing Committee, we are delighted you have decided to attend the STI & HIV 2019 World Congress to be held July 14 – 17, 2019, at the Vancouver Convention Centre East Building, in Vancouver, British Columbia, Canada.

This Congress is a joint meeting of the International Society for Sexually Transmitted Diseases Research (ISSTDR) and the International Union Against Sexually Transmitted Infections (IUSTI). This biennial meeting is the world's largest international meeting on sexually transmitted infections, drawing delegates from around the globe.

Under the theme of 'The Evolving Landscape of STI and HIV Elimination', this meeting will provide an excellent opportunity for the world’s most prominent researchers and health professionals to come together in the shared goal of improving global public health in the field of sexually transmitted infections, including HIV. The meeting will provide Congress attendees the opportunity to network with experts, present their research findings to an international audience, hear the latest scientific developments from world leaders in the STI/HIV field, and contribute to discussions that will shape future health policies and patient care around the world.

The STI & HIV 2019 World Congress is taking place in one of the most stunning cities in the world. Vancouver is a safe, modern, multicultural city with a vibrant local arts and culture scene and abundant opportunities for outdoor adventures amongst a setting of incomparable natural beauty.

We welcome you to Vancouver and look forward to providing you with an exceptional scientific and cultural experience!

Warm regards,

Caroline Cameron, Chair
International Society for Sexually Transmitted Diseases Research, President
University of Victoria, Canada

Charlotte Gaydos, Co-Chair
International Union Against Sexually Transmitted Infections, President
Johns Hopkins University, USA

A Message from the Mayor

On behalf of my colleagues on Vancouver City Council and the citizens of Vancouver I want to extend my warmest greetings to the delegates of the International Society for Sexually Transmitted Diseases Research (ISSTDR) and the International Union Against Sexually Transmitted Infections (IUSTI) who are co-hosting the STI & HIV 2019 World Congress.

The opportunity to share research and scientific developments is crucial to developing policies and platforms that enhance the well-being of all citizens. With the goal of improving global public health in the field of sexually transmitted infections including HIV/AIDS, ISSTDR and IUSTI help shape discussions around future health policies and patient care around the world.

We are proud to host the STI & HIV 2019 World Congress in Vancouver and I hope that in addition to attending the conference you are able to experience the many cultural and recreational activities the City has to offer. I know everyone involved in organizing the conference will ensure your time with us is special.

Best wishes on a successful and productive conference.

Mayor Kennedy Stewart
COMMITTEES

Scientific Committee

Co-Chairpersons

David Lewis
Western Sydney Sexual Health Centre, Western Sydney Local Health District, Parramatta, Australia; Westmead Clinical School, University of Sydney, Sydney, Australia; Division of Medical Virology, University of Cape Town, Cape Town, South Africa

James Blanchard
Departments of Community Health Sciences and Medical Microbiology, Centre for Global Public Health, Canada Research Chair in Epidemiology and Global Public Health, Faculty of Medicine University of Manitoba

Basic & Translational Science Track Team

Chairperson:
Sheila Lukehart
University of Washington, USA

Track Members:
Jo-Anne Dillon
Canada
Laura Sycuro
Canada
Magnus Unemo
Sweden
David Whiley
Australia

Behavioural & Social Sciences Track Team

Chairperson:
Jacky Jennings
Johns Hopkins School of Medicine, Bloomberg School of Public Health, Center for Child and Community Health Research, USA

Track Members:
Valeria Stuardo Avila
Chile
Kit Fairley
Australia
Joe Tucker
USA
Sarah Bernays
Australia
Robert Lorway
Canada
Clinical Science Track Team

Chairperson:
Matthew Golden
University of Washington (UW)
School of Medicine, Seattle & King County HIV/STD Program,
UW Public Health Capacity Building Center, USA

Track Members:
Catriona Bradshaw
Australia
Julie Dombrowski
USA
Daniel Richardson
Australia
Ping Yu Zhou
China
Craig Cohen
USA
Gina Ogilvie
Canada
Janet Wilson
UK

Epidemiology & Monitoring Track Team

Chairperson:
Gwenda Hughes
National Infection Service at Public Health England,
Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP), UK

Track Members:
Michel Alary
Canada
Viviane Bremer
Germany
Sinead Delaney-Moretlwe
South Africa
Jane Hocking
Australia
Kyle Bernstein
USA
Xiang-Sheng Chen
China
Maria Amelia de Sousa Mascena Veras
Brazil

Policy & Community Engagement Track Team

Chairperson:
Helen Ward
Imperial College
London, UK

Track Members:
Patricia Garcia
Peru
Maryam Shahmanesh
UK
Morten Skovdal
Denmark
Francis Ndowa
Zimbabwe
Kate Shannon
Canada
Program & Implementation Science Track Team

Chairperson:

Sevgi Aral
US Centers for Disease Control, Emory University, USA, University of Manitoba, Canada

Track Members:

Marissa Becker
Canada

Parinita Bhattacharjee
Kenya/Canada

Harrell Chesson
USA

James Hargreaves
UK

Sharmistha Mishra
Canada

Ian Spicknall
USA

Anneli Uusküla
Estonia

Local Organizing Committee

Chair:
Caroline Cameron
University of Victoria, Canada

Co-Chair:
Charlotte Gaydos
Johns Hopkins University, USA

Lindsay Frehlick
University of Victoria, Canada

Mark Gilbert
University of British Columbia, British Columbia Centre for Disease Control, Canada

Troy Grennan
University of British Columbia, British Columbia Centre for Disease Control, Canada

King Holmes
University of Washington, USA

Rupert Kaul
University of Toronto, Canada

Mel Krajden
University of British Columbia, British Columbia Centre for Disease Control, Canada

Nathan Lachowsky
University of Victoria, Canada

Sheila Lukehart
University of Washington, USA

Lisa Manhart
University of Washington, USA

Jeanne Marrazzo
University of Alabama, USA

Deborah Money
University of British Columbia, Canada

Muhammed Morshed
University of British Columbia, British Columbia Centre for Disease Control, Canada

Gina Ogilvie
University of British Columbia, British Columbia Centre for Disease Control, Canada

Michael Rekart
University of British Columbia, British Columbia Centre for Disease Control, Canada

Ameeta Singh
University of Alberta, Canada

Mark Tyndall
University of British Columbia, British Columbia Centre for Disease Control, Canada

Jason Wong
University of British Columbia, British Columbia Centre for Disease Control, Canada
nḗcəʔmat ct Indigenous Sexual Health Committee

The purpose of this committee is to raise the prominence of Indigenous sexual health within the conference and to work with the Local Organizing Committee to establish relations in a good way with the local Coast Salish peoples on whose traditional, ancestral and unceded territories the conference is held on, specifically the Skwxwú7mesh (Squamish), Selílíwitulh (Tsleil-Waututh), and xʷməθkʷəy̓əm (Musqueam) Nations.

We are grateful to the Elders of the VCH Aboriginal Health Elder Advisory Council for guiding us in doing this work, including Elder Roberta Price, Elder Doris Fox, Elder Iris Newman, Elder Iggy George, Elder Dee George, Elder Marr Dorvault, Elder Glida Morgan, Elder Lillian Daniels, and Elder Jean Wasegijig.

The word nḗcəʔmat ct embodies the concept of “We are One” in the hən̓q̓ı̑mən̓əm (Musqueam) language.

### Committee Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Chenery</td>
<td>Penelakut, Chee Mamuk, Clinical Prevention Services, BC Centre for Disease Control</td>
<td>Committee Member</td>
</tr>
<tr>
<td>Sarah Chown</td>
<td>YouthCO HIV &amp; Hep C Society</td>
<td>Committee Member</td>
</tr>
<tr>
<td>Jennifer Coward</td>
<td>Indigenous Wellness Team, First Nations Health Authority</td>
<td>Committee Member</td>
</tr>
<tr>
<td>Andrea Derban</td>
<td>Indigenous Wellness Team, First Nations Health Authority</td>
<td>Committee Member</td>
</tr>
<tr>
<td>Mark Gilbert</td>
<td>British Columbia Centre for Disease Control</td>
<td>Committee Member</td>
</tr>
<tr>
<td>Nathan Lachowsky</td>
<td>University of Victoria &amp; Community Based Research Centre</td>
<td>Committee Member</td>
</tr>
<tr>
<td>Matthew Louie</td>
<td>Indigenous Wellness Team, First Nations Health Authority</td>
<td>Committee Member</td>
</tr>
<tr>
<td>Ameeta Singh</td>
<td>University of Alberta</td>
<td>Committee Member</td>
</tr>
<tr>
<td>Larissa Wahpooseyan</td>
<td>Yúusnewas Program, YouthCO HIV &amp; Hep C Society</td>
<td>Committee Member</td>
</tr>
</tbody>
</table>

### Scholarship Committee

**Chair:**

Jeanne Marrazzo
University of Alabama, USA

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basil Donovan</td>
<td>University of New South Wales, Australia</td>
</tr>
<tr>
<td>Lynn Barclay</td>
<td>American Sexual Health Association, USA</td>
</tr>
<tr>
<td>Dennis Fortenberry</td>
<td>Indiana University, USA</td>
</tr>
<tr>
<td>Barbara Van Der Pol</td>
<td>University of Alabama, USA</td>
</tr>
<tr>
<td>Jane Hocking</td>
<td>University of Melbourne, Australia</td>
</tr>
<tr>
<td>Caroline Cameron</td>
<td>University of Victoria, Canada</td>
</tr>
</tbody>
</table>


**Sponsorship Committee**

**Chair:**  
**Caroline Cameron**  
*University of Victoria, Canada*

- **Charlotte Gaydos**  
  *Johns Hopkins University, USA*

- **Barbara Van der Pol**  
  *University of Alabama, USA*

- **Edward W. Hook III**  
  *University of Alabama, USA*

- **Muhammad Morshed**  
  *University of British Columbia/British Columbia Centre for Disease Control, Canada*

- **Gina Ogilvie**  
  *University of British Columbia/British Columbia Centre for Disease Control, Canada*

- **Jeffrey Klausner**  
  *UCLA - David Geffen School Of Medicine, USA*

- **Leonard Foster**  
  *University of British Columbia, Canada*

- **Lindsay Frehlick**  
  *University of Victoria, Canada*

**Promotion Committee**

**Chair:**  
**Nicola Low**  
*Universität Bern, Switzerland*

- **Caroline Cameron**  
  *University of Victoria, Canada*

- **Charlotte Gaydos**  
  *Johns Hopkins University, USA*

- **Thomas Quinn**  
  *Johns Hopkins University/National Institutes of Health, USA*

- **Myron Cohen**  
  *University of North Carolina, USA*

- **Heather Pedersen**  
  *British Columbia Centre for Disease Control/University of British Columbia/Women’s Health Research Institute, Canada*

- **Henry de Vries**  
  *University of Amsterdam, Netherlands*

- **Karen Lithgow**  
  *University of Victoria, Canada*

- **Kit Fairley**  
  *Monash University, Australia*

- **Sean Waugh**  
  *University of Victoria, Canada*

- **Troy Grennan**  
  *University of British Columbia/British Columbia Centre for Disease Control, Canada*

- **Wilhelmina (Willa) Huston**  
  *University of Technology Sydney, Australia*

- **Katy Turner**  
  *University of Bristol, UK*

- **Lori Brotto**  
  *University of British Columbia/Women’s Health Research Institute, Canada*
The International Society for Sexually Transmitted Diseases Research (ISSTDR) exists to promote research on sexually transmitted diseases and facilitate the timely exchange of information among research investigators. To these ends, ISSTDR sponsors a biennial, interdisciplinary scientific meeting. The ISSTDR meetings have been the premier scientific conferences that address the entire breadth of research on STDs, including HIV, and encompasses microbiology, virology, immunobiology, pathogenesis, and other basic sciences; clinical sciences, social and behavioral sciences, epidemiology, and prevention; and research in health services, public health, and prevention policy. ISSTDR was founded in 1977 and is governed by an international Board of Directors who currently represent 6 countries. The ISSTDR Conference Support Foundation provides support in respect of the conferences of the ISSTDR.

The International Union against Sexually Transmitted Infections (IUSTI) was founded in 1923 and it is organized on both a global and regional basis. It is the oldest international organization with the objective of fostering international cooperation in the control of sexually transmitted infections including HIV/AIDS. IUSTI is concerned with the medical, scientific, social and epidemiological aspects of sexually transmitted infections and their control. IUSTI is on the Roster of the United Nations Economic and Social Council. It is an Official Non-Government Organization in Consultative Status with the World Health Organization. IUSTI organizes frequent international and regional conferences on sexually transmitted infections and, in collaboration with the International Journal for STD and AIDS, publishes expert clinical guidelines for their management.
<table>
<thead>
<tr>
<th>NAME</th>
<th>COUNTRY</th>
<th>ROLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caroline Cameron</td>
<td>Canada</td>
<td>President</td>
</tr>
<tr>
<td>Henry de Vries</td>
<td>Netherlands</td>
<td>President-Elect</td>
</tr>
<tr>
<td>Jeanne Marrazzo</td>
<td>USA</td>
<td>Immediate Past President and ISSTDR Foundation President</td>
</tr>
<tr>
<td>Basil Donovan</td>
<td>Australia</td>
<td>Past President and Chair of the 21st Meeting, 2015</td>
</tr>
<tr>
<td>Barbara Van Der Pol</td>
<td>USA</td>
<td>Secretary General</td>
</tr>
<tr>
<td>Christopher Fairley</td>
<td>Australia</td>
<td>Member</td>
</tr>
<tr>
<td>Edward Hook III</td>
<td>USA</td>
<td>Member</td>
</tr>
<tr>
<td>Nicola Low</td>
<td>Switzerland</td>
<td>Member</td>
</tr>
<tr>
<td>Helen Ward</td>
<td>UK</td>
<td>Member</td>
</tr>
<tr>
<td>Jeff Klausner</td>
<td>USA</td>
<td>Member</td>
</tr>
<tr>
<td>Jane Hocking</td>
<td>Australia</td>
<td>Member</td>
</tr>
<tr>
<td>Charlotte Gaydos</td>
<td>USA</td>
<td>IUSTI World President, Observer</td>
</tr>
<tr>
<td>Gail Bolan</td>
<td>USA</td>
<td>CDC Observer</td>
</tr>
<tr>
<td>NAME</td>
<td>COUNTRY</td>
<td>ROLE</td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Charlotte A Gaydos</td>
<td>USA</td>
<td>President</td>
</tr>
<tr>
<td>Janet Wilson</td>
<td>UK</td>
<td>President-Elect</td>
</tr>
<tr>
<td>David Lewis</td>
<td>Australia</td>
<td>Immediate Past President</td>
</tr>
<tr>
<td>Elizabeth Foley</td>
<td>UK</td>
<td>Secretary General</td>
</tr>
<tr>
<td>Jonathan Ross</td>
<td>UK</td>
<td>Treasurer</td>
</tr>
<tr>
<td>Christopher Fairley</td>
<td>Australia</td>
<td>Assistant Secretary General &amp; Webmaster</td>
</tr>
<tr>
<td>Bradley Stoner</td>
<td>USA</td>
<td>Membership Secretary</td>
</tr>
<tr>
<td>Francis Ndowa</td>
<td>Zimbabwe</td>
<td>Regional Director, Africa-MENA</td>
</tr>
<tr>
<td>Somesh Gupta</td>
<td>India</td>
<td>Regional Director, Asia Pacific</td>
</tr>
<tr>
<td>Airi Põder</td>
<td>Estonia</td>
<td>Regional Director, Europe</td>
</tr>
<tr>
<td>Adele Schwartz Benzaken</td>
<td>Brazil</td>
<td>Regional Director, Latin America and the Caribbean</td>
</tr>
<tr>
<td>Cornelis Rietmeijer</td>
<td>USA</td>
<td>Regional Director, North America</td>
</tr>
<tr>
<td>Amina Hansali</td>
<td>Morocco</td>
<td>Regional Chair, Africa-MENA</td>
</tr>
<tr>
<td>Kaushal Verma</td>
<td>India</td>
<td>Regional Chair, Asia Pacific</td>
</tr>
<tr>
<td>Claudia Heller-Vitouch</td>
<td>Austria</td>
<td>Regional Chair, Europe</td>
</tr>
<tr>
<td>Angelica Espinosa Miranda</td>
<td>Brazil</td>
<td>Regional Chair, Latin America and the Caribbean</td>
</tr>
<tr>
<td>Barbara Van Der Pol</td>
<td>USA</td>
<td>Regional Chair, North America</td>
</tr>
<tr>
<td>Sarah Lowe</td>
<td>Zimbabwe</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Ranmini Kularatne</td>
<td>South Africa</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Keith Radcliffe</td>
<td>UK</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Edward Hook III</td>
<td>USA</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Dennis Fortenberry</td>
<td>USA</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Name</td>
<td>Country</td>
<td>Role</td>
</tr>
<tr>
<td>--------------------------</td>
<td>----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Sunil Sethi</td>
<td>India</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Maria Eugenia Escobar</td>
<td>Argentina</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Patricia Galarza</td>
<td>Argentina</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Gloria Aguilar</td>
<td>Paraguay</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Laith Abu-Raddad</td>
<td>Qatar</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Ryoichi Hamasuna</td>
<td>Japan</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Suzanne Garland</td>
<td>Australia</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Marco Cusini</td>
<td>Italy</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Mihael Skerlev</td>
<td>Croatia</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Jo-Anne Dillon</td>
<td>Canada</td>
<td>Elected Member</td>
</tr>
<tr>
<td>Nathalie Broutet</td>
<td>Switzerland</td>
<td>WHO Liaison Officer</td>
</tr>
<tr>
<td>Caroline Cameron</td>
<td>Canada</td>
<td>ISSTDR President, Observer</td>
</tr>
<tr>
<td>Raj Patel</td>
<td>UK</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Chavalit Mangkalaviraj</td>
<td>Thailand</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Patricia Garcia</td>
<td>Peru</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Lew Drusin</td>
<td>USA</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Julius Schachter</td>
<td>USA</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Thomas Quinn</td>
<td>USA</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Sevgi Aral</td>
<td>USA</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Angelika Stary</td>
<td>Austria</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Hunter Handsfield</td>
<td>USA</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>Mikhail Gomberg</td>
<td>Russia</td>
<td>Senior Counsellor</td>
</tr>
<tr>
<td>King Holmes</td>
<td>USA</td>
<td>Senior Counsellor</td>
</tr>
</tbody>
</table>
Keynote Speakers

Dr. Rino Rappuoli is Chief Scientist and Head of External R&D at GSK Vaccines, based in Siena, Italy and Professor at Imperial College, London, UK. Prior positions include Head of Vaccine R&D at Novartis, CSO of Chiron Corporation, and Head of R&D at Sclavo. He obtained his PhD in Biological Sciences at the University of Siena, Italy, and has been a visiting scientist at both Rockefeller University and Harvard Medical School in the United States.

He is elected member of US National Academy of Sciences (NAS), American Academy of Arts and Sciences (AAAS), the European Molecular Biology Organization (EMBO), and the Royal Society of London. Dr. Rappuoli has received numerous awards including the Gold Medal of the Italian President, the Albert B Sabin Gold Medal, the Canada Gairdner International Award and the European Inventor Award for Lifetime Achievement. He was recently nominated as the third most influential person worldwide in the field of vaccines (Terrapin). He has published more than 650 works in peer-reviewed journals.

Dr. Rappuoli has developed and implemented a number of novel scientific concepts critical for vaccine development in the areas of genetic detoxification, cellular microbiology, reverse vaccinology and the pangenome. With others, he has developed several licensed vaccines and related adjuvants/carriers, including the acellular pertussis vaccine, which contains a non-toxic mutant of pertussis toxin; the first conjugate vaccine against meningococcus C; MF59, the first vaccine adjuvant after aluminium salts, which stimulates production of CD4 memory cells following meningococcal B vaccination; and CRM 197, a non-toxic mutant of diphtheria toxin that is used as carrier protein for polysaccharides and haptons to make them immunogenic in conjugate vaccines for several diseases, including meningococcal and pneumococcal infections. Recently he used a genome-based approach, named reverse vaccinology, to discover antigens for a new vaccine against meningococcus B.
Charlotte Watts
London School of Hygiene and Tropical Medicine, UK

Professor Charlotte Watts is Chief Scientific Adviser to the UK Department of International Development (DFID). In this role she is Director of the Research and Evidence Division and Head of the Science and Engineering Profession for DFID. Professor Watts is seconded to DFID from the London School of Hygiene and Tropical Medicine, where she is Professor of Social and Mathematical Epidemiology.

Originally trained as a mathematician, with a Ph.D. in theoretical mathematics from the University of Warwick, she became interested in global health whilst conducting post-doctoral research on the epidemiology of HIV at the University of Oxford. Moving to LSHTM in 1994, after gaining further training in economics and social science, and fieldwork experience in Zimbabwe and other developing countries, she founded the Social and Mathematical Epidemiology Group. The multidisciplinary group uses mathematical, epidemiological and economic research to assess the impact of current and new HIV prevention technologies, and evaluate interventions that tackle the determinants of HIV risk.

Professor Watts is a global expert in violence prevention. She was Senior Technical Advisor to the WHO 10 country population surveys on women’s health and domestic violence; led the systematic review of the global prevalence and health burden of interpersonal violence, and has been senior researcher on 5 cluster randomised controlled intervention trials in sub-Saharan Africa - showing that violence is preventable.

Professor Watts is a Fellow of the Academy of Medical Sciences, and Foreign Associate Member of the US National Academy of Medicine. She has 200 academic publications, and has served on numerous UN technical and Government advisory boards.
Contributor Irin Carmon is a journalist, the bestselling co-author of Notorious RBG, and a frequent speaker around the country. A New York magazine senior correspondent and on-air CNN contributor, she reports and comments on gender, politics, and the law. Carmon and her co-author were featured in the award-winning and Oscar nominated 2018 documentary RBG. The New York Times described Carmon as being “known for her smarts and feminist bona fides. In 2017 and 2018, Carmon teamed up with the Washington Post’s investigative team to break the news of sexual harassment and assault allegations against Charlie Rose, as well as CBS’s knowledge of his conduct. That work was recognized with a 2018 Mirror Award. She was also a contributing writer to the Post’s Outlook section. Carmon previously served as staff reporter focusing on women’s rights at MSNBC and NBC News, Salon and Jezebel. Her reporting and commentary has appeared across print, radio, television, and digital platforms. Of Notorious RBG: The Life and Times of Ruth Bader Ginsburg (2015) which spent three months on the Times’ bestseller list, the paper’s staff book critic wrote, “That I responded so personally to it is a testimony to Ms. Carmon’s storytelling and panache.” She speaks frequently across the country on women’s leadership and rights. In 2011, she was one of Forbes’ 30 Under 30 in Media. She graduated from Harvard, magna cum laude with highest honors in literature, in 2005. Irin’s key topics include: I Dissent: How Ruth Bader Ginsburg Became the Notorious RBG, What Ruth Bader Ginsburg’s Life & Work Can Teach Us About Reproductive Freedom, What’s at Stake for Women at The Supreme Court, Reporting on #MeToo: An Account from the Journalistic Trenches.

Wafaa El-Sadr is the founder and director of ICAP at Columbia University, University Professor of Epidemiology and Medicine and Mathilde Krim-amfAR Professor of Global Health at Columbia University. She established ICAP at the Columbia Mailman School of Public Health, a large Center engaged in the design and implementation of programs in more than 30 countries around the world.

Dr. El-Sadr currently serves as co-principal investigator of the NIH-funded HIV Prevention Trials Network (HPTN) which supports diverse HIV prevention research studies around the world. Her research interests are diverse and include research on the prevention and treatment of HIV, tuberculosis, non-communicable diseases, maternal-child health among others. She was born in Egypt, received her medical degree from Cairo University, a master’s in public health (in Epidemiology) from Columbia’s Mailman School of Public Health and a master’s in public administration from Harvard University’s Kennedy School of Government. She was named as McArthur fellow in 2008 and is a member of the National Academy of Medicine.
Geoff Garnett works as a Deputy Director at the Bill and Melinda Gates Foundation on improving the effectiveness and sustainability of HIV testing, treatment and prevention programs. Prior to this Geoff was a Professor at Imperial College London researching the epidemiology, evolution and control of HIV and other sexually transmitted infections. Geoff’s work combines mathematical modeling of the transmission dynamics of HIV and STIs and methods of evaluation and uses mathematical models to understand the potential impact, effectiveness, cost effectiveness and budget impact of interventions. His current research interests include the use of HIV prevention cascades in the planning and monitoring of HIV prevention interventions, understanding the drivers of HIV risk behavior and adoption of prevention interventions, and how targets and indicators can be sued to improve HIV interventions.

Dr. Kevin Hybiske is an Assistant Professor in the Division of Allergy and Infectious Diseases at the University of Washington, Seattle, USA. He has adjunct appointments in the Departments of Microbiology and Global Health at the University of Washington. His ongoing research interests concern the pathogenesis of and mechanisms of host manipulation by Chlamydia.

Rena Janamnuaysook is a transgender woman and a health and human rights advocate from Bangkok, Thailand. She works as a program manager for transgender health at the Thai Red Cross AIDS Research Centre, where she established the Tangerine Community Health Center, the first sexual health and well-being clinic for transgender people in the region. Rena also leads the Tangerine Academy for Transgender Health, where she provides technical assistance and capacity building interventions on key population-led health services, including HIV testing, PrEP, Same-Day ART and implementation research to community-based health centers, government partners and private sectors. Rena co-founded the Thai Transgender Alliance, the first transgender-owned human rights organization in Thailand. She received a master’s degree in international development from the University of Birmingham, United Kingdom. Rena currently serves as a board member of the Asia Pacific Transgender Network and the Planned Parenthood Association of Thailand.
Dr. Jørgen Skov Jensen is a consultant physician at SSI where he is heading the Research Unit for Reproductive Microbiology. For more than 25 years, he has been working with mycoplasmas, in particular *Mycoplasma genitalium*. His current focus is on *M. genitalium* antimicrobial susceptibility aiming to improve treatment. He has been part of the European STI Guidelines Project Editorial Board since 2006 and was the lead author on the *M. genitalium* guideline – an area where hard evidence from treatment trials is limited.

Dr. Charlotte Loppie is a Professor in the School of Public Health and Social Policy and Research Lead for the Faculty of Human and Social Development, University of Victoria. Dr. Loppie’s research partners have included individual First Nation communities, regional and national Indigenous organizations as well as provincial and national government stakeholders. Dr. Loppie has undertaken research and published in the areas of: Indigenous health, Indigenous HIV/AIDS, social determinants of Indigenous health, racism and cultural safety, Indigenous ethics and research capacity building as well as the sexual and reproductive health of Indigenous women.

Dr. Marra completed residency training in Neurology and fellowship training in Infectious Diseases at the University of Washington, in Seattle, Washington, USA. She is Professor and Vice Chair for Academic Affairs in Neurology, and she has an adjunct appointment in Medicine (Infectious Diseases), at the University of Washington. Dr. Marra directs a US National Institute of Health-funded clinical and translational research program on factors that influence the clinical course of syphilis, with a particular focus on HIV and on neurosyphilis. She received the American Sexually Transmitted Diseases Association Achievement Award in 2014 for work in this area. She also participates in multi-center clinical research on the neurological consequences of HIV, and she provides general neurological care in inpatient and outpatient settings, including a multispecialty HIV clinic.
Johan Melendez, MS, PhD, is a research fellow in the Division of Infectious Diseases at the Johns Hopkins School of Medicine. Dr. Melendez has almost 20 years of experience in the development and evaluation of molecular approaches for characterization of gonorrhea, chlamydia and other infectious agents, and biomarkers of human sexual behavior. His current research focuses on the development, evaluation, and implementation of rapid tests for the diagnosis of STIs and characterization of antimicrobial resistant gonorrhea.

David Peters is an internationally renowned expert in health systems who has worked as a researcher, policy advisor, educator, manager, and clinician in dozens of low and middle-income countries (LMICs). Peters' work seeks to improve the performance of health systems in LMICs through implementation science, and by building institutional capacity and creating innovations in organization, technology, and financing of health systems. He has published 8 books and monographs, more than 20 book chapters, and over 125 peer-reviewed articles. While working at the World Bank, he pioneered the Sector Wide Approaches (SWAps) in health, which is used by countries to define and implement national strategies and the allocation of foreign aid. In India, he led a research program to examine health systems and inequities, which became the basis for national policies to improve access and financing for health care. In Afghanistan, he created the first nationally implemented Balanced Scorecard to assess and manage health services.

Dr. Poteat is an Assistant Professor of Social Medicine at the University of North Carolina in the Center for Health Equity Research. Her research, teaching, and clinical practice focus on HIV and LGBTQ health with particular attention to the role of stigma in driving health disparities. Certified as an HIV Specialist by the American Academy of HIV Medicine, she is a leader in HIV research and care with transgender persons. She has a special interest in the intersections of gender, sexuality, race, class, and health. Dr. Poteat received a Master of Medical Science degree from Emory University’s Physician Assistant (PA) Program; a Master’s of Public Health from Rollins School of Public Health; and a PhD in the Social and Behavioral Interventions Program in the Department of International Health at Johns Hopkins School of Public Health.
Helena Seth-Smith uses genomic data to investigate bacterial evolution. In her current role within the Division of Clinical Microbiology at the University Hospital Basel, Switzerland, she tries to answer questions relating to emerging pathogens, outbreaks and transmission. An ongoing interest is in sexually transmitted pathogens, having worked for many years on Chlamydia trachomatis (in addition to Chlamydia suis, abortus and pecorum), published cases on sexually transmitted Shigella sonnei, and now exploring diversity and antibiotic resistance in Neisseria gonorrhoeae. She cut her genomic teeth at the Sanger Institute in Cambridge, UK, analysing the genomes of many and varied pathogens. Her PhD at the Institute of Biotechnology, University of Cambridge identified a gene cluster involved in explosive breakdown by Rhodococcus. As bacterial pathogens show no sign of weakening, and STIs will always transmit, she is pleased that she has chosen a fascinating and satisfying career in a field which can only expand.

Rebecca C. Thurston, PhD. Dr. Thurston is Professor of Psychiatry, Epidemiology, Psychology, and Clinical and Translational Science, and Director of the Women's Biobehavioral Health Research Program at the University of Pittsburgh. Dr. Thurston's research interests focus on midlife women's psychosocial experiences, reproductive aging, and cardiovascular health. She takes a biopsychosocial perspective, focusing on exposures prevalent among women and important to their cardiovascular health. As such, Dr. Thurston is Principal Investigator of NIH R01-funded studies on cardiovascular disease and brain aging in women as well as a NIH K24 award supporting interdisciplinary mentoring and training in midlife women's cardiovascular health. For the past 14 years, Dr. Thurston has been an investigator of the Study of Women's Health Across the Nation, one of the largest multiethnic prospective cohort studies of midlife aging in women. Dr. Thurston is a recipient of the Henry Burger Award from the International Menopause Society, is President Elect of the North American Menopause Society, and is an elected fellow of the Academy of Behavioral Medicine Research.

David Wilson is Program Director in the World Bank’s Health, Population and Nutrition global practice. He leads the World Bank’s Global Solutions Groups in support of Health Systems Strengthening for UHC and also leads a Decision Science initiative focusing on technological innovation. Before joining the Bank in 2003, David worked as an academic, development practitioner and global health advisor for 20 years. David has over published over 100 scientific papers and delivered over 1,000 scientific addresses. He has worked in high- and low-income contexts in over 50 countries on all continents.
Debate Speakers

Christopher Fairley
Monash University, Australia

Christopher Fairley is the Director of Melbourne Sexual Health Centre, Alfred Health and Professor of Public Health at Monash University. He holds three specialist medical fellowships from the College of Physicians (Infectious Diseases), Faculty of Public Health and Chapter of Sexual Health Medicine, and is a fellow of the Royal College of Physicians and a fellowship of the Australian Academy of Health and Medical Sciences. He is an editor of the Journal ‘Sexual Health’. His principle research interests are the public health control of sexually transmitted diseases and the effectiveness of clinical services. He sits on the boards of IUSTI and ISSTDR.

Hunter Handsfield
University of Washington, USA

Dr. Handsfield is Professor Emeritus of Medicine, University of Washington. He received his medical degree from Columbia University and served his residency training in internal medicine and fellowship in infectious diseases at the University of Washington. His 40-year career has addressed the clinical aspects, epidemiology, and prevention of STDs. For 25 years he directed the Public Health—Seattle & King County STD Control Program, Seattle, Washington. Dr. Handsfield is former president of ISSTDR and a current IUSTI Senior Counselor, former president of the American Sexually Transmitted Diseases Association, a current member of ASTDA’s Executive Committee, an Associate Editor of Sexually Transmitted Diseases, and the 2010 recipient of the ASTDA’s Distinguished Career Award (formerly Thomas Parran Award).
Through generous donations, the following 28 scholarship recipients have been provided with support to attend the STI & HIV 2019 World Congress. Thank you to the American, Sexually Transmitted Diseases Association (ASTDA), the International Union Against Sexually Transmitted Infections (IUSTI), International Society for Sexually Transmitted Diseases Research (ISSTDR) Foundation, and the British Association for Sexual Health and HIV (BASHH).

Funded by a full scholarship from the American Sexually Transmitted Diseases Association (ASTDA)
- Raphael Ondondo, Kenya
- Beatriz Paiatto, Brazil

Funded by a full scholarship from the International Union Against Sexually Transmitted Infections (IUSTI)
- Anthony Ajayi, South Africa
- Natsayi Chimbindi, South Africa
- Liza Coyer, Netherlands
- Douglas Gaitho, Kenya
- Lorraine McDonagh, United Kingdom
- Avid Mohammadi, Canada

Funded by a full scholarship from the International Society for Sexually Transmitted Diseases Research (ISSTDR) Foundation
- Adebola Adejimi, Nigeria
- Iyalo Konstantinus, Namibia
- YiQiao Li, Canada
- Ismaël Maatouk, Lebanon
- Charlotte Peters, Netherlands
- Laura Thompson, Canada

Funded by a full scholarship from the BASHH - ISSTDR (ISON) Scholarships
- Ling Yuan Kong, United Kingdom
- Diarmuid Nugent, United Kingdom

Funded by a partial scholarship from the International Society for Sexually Transmitted Diseases Research (ISSTDR) Foundation
- Louis MacGregor, United Kingdom
- Brian van der Veer, Netherlands

Funded by a partial scholarship from the International Union Against Sexually Transmitted Infections (IUSTI)
- Uma Chaudhry, India

Partial travel bursaries provided by BASHH
- Sophie Candfield, United Kingdom
- Jessica Doctor, United Kingdom
- Deborah Goode, United Kingdom
- Emma Wallis, United Kingdom

Funded by a STI & HIV 2019 World Congress Scholarship
- Jonathan Gootenberg, United States
- Smarajit Jana, India
- Primrose Matambanadzo, Zimbabwe
- Mark Pakianathan, United Kingdom
- Pachara Siriivongrangson, Thailand
<table>
<thead>
<tr>
<th>FIRST NAME</th>
<th>LAST NAME</th>
<th>COUNTRY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oluwafemi</td>
<td>Adeagbo</td>
<td>South Africa</td>
</tr>
<tr>
<td>Michel</td>
<td>Alary</td>
<td>Canada</td>
</tr>
<tr>
<td>Mat</td>
<td>Beale</td>
<td>UK</td>
</tr>
<tr>
<td>Tara</td>
<td>Beattie</td>
<td>UK</td>
</tr>
<tr>
<td>Marissa</td>
<td>Becker</td>
<td>Canada</td>
</tr>
<tr>
<td>Adele</td>
<td>Benzaken</td>
<td>Brazil</td>
</tr>
<tr>
<td>Julie</td>
<td>Bettinger</td>
<td>Canada</td>
</tr>
<tr>
<td>James</td>
<td>Blanchard</td>
<td>Canada</td>
</tr>
<tr>
<td>Chris</td>
<td>Bourne</td>
<td>Australia</td>
</tr>
<tr>
<td>Viviane</td>
<td>Bremer</td>
<td>Germany</td>
</tr>
<tr>
<td>Kate</td>
<td>Brookmeyer</td>
<td>USA</td>
</tr>
<tr>
<td>Rebecca</td>
<td>Brotman</td>
<td>USA</td>
</tr>
<tr>
<td>Denton</td>
<td>Callander</td>
<td>Australia</td>
</tr>
<tr>
<td>Caroline</td>
<td>Cameron</td>
<td>Canada</td>
</tr>
<tr>
<td>Allison</td>
<td>Carter</td>
<td>Australia</td>
</tr>
<tr>
<td>Nomathemba</td>
<td>Chandiwana</td>
<td>South Africa</td>
</tr>
<tr>
<td>Xiang-Sheng</td>
<td>Chen</td>
<td>China</td>
</tr>
<tr>
<td>Marcus</td>
<td>Chen</td>
<td>Australia</td>
</tr>
<tr>
<td>Harrell</td>
<td>Chesson</td>
<td>USA</td>
</tr>
<tr>
<td>Admire</td>
<td>Chikandiwa</td>
<td>South Africa</td>
</tr>
<tr>
<td>Eric</td>
<td>Chow</td>
<td>Australia</td>
</tr>
<tr>
<td>Frances</td>
<td>Cowan</td>
<td>UK</td>
</tr>
<tr>
<td>Marco</td>
<td>Cusini</td>
<td>Italy</td>
</tr>
<tr>
<td>Alex</td>
<td>de Voux</td>
<td>USA</td>
</tr>
<tr>
<td>Henri</td>
<td>de Vries</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Souleymane</td>
<td>Diabaté</td>
<td>Côte d'Ivoire</td>
</tr>
<tr>
<td>Patricia</td>
<td>Dittius</td>
<td>USA</td>
</tr>
<tr>
<td>Basil</td>
<td>Donovan</td>
<td>Australia</td>
</tr>
<tr>
<td>Mark</td>
<td>Drew Crosland Guimarães</td>
<td>Brazil</td>
</tr>
<tr>
<td>Krista</td>
<td>English</td>
<td>Canada</td>
</tr>
<tr>
<td>Nigel</td>
<td>Field</td>
<td>UK</td>
</tr>
<tr>
<td>Errol</td>
<td>Fields</td>
<td>USA</td>
</tr>
<tr>
<td>Dennis</td>
<td>Fortenberry</td>
<td>USA</td>
</tr>
<tr>
<td>Jamie</td>
<td>Frankis</td>
<td>UK</td>
</tr>
<tr>
<td>Hongyun</td>
<td>Fu</td>
<td>USA</td>
</tr>
<tr>
<td>Patricia</td>
<td>Galarza</td>
<td>Argentina</td>
</tr>
<tr>
<td>Patricia</td>
<td>Garcia</td>
<td>Peru</td>
</tr>
<tr>
<td>Suzanne</td>
<td>Garland</td>
<td>Australia</td>
</tr>
<tr>
<td>Charlotte</td>
<td>Gaydos</td>
<td>USA</td>
</tr>
<tr>
<td>Dionne</td>
<td>Gesink</td>
<td>Canada</td>
</tr>
<tr>
<td>Khalil</td>
<td>Ghanem</td>
<td>USA</td>
</tr>
<tr>
<td>Lorenzo</td>
<td>Giacani</td>
<td>USA</td>
</tr>
<tr>
<td>Jane</td>
<td>Goller</td>
<td>Australia</td>
</tr>
<tr>
<td>Sami</td>
<td>Gottlieb</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Hunter</td>
<td>Handsfield</td>
<td>USA</td>
</tr>
<tr>
<td>Devon</td>
<td>Hensel</td>
<td>USA</td>
</tr>
<tr>
<td>Betsy</td>
<td>Herold</td>
<td>USA</td>
</tr>
<tr>
<td>Jane</td>
<td>Hocking</td>
<td>Australia</td>
</tr>
<tr>
<td>Matthew</td>
<td>Hogben</td>
<td>USA</td>
</tr>
<tr>
<td>Ned</td>
<td>Hook</td>
<td>USA</td>
</tr>
<tr>
<td>Gwenda</td>
<td>Hughes</td>
<td>UK</td>
</tr>
<tr>
<td>Shaify</td>
<td>Isac</td>
<td>India</td>
</tr>
<tr>
<td>Jorgen</td>
<td>Jensen</td>
<td>Denmark</td>
</tr>
<tr>
<td>Jeff</td>
<td>Jin</td>
<td>Australia</td>
</tr>
<tr>
<td>Christine</td>
<td>Johnston</td>
<td>USA</td>
</tr>
<tr>
<td>Bob</td>
<td>Kirkaldy</td>
<td>USA</td>
</tr>
<tr>
<td>Patricia</td>
<td>Kissinger</td>
<td>USA</td>
</tr>
<tr>
<td>David</td>
<td>Koelle</td>
<td>USA</td>
</tr>
<tr>
<td>Fabian</td>
<td>Kong</td>
<td>Australia</td>
</tr>
<tr>
<td>Jami</td>
<td>Leichtliter</td>
<td>USA</td>
</tr>
<tr>
<td>David</td>
<td>Lewis</td>
<td>Australia</td>
</tr>
<tr>
<td>Name</td>
<td>Last Name</td>
<td>Country</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Penny</td>
<td>Loosier</td>
<td>USA</td>
</tr>
<tr>
<td>Sarah</td>
<td>Lowe</td>
<td>Zimbabwe</td>
</tr>
<tr>
<td>Carla Gianna</td>
<td>Luppi</td>
<td>Italy</td>
</tr>
<tr>
<td>Liao</td>
<td>Magno</td>
<td>Brazil</td>
</tr>
<tr>
<td>Irene</td>
<td>Martin</td>
<td>Canada</td>
</tr>
<tr>
<td>Philippe</td>
<td>Mayaud</td>
<td>UK</td>
</tr>
<tr>
<td>Nick</td>
<td>Medland</td>
<td>Australia</td>
</tr>
<tr>
<td>Supriya</td>
<td>Mehta</td>
<td>USA</td>
</tr>
<tr>
<td>Hana</td>
<td>Mijovic</td>
<td>Canada</td>
</tr>
<tr>
<td>Angelica Espinosa</td>
<td>Miranda</td>
<td>Brazil</td>
</tr>
<tr>
<td>Shamistha</td>
<td>Mishra</td>
<td>Canada</td>
</tr>
<tr>
<td>Hamish</td>
<td>Mohammed</td>
<td>UK</td>
</tr>
<tr>
<td>Sinead Delany</td>
<td>Morelwe</td>
<td>South Africa</td>
</tr>
<tr>
<td>Christina</td>
<td>Muzny</td>
<td>USA</td>
</tr>
<tr>
<td>Landon</td>
<td>Myer</td>
<td>South Africa</td>
</tr>
<tr>
<td>Chmbindi</td>
<td>Natsayi</td>
<td>South Africa</td>
</tr>
<tr>
<td>Ndeindo</td>
<td>Ndeikoundam</td>
<td>France</td>
</tr>
<tr>
<td>Francis</td>
<td>Ndowa</td>
<td>Zimbabwe</td>
</tr>
<tr>
<td>Trang</td>
<td>Nguyen</td>
<td>USA</td>
</tr>
<tr>
<td>Abby</td>
<td>Norris Turner</td>
<td>USA</td>
</tr>
<tr>
<td>Catherine</td>
<td>O'Connor</td>
<td>Australia</td>
</tr>
<tr>
<td>Gina</td>
<td>Ogilvie</td>
<td>Canada</td>
</tr>
<tr>
<td>Jason</td>
<td>Ong</td>
<td>UK</td>
</tr>
<tr>
<td>Mark</td>
<td>Pakianathan</td>
<td>UK</td>
</tr>
<tr>
<td>Preeti</td>
<td>Pathela</td>
<td>USA</td>
</tr>
<tr>
<td>Tom</td>
<td>Peterman</td>
<td>USA</td>
</tr>
<tr>
<td>Remco</td>
<td>Peters</td>
<td>South Africa</td>
</tr>
<tr>
<td>Michael</td>
<td>Pickles</td>
<td>Canada</td>
</tr>
<tr>
<td>Ravi</td>
<td>Prakash</td>
<td>India</td>
</tr>
<tr>
<td>Alison</td>
<td>Quayle</td>
<td>USA</td>
</tr>
<tr>
<td>BM</td>
<td>Ramesh</td>
<td>Canada</td>
</tr>
<tr>
<td>Kees</td>
<td>Rietmeijer</td>
<td>USA</td>
</tr>
<tr>
<td>Anne</td>
<td>Rompalo</td>
<td>USA</td>
</tr>
<tr>
<td>Minttu</td>
<td>Ronn</td>
<td>USA</td>
</tr>
<tr>
<td>Jonathan</td>
<td>Ross</td>
<td>UK</td>
</tr>
<tr>
<td>Tariq</td>
<td>Sadiq</td>
<td>UK</td>
</tr>
<tr>
<td>Shailendra</td>
<td>Sawleshwarkar</td>
<td>Australia</td>
</tr>
<tr>
<td>Euphemia</td>
<td>Sibanda</td>
<td>Zimbabwe</td>
</tr>
<tr>
<td>Mihael</td>
<td>Skerlev</td>
<td>Croatia</td>
</tr>
<tr>
<td>Pam</td>
<td>Sonnenberg</td>
<td>UK</td>
</tr>
<tr>
<td>Ian</td>
<td>Spicknall</td>
<td>USA</td>
</tr>
<tr>
<td>Gianfranco</td>
<td>Spiteri</td>
<td>Sweden</td>
</tr>
<tr>
<td>Weiming</td>
<td>Tang</td>
<td>USA</td>
</tr>
<tr>
<td>Amanda</td>
<td>Tanner</td>
<td>USA</td>
</tr>
<tr>
<td>Meredith</td>
<td>Temple-Smith</td>
<td>Australia</td>
</tr>
<tr>
<td>Caroline</td>
<td>Thng</td>
<td>Australia</td>
</tr>
<tr>
<td>James</td>
<td>Thomas</td>
<td>USA</td>
</tr>
<tr>
<td>Peter</td>
<td>Timms</td>
<td>Australia</td>
</tr>
<tr>
<td>Elizabeth</td>
<td>Torrone</td>
<td>USA</td>
</tr>
<tr>
<td>Katy</td>
<td>Turner</td>
<td>UK</td>
</tr>
<tr>
<td>Anneli</td>
<td>Uusküla</td>
<td>Estonia</td>
</tr>
<tr>
<td>Birgit</td>
<td>van Benthem</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Rick</td>
<td>Varma</td>
<td>Australia</td>
</tr>
<tr>
<td>Maria</td>
<td>Veras</td>
<td>Brazil</td>
</tr>
<tr>
<td>Lenka</td>
<td>Vodstrcil</td>
<td>Australia</td>
</tr>
<tr>
<td>Bea</td>
<td>Vuylsteke</td>
<td>Belgium</td>
</tr>
<tr>
<td>Reynolds</td>
<td>Washington</td>
<td>India</td>
</tr>
<tr>
<td>Janet</td>
<td>Wilson</td>
<td>UK</td>
</tr>
<tr>
<td>Rachel</td>
<td>Winer</td>
<td>USA</td>
</tr>
<tr>
<td>Gwen</td>
<td>Wood</td>
<td>USA</td>
</tr>
<tr>
<td>Iryna</td>
<td>Zablotska-Manos</td>
<td>Australia</td>
</tr>
<tr>
<td>Jonathan</td>
<td>Zenilman</td>
<td>USA</td>
</tr>
</tbody>
</table>
## PROGRAM AT A GLANCE

<table>
<thead>
<tr>
<th>SATURDAY</th>
<th>JULY 13, 2019</th>
<th>SUNDAY</th>
<th>JULY 14, 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>ISSTDRI Board Meeting (By Invitation Only) [08:00 - 12:30]</td>
<td>Pre-Congress Symposia [08:00 - 12:00]</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td>Pre-Congress Symposia [13:00 - 17:00]</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td>Welcome Ceremony [17:30 - 18:30]</td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td>Opening Keynote Lecture [18:30 - 19:30]</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td>Welcome Reception [19:30 - 21:00]</td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td>Presidents’ Dinner (By Invitation Only) [19:30 - 22:00]</td>
</tr>
<tr>
<td>13:00</td>
<td>1st IUSTI Executive Meeting (By Invitation Only) [13:00 - 18:00]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22:00</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Join the preeminent professional association of STD researchers, practitioners, and prevention specialists in the United States and Canada.

**ASTDA AWARDS LUNCHEON**
**TUESDAY, JULY 16, 12:15-13:45**

- **Distinguished Career Award**
  Charlotte Gaydos, DrPH, MPH

- **Achievement Award**
  Patricia Kissinger, PhD, MPH

- **Young Investigator Award**
  Yonatan Grad, MD, PhD

**Exclusive Membership Benefits**

Joint ASTDA & IUSTI members get benefits from both organizations. These include:

- Free subscription to ASTDA’s journal, *Sexually Transmitted Diseases*.
- A 40% discount on a subscription to IUSTI’s journal, the *International Journal of STD and AIDS*.
- Reduced registration fees for the biannual STD Conference and most IUSTI regional and world meetings.

**Sexually Transmitted Diseases Journal**

- Submit your STD-related manuscripts.
- Read the latest peer-reviewed, original articles on current research.
- Explore the “Real World of STD Prevention,” focused on clinical and prevention practice and the science-to-program interface.

**Join TODAY at www.ASTDA.org**
SCIENTIFIC PROGRAM  (SATURDAY & SUNDAY)

- Career Development Symposium for Emerging Investigators and Program Leaders .................................... Saturday, July 13
- Pre-Congress Symposia and Opening Keynote ........................... Sunday, July 14
- Scientific Program ................................................................. Monday, July 15
- Scientific Program ................................................................. Tuesday, July 16
- Scientific Program ................................................................. Wednesday, July 17
- Posters

SATURDAY, JULY 13, 2019
08:45 - 15:30  IUSTI Canada - ASTDA Career Development Symposium for Emerging Investigators and Program Leaders
(By Invitation Only)
Location: MR 11+12

09:00 - 09:20 Introductions
- Marc Steben

09:20 - 10:30  “Speed Intros”

10:30 - 10:45 Coffee Break

10:45 - 11:45 Finding Funding:
Canada: Scott Gray-Owen
USA: Julie Dombrowski

11:45 - 13:00 Lunch / Career Panel
- Chris L. McGowin, Max Chernesky, Petra Smyczek

13:00 - 14:00 Manuscript Workshop
- Bill Miller

14:00 - 15:00 Small Group Discussions
- Work-life balance and avoiding burnout: Abigail Norris-Turner
- How to grow your network/increase visibility: Max Chernesky
- Thorny issues in collaboration: Julie Dombrowski
- Balancing clinical, research and teaching: Irene Martin
- Community engagement, health departments & advisory boards: Marc Steben

15:00 - 15:30 Conclusion and Next Steps

SUNDAY, JULY 14, 2019
PRE-CONGRESS SYMPOSIA
09:00 - 16:30  Pre-Congress Symposium 1 - Phase specific strategies for STI and HIV control redux: Resurgence, concentrations, networks, key populations, and magic bullets
Location: MR 11+12

09:05 - 09:35 STI/HIV prevention today
- Sevgi Aral, Centers for Disease Control and Prevention, USA

09:35 - 10:05 Background and progress in phase-specific strategies
- Judy Wasserheit, University of Washington, USA

10:05 - 10:35 Emerging research methods and collaborations to improve program design and implementation
- Geoff Garnett, Bill & Melinda Gates Foundation, USA
Pre-Congress Symposium 2 - The global challenges and opportunities of STIs in pregnancy
Location: MR 9
Organized by University of California Los Angeles

08:00 - 08:10 Welcome
- Jackie McDowell, Cepheid

08:10 - 08:30 Overview
- Jeffrey D Klausner, UCLA - David Geffen School Of Medicine, Los Angeles, USA

08:30 - 08:55 Curable STIs in pregnant women living in Brazil; A challenge ripe for intervention
- Nava Yeganeh, University of California, Los Angeles, USA

08:55 - 09:20 Syndromic management for STIs during pregnancy just doesn’t cut it anymore: Implementing diagnostic screening to reduce adverse birth outcomes in South Africa
- Andrew Medina-Marino, Foundation of Professional Development, South Africa

09:20 - 09:45 Point-of-care testing and treatment of sexually transmitted and genital infections to improve birth outcomes in high-burden, low-income settings: The WANTAIM Trial, Papua New Guinea
- Andrew Vallely, Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea & The Kirby Institute, UNSW Sydney, Australia

09:45 - 10:10 Antenatal *Chlamydia trachomatis* and *Neisseria gonorrhoeae* testing compared to syndromic management in Botswana: A cost-effectiveness study
- Adriane Wynn, University of California, San Diego, USA

10:20 - 10:45 *Chlamydia trachomatis* screening and treatment among pregnant women in China: Evidence and challenges
- Weiming Tang, University of North Carolina at Chapel Hill, USA
10:45 - 11:10 The ASPIRE Trial – aiming for safe pregnancies: Reducing malaria and infections of the reproductive tract in Zambia
- Matthew Chico, London School of Hygiene & Tropical Medicine, United Kingdom

11:10 - 11:35 Enhancing nutrition and antenatal infection treatment for maternal and child health (ENAT) study: Screening and treating genitourinary tract infections to improve birth outcomes in Amhara, Ethiopia
- Rose L. Molina, Beth Israel Deaconess Medical Center, Harvard Medical School, USA

11:35 - 12:00 Summary and next steps
- Nicola Low, Institute of Social and Preventive Medicine, University of Bern, Switzerland

Pre-Congress Symposium 3 - Understanding variability and improving the reproducibility of genital microbiome research
Location: MR 2+3
Chair: Jen Balkus, University of Washington, USA

08:00 - 08:15 Introductions and motivations for the Vaginal Microbiome Laboratory Variability Project (MLVP)
- Jen Balkus, University of Washington, USA

08:15 - 08:30 Overview of the Vaginal Microbiome Laboratory Variability Project
- David Fredricks, Fred Hutchinson Cancer Research Center, USA

08:30 - 09:00 Laboratory challenges and opportunities to reduce variability: Lessons learned from the MLVP
- Sujatha Srinivasan, Fred Hutchinson Cancer Research Center, USA
- Darrell Dinwiddie, University of New Mexico, USA

09:00 - 09:30 Bioinformatics challenges and opportunities to reduce variability: Lessons learned from the MLVP
- Johanna Holm, University of Maryland, USA
- Liam Van Der Pol, University of Alabama, USA

10:00 - 10:20 Statistical analyses and challenges for assessing variability
- Jim Hughes, University of Washington, USA
- Pawel Gajer, University of Maryland, USA

10:20 - 10:40 Successes and challenges of implementing the MLVP and opportunities to improve reproducibility moving forward
- Jacques Ravel, University of Maryland, USA

10:40 - 11:30 Round table discussion with other experts engaged in vaginal microbiome research
- Carolyn Deal, NIAUD/DMID, USA
- Jennifer Fettweis, VCU, USA
- Doug Kwon, Ragon Institute, USA
- Deborah Money, UBC, Canada

Pre-Congress Symposium 4 - Shaking the trees: Optimizing treatment and antimicrobial stewardship for STIs
Location: MR 1
Facilitators: Laura Bachmann, MD, MPH - Medical Director, CDC Division of STD Prevention & Christine Johnson, MD, MPH - Associate Professor, University of Washington at Seattle; Medical Director, University of Washington STD Prevention Training Centers

Talk 1. Global STI trends and priorities for antimicrobial resistance
- Teodora Elvira Wi, STI Department of Reproductive Health and Research, World Health Organization, Switzerland
Pre-Congress Symposium 5 - The resurgence of syphilis: What have we learned and how can we respond?
Location: MR: 8+15
Organized by David Lewis and Gwenda Hughes
Refreshments supported by Western Sydney Sexual Health, University of Sydney, Australia

08:00 - 08:10 Welcome and Introduction
08:10 - 08:30 Syphilis: A historical overview
- David Lewis, University of Sydney, Australia
08:30 - 09:00 Keynote lecture: Syphilis: What we know and what we need to know
- Sheila Lukehart, University of Washington, USA
09:00 - 09:20 The application of modern technologies to the goal of syphilis elimination
- Caroline Cameron, University of Victoria, Canada
09:20 - 09:40 What can we learn about syphilis from whole genome sequencing of global Treponema pallidum strains
- Nick Thomson, Sanger Institute, UK
09:40 - 10:00 Syphilis in the context of HIV co-infection
- Khalil Ghanem, Johns Hopkins University, USA
10:00 - 10:20 Syphilis, the great imitator: Unusual case presentations of syphilis in adults
- Somesh Gupta, All India Institute of Medical Sciences, India
10:40 - 11:00 Recent trends in syphilis in women and congenital syphilis in developed countries: A changing epidemiology?
- Gwenda Hughes, Public Health England, UK
11:00 - 11:20 Drivers and determinants for the rising incidence of syphilis in men-who-have-sex-with-men
- Kyle Bernstein, Centers for Disease Control and Prevention, USA
11:20 - 11:40 Responding to syphilis in China: The importance of key populations
- Xiang-Sheng Chen, National Center for STD Control, China
11:40 - 12:00 Syphilis control efforts and public health policy: Global perspectives
- Francis Ndowa, Skin & GU Medicine Clinic, Harare, Zimbabwe
08:00 - 12:00

Pre-Congress Symposium 6 - The role of brief behavioural interventions in a combination prevention approach to sexually transmitted infections, including HIV
Location: MR 7

PART I - SRH behavioural interventions Global State of Affairs
Co-chairs:
- Igor Toskin, World Health Organization, Switzerland
- King Holmes, Dept. of Global Health & Medicine, University of Washington, USA
- Carmen Logie, University of Toronto, Canada

08:00 - 08:20  WHO perspective on behavioural interventions
- Igor Toskin, World Health Organization, Switzerland

08:20 - 08:40 Exploring the landscape of behavioural HIV/STI prevention interventions in Canada
- Carmen Logie, University of Toronto, Canada

08:40 - 09:00 Scientific evidence of effectiveness of behavioural interventions for shifting sexual health outcomes
- Rob Stephenson, Center for Sexuality and Health Disparities, University of Michigan, USA

09:00 - 09:20 Delivering behavioural interventions through e-health and mHealth technologies
- Keith Horvath, University of Minnesota, USA

09:40 - 10:00 Screening of a behavioural intervention using Motivational Interviewing (MI)

PART II - Country perspectives behavioural interventions and WHO Brief Sexuality-related Communication (BSC) feasibility study
Co-chairs:
- Igor Toskin, World Health Organization, Switzerland
- King Holmes, Dept. of Global Health & Medicine, University of Washington, USA
- Carmen Logie, University of Toronto, Canada

10:30 - 10:50  MI in France
- Thierry Troussier, Chaire UNESCO Santé sexuelle et Droits humains, Paris, France

10:50 - 11:00 Introduction of the WHO BSC feasibility study
- Sofia de Vasconcelos, World Health Organization, Switzerland

11:00 - 11:15 WHO BSC feasibility study in Peru: Results of the formative phase and next steps
- Carlos Caceres, Universidad Peruana Cayetano Heredi, Peru

11:15 - 11:30 WHO BSC feasibility study in Moldova: Populations and objectives
- Natalia Bakunina, World Health Organization, Switzerland / Larisa Boderscova, WHO, Moldova

11:30 - 11:45 Behavioural intervention showcase (video)
- youth counselling
- M-health intervention
- BSC training video Peru
Pre-Congress Symposium 7 - Ibero-American Network on Gay Men, others MSM and Trans Studies (RIGHT) and the Latin American Men Who Have Sex With Men Internet Survey (LAMIS)
Location: MR 13

Talk 1. The Ibero-American network on gay men, others MSM and trans studies (RIGHT)
- Valeria Stuardo Ávila, Escuela de Salud Pública, Facultad de Medicina, Universidad de Chile, Santiago, Chile

Talk 2. The methodological framework of Latin American men who have sex with men internet survey (LAMIS) in light of the prior EMIS studies
- Ulrich Marcus, Robert Koch Institute, Berlin, Germany

Talk 3. Implementation of LAMIS as a collaborative effort in Latin American countries
- Carlos Cáceres, Centro de Investigación Interdisciplinaria en Sexualidad, SIDA y Sociedad, Universidad Peruana Cayetano Heredia, Lima, Peru

Talk 4. General results - descriptive analysis of LAMIS 2018: Implications for collaborative public policies in the Latin American region
- Jordi Casabona, Centre d’EstudisEpidemiològics sobrelesInfeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Barcelona, Spain

Talk 5. HIV among MSM and TGW in Brazil: Different approaches, same striking results
- Maria Amélia Veras, Faculdade de Ciências Médicas da Santa Casa de São Paulo, Núcleo de Pesquisa em Direitos Humanos e Saúde LGBT, Brazil

Pre-Congress Symposium 8 - The next frontier of treatment and prevention of sexually transmitted infections: Expedited partner therapy use in heterosexuals, adolescents, men who have sex with men, and transgender women
Location: MR 14

Talk 1. Expedited partner therapy
- Okeoma Mmeje, University of Michigan, USA

Talk 2. MPH expedited partner therapy use in heterosexuals
- Jenell Coleman, Johns Hopkins University, USA

Talk 3. Expedited partner therapy use in adolescents & school-based clinics
- Nicole Speck, University of Michigan, USA

Talk 4. Support for expedited partner therapy use in men who have sex with men & transgender women
- Kristi Gamarel, University of Michigan, USA
- Raha Richardson, University of Michigan, USA

Talk 5. Implications for expedited partner therapy use in men who have sex with men
- Julia Schillinger, Centers for Disease Control and Prevention, USA

Pre-Congress Symposium 9 - Highlights of selected topics from the Canadian STI guidelines
Location: MR 8+15
Chair(s): Max Chernesky, McMaster University, Canada
Margaret Gale-Rowe, PHAC, Canada
Pre-Congress Symposium 10 - IUSTI Canada Symposium: Innovative platforms and interventions against gonorrhoea
Location: MR 8+15

Talk 1. International dissemination of ceftriaxone-resistant *Neisseria gonorrhoeae* strain (FC428)
- Petra Smyczek, Alberta Health Services, Edmonton, Alberta, Canada

Talk 2. What's new in gonococcal antimicrobial resistance and diagnosis of AMR
- Jo-Anne Dillon, Department of Biochemistry, Microbiology and Immunology, University of Saskatchewan, Saskatoon, Canada

Talk 3. New anti-gonococcal antibiotics, discovery and pipeline
- Gerry Wright, McMaster University, Hamilton, Ontario, Canada

Talk 4. Almost Human: Advanced preclinical models for gonococcal vaccine and drug development
- Scott Gray-Owen, University of Toronto, Toronto, Ontario, Canada

Pre-Congress Symposium 11 - Proteomics
Location: MR 14
Chair: Leonard Foster, UBC, Canada

Talk 1. Metaproteomics for discovering mechanisms and biomarkers in the vaginal microbiome
- Adam Burgener, University of Manitoba, Canada

Talk 2. Towards the development of a SISCAPA assay for direct measurement of *T. pallidum* proteins in bodily fluids
- Morty Razavi, SISCAPA Assay Technologies (SAT), Canada

Talk 3. When and how to bring in proteomics
- Leonard Foster, UBC, Canada

Talk 4. Practical considerations for moving proteomic tests into the clinic
- Angela Fung, Clinical Chemist, St. Paul's Hospital, Vancouver, Canada

Pre-Congress Symposium 12 - Sexually transmitted infection vaccines - opportunities for research, development and implementation
Location: MR 1

Opening remarks:
- Troy Grennan & Monika Naus, University of British Columbia & the BC Centre for Disease Control, Canada
13:10 - 13:25 The current landscape of STI vaccines
- Carolyn Deal, National Institute of Allergy and Infectious Diseases, USA

13:25 - 13:40 STI vaccine roadmap
- Sami Gottlieb, World Health Organization, Switzerland

13:40 - 13:55 Will the world accept STI vaccines? Lessons from the HPV vaccine
- Simon Dobson, University of British Columbia, Canada

13:55 - 14:55 STI vaccine development updates: Current science and future directions
- Syphilis: Caroline Cameron, University of Victoria, Canada
- Gonorrhea: Rino Rappuoli, GSK Vaccines, Italy
- Chlamydia: Kevin Hybiske, University of Washington, USA
- HSV: Anna Wald, University of Washington, USA

15:10 - 15:55 Priority setting for future science & research (panel discussion)
- Moderated by: Scott Lamontagne, University of Washington, USA
- Caroline Cameron, University of Victoria, Canada
- Carolyn Deal, National Institute of Allergy and Infectious Diseases, USA
- Rino Rappuoli, GSK Vaccines, Italy
- Peter Dull, Bill & Melinda Gates Foundation

15:55 - 16:40 Implementation challenges in public health (panel discussion)
- Moderated by: Scott Lamontagne, University of Washington, USA
- Sami Gottlieb, World Health Organization, Switzerland
- Bonnie Henry, Government of British Columbia, Canada
- Manish Sadarangani, Vaccine Evaluation Centre, Canada
- Peter Dull, Bill & Melinda Gates Foundation

Closing remarks:
- Manish Sadarangani, Vaccine Evaluation Centre, Canada
- Gina Ogilvie, School of Population and Public Health (SPPH), Canada

13:00 - 17:00

Pre-Congress Symposium 13 - Accelerating development and implementation of point-of-care tests for sexually transmitted infections: Challenges, achievements, and way forward
Location: MR 9

PART I - STI POCT Global State of Affairs
Chair(s):
- Igor Toskin, World Health Organization, Switzerland
- Rosanna Peeling, London School of Hygiene and Tropical Medicine, United Kingdom

13:00 - 13:15 WHO Initiative on STI POCT: vision, progress and way forward
- Igor Toskin, World Health Organization, Switzerland

13:15 - 13:25 Epidemiology of gonococcal infections in infertile populations: Systematic review and meta-analytics
- Hiam S. Chemaitelly, Weill Cornell Medical College, Qatar

13:25 - 13:45 POC diagnostic tests and technologies for sexually transmitted infections: A landscape analysis
- Maurine Murtagh, World Health Organization, Switzerland

13:45 - 14:05 Policy development and Implementation successes and challenges in introducing STI POCTs
- Rosanna Peeling, London School of Hygiene and Tropical Medicine, United Kingdom
14:05 - 14:25 Rapid AMR-test technology to enable immediate accurate treatment and enhance AMR surveillance  
- Tariq Sadiq, St George’s University of London, United Kingdom

14:25 - 14:35 Sample self-collection and STI self-testing  
- Ellen Kersh, Centers for Disease Control and Prevention (CDC), Atlanta, USA

**PART II - Country Perspective and Current WHO STI POCT Evaluation Studies**

*Chair(s):*
- Ranmini Kularatne, Centre for HIV & STIs, National Institute for Communicable Diseases, Johannesburg, South Africa
- Ron Ballard, World Health Organization, Switzerland

15:15 - 15:40 Independent multi-country clinic-based evaluation of STI POCTs: Study design, methodology, research instruments, data management system and current status  
- Soe Soe Thwin, World Health Organization, Switzerland
- Massimo Mirandola, University of Verona, UoV, Italy
- Karel Blondeel, World Health Organization, Switzerland

15:40 - 16:00 Independent multi-country clinic-based evaluation of STI POCTs: internal quality control and external quality assurance:  
- NG/CT/TV: Ellen Kersh, Centers for Disease Control and Prevention (CDC), Atlanta, USA
- HIV/syphilis: Kelly Andrewartha, Flinders University, Adelaide, Australia

16:00 - 16:35 Independent multi-country clinic-based evaluation of STI POCTs, implementation in selected sites:  
- Italy: challenges and opportunities in piloting the study procedures and engaging with MSM in an outpatient setting  
  - Maddalena Cordioli, University of Verona, UoV, Italy
- South Africa: Current status, programmatic needs and challenges  
  - Ranmini Kularatne, Centre for HIV & STIs, National Institute for Communicable Diseases, Johannesburg, South Africa
- Peru  
  - Carlos Cáceres, Universidad Peruana Cayetano Heredia, Peru

16:35 - 16:45 Independent multi-country clinic-utility evaluation of STI diagnostics: study design, methodology, research instruments, data management system and current status  
- Jordi Casabona, Centre d’Estudis Epidemiològics sobre les ITS i Sida de Catalunya, CEEISCAT, Spain

**Pre-Congress Symposium 14 - Preparing Sexual Health Services for Antimicrobial Resistance Bacteria: A Global Perspective**

*Location: MR 2+3*

*Organizing committee: Dr Katy Turner, Prof Nicola Low, Dr Yonatan Grad, Prof Teodora Wi, Prof Magnus Unemo, Dr Minttu Ronn*

13:00 - 17:00

13:00 Session 1 - Setting the scene

Talk 1. WHO perspectives on the threat of AMR – global challenges of surveillance  
- Teodora Wi, World Health Organization, Switzerland
Talk 2. Antimicrobial resistance in *Neisseria gonorrhoeae* and *Mycoplasma genitalium*
- Magnus Unemo, World Health Organization Collaborating Centre for Gonorrhoea and Other STIs, Örebro University, Sweden

Talk 3. Epidemiological trends in AMR in *Neisseria gonorrhoeae* and implications for services
- Nicola Low, University of Bern, Switzerland

13:45 Quantifying the surveillance needed to sustain genetic marker-based antibiotic resistance diagnostics
- Yonatan Grad, Harvard T.H. Chan School of Public Health, USA

13:50 Modelling evolution of resistance over time in *N. gonorrhoeae*
- Lilith Whitting, Imperial College London, UK

14:00 Modelling the impact of resistance on gonorrhoea epidemiology
- Katy Turner, University of Bristol, UK

14:00 Session 2 - Global perspective

14:30 Modelling vaccination as a way to control AMR
- Laith Abu Raddad, Weill Cornell Medical College, Qatar

14:45 Impact of vaccination on the sustainable transmission of Neisseria gonorrhoeae [Neisseria gonorrhoea in italics] drug-resistant strains
- Shaheen Seedat, Stellenbosch University, South Africa

14:55 The Brazilian public health policy for gonorrhea
- Pâmela Cristina Gaspar, Ministry of Health, Brazil

15:10 Gonorrhea in the era of AMR, diagnostic needs for improved antimicrobial stewardship in low and middle income countries
- Cecilia Ferreyra, FIND, Switzerland

13:00 - 17:00

**Pre-Congress Symposium 15 - Understanding the costs and benefits of sexual health services and interventions: A guide for clinicians and researchers**

*Location: MR 13*

*Organized by Dr Louise Jackson*

13:00 - 13:15 The economics of sexual health services and interventions – a service perspective
- Jonathan Ross, University of Birmingham, UK

13:15 - 14:00 Overview of key principles in analysing costs and benefits in Sexual Health
- Tracy Roberts, University of Birmingham, UK

14:00 - 14:45 A practical guide to collecting and analysing data on costs and benefits
- Louise Jackson, University of Birmingham, UK

15:00 - 16:00 Activity – analysing an economic study

16:00 - 16:40 Workshop – developing an evaluation

16:40 - 17:00 Synthesis & next steps
- Jonathan Ross, University of Birmingham, UK
- Tracy Roberts, University of Birmingham, UK
Pre-Congress Symposium 16 - BS21 Network: Behavioural surveillance for HIV and STIs in the 21st century
Location: MR 7

Talk 1. Introduction to contemporary behavioural surveillance
- Lisa McDaid, University of Glasgow, UK
- Nathan Lachowsky, University of Victoria, Canada

Talk 2. The current state of behavioural surveillance (panel discussion)
- Nathan Lachowsky, University of Victoria, Canada
- Patrick Sullivan, Emory University, USA
- Benjamin Bavinton, Kirby Institute, Australia
- Peter Saxton, University of Auckland, New Zealand
- Jamie Frankis, Glasgow Caledonian University, UK

Talk 3. Changing HIV epidemics and representativeness of behavioural surveillance research (panel discussion)
- Peter Saxton, University of Auckland, New Zealand
- Nathan Lachowsky, University of Victoria, Canada
- Jamie Frankis, Glasgow Caledonian University, UK

Talk 4. Why do we still need behavioural surveillance in the age of biomedical HIV prevention? (panel discussion)
- Benjamin Bavinton, Kirby Institute, Australia
- Jamie Frankis, Glasgow Caledonian University, UK
- Patrick Sullivan, Emory University, USA

Talk 5. Neglected populations and regions (panel discussion)
- Jacqueline Gahagan, Dalhousie University, Canada
- Tyrone Curtis, University College London, UK
- Harlan Pruden, BC Centre for Disease Control, Canada
- Patrick Sullivan, Emory University, USA
- Jamie Frankis, Glasgow Caledonian University, UK
- John Kim, Public Health Agency of Canada, Canada

Talk 7. Community engagement in behavioural surveillance research (panel discussion)
- David Brennan, University of Toronto, Canada
- Jeff Morgan, CBRC - Community Based Research Centre for Gay Men's Health, Canada
- Lisa McDaid, University of Glasgow, UK

Talk 8. Application of theoretical models to periodic behavioural surveillance and what is missed if you do not have one (panel discussion)
- Paul Flowers, Glasgow Caledonian University, UK
- Kiffer Card, Simon Fraser University, Canada

LOCATION: BALLROOM

17:30 - 18:30
Welcome Ceremony
Chairpersons: Caroline Cameron, ISSTDR President and Congress President, and Charlotte Gaydos, IUSTI President and Congress Co-President

18:30 - 19:30
K01 Opening Keynote Lecture
Chairpersons: Caroline Cameron, President, International Society for Sexually Transmitted Diseases Research, University of Victoria, Canada and Henry de Vries, STI & HIV 2021 World Congress President, Amsterdam University Medical Centers, The Netherlands
2019 ISSTDR PRESTIGIOUS LECTURE: BACTERIAL STI VACCINES - ETERNAL DREAM OR FUTURE REALITY?
Rino Rappuoli, GSK Vaccines, Italy

19:30 - 21:00
Welcome Reception
Location: Exhibit Hall A
MONDAY, JULY 15, 2019

07:00 - 08:00

CCS01 Clinical Case Series - Syphilis: The great imitator
Location: MR 8+15
Chairpersons: Stephanie Cohen, San Francisco Department of Public Health, USA and Khalil Ghanem, Johns Hopkins University, USA

CCS01.1 Neurosyphilis is more common among malignant syphilis: Based on case series evidence
- Pingyu Zhou, Shanghai Skin Disease Hospital, China

CCS01.2 A case series of syphilis masquerading as thoracic malignancy
- Jessica Doctor, Guys’ and St Thomas’s NHS Foundation Trust, UK

CCS01.3 Syphilis as fibromyalgia with unexplained hepatosplenomegaly
- Jackie Sherrard, Buckinghamshire Healthcare NHS Trust, UK

LOCATION: BALLROOM

08:15 - 08:50

PL01.1 Plenary 1
Chairperson: Sheila Lukehart, University of Washington, USA
The role of genomics in the diagnosis and management of STIs
Helena Seth-Smith, University Hospital Basel, Switzerland

08:50 - 09:25

PL02.1 Plenary 2
Chairperson: Edward Hook, University of Alabama at Birmingham, USA
Identification and management of complicated syphilis
Christina Marra, University of Washington, USA

09:25 - 10:00

PL03.1 Plenary 3
Chairperson: James Ward, South Australian Health and Medical Research Institute, Australia
Engaging indigenous communities in health programs
Charlotte Loppie, University of Victoria, Canada

10:00 - 10:15

Welcome by Elder, Coast Salish Nations
Chairperson: Mark Gilbert, BCCDC, Canada

10:15 - 10:45

Coffee Break
Location: Exhibit Hall A
S01 Symposium 1
Program science/implementation science methods: Moving beyond the traditional RCT
Chairpersons: Nicola Low, Institute of Social and Preventative Medicine, Switzerland and Marissa Becker, University of Manitoba, Canada
Location: MR 11+12

S01.1 Must the evaluation of complex interventions be complex? Learning from the impact evaluation of DREAMS
- Isolde Birdthistle, The London School of Hygiene & Tropical Medicine, UK

S01.2 HPTN 071 (PopART): Findings and lessons from a non-traditional RCT
- Richard Hayes, The London School of Hygiene & Tropical Medicine, UK

S01.3 Using multiple data sources for program evaluation: Integration of program monitoring data with other research studies
- Banadakoppa Ramesh, University of Manitoba, Canada

S01.4 Evaluating complex public health issue violence - understanding and measuring violence and evaluating violence interventions - lessons from STRIVE
- Sinead Delany-Moretlwe, Wits Reproductive Health and HIV Institute, South Africa

S02 Symposium 2
HIV and syphilis self-testing and self-collection: Empowerment, agency and implementation
Chairpersons: Judith Wasserheit, University of Washington, USA and Adele Schwartz Benzaken, Tropical Medicine Foundation, Brazil
Location: MR 1

S02.1 HIV self-testing in Eastern and Southern Africa: The STAR project
- Maryam Shahmanesh, Institute for Global Health, University College London, UK

S02.2 Syphilis self-testing: A nationwide pragmatic study among men who have sex with men in China
- Cheng Wang, Southern Medical University, China

S02.3 HPV self-collection in Peru: Project HOPE
- Patricia Garcia, Universidad Peruana Cayetano Heredia, Peru

S02.4 Empowerment and approaches for stigma reduction: Implementation of HIV self-testing among female sex workers
- Catherine Oldenburg, University of California, San Francisco, USA

S03 Symposium 3
Epidemiological aspects of STI transmission in MSM
Chairpersons: Gwenda Hughes, Public Health England, UK and Maarten Schim van der Loeff, Center for Infection and Immunity Amsterdam, Academic Medical Center, Amsterdam, The Netherlands
Location: Ballroom

S03.1 Impact of HIV PrEP on risk compensation and STI epidemiology – what does the evidence show?
- Helen Ward, Imperial College London, UK

S03.2 The role of oral-anal transmission in persistence of chlamydial infection
- Henry de Vries, University of Amsterdam, Netherlands

S03.3 Sexual transmission of N. meningitidis in MSM and implications for public health
- Anna McNulty, Sydney Sexual Health Centre, Australia

S03.4 Hepatitis C in HIV-negative MSM – a growing concern?
- Axel J. Schmidt, London School of Hygiene & Tropical Medicine, UK
S04 Symposium 4
The impact of advances in diagnostic technology on policy, program and practice (ISSTDR Special Symposium)
Chairpersons: Barbara van der Pol, University of Alabama at Birmingham, USA and Rosanna Peeling, London School of Hygiene & Tropical Medicine, UK
Location: MR 2+3

S04.1 Resistance-guided therapy for *M. genitalium*: Impact of diagnostic resistance assays on practice and policy
- Catriona Bradshaw, Central Clinical School, Monash University, Australia

S04.2 Point of care and home testing opportunities: Implications for quality public health practice
- Patricia Dittus, Centers for Disease Control and Prevention, USA

S04.3 Home based testing: Unintended consequences and implications for antimicrobial stewardship – should we be concerned?
- Paddy Horner, Population Health Sciences, University of Bristol, UK

S04.4 Implementing molecular testing to predict *Neisseria gonorrhoeae* susceptibility in clinical practice
- Jeffrey D. Klausner, UCLA - David Geffen School Of Medicine, USA

001 Oral Presentation Session 1
Development of vaccines for bacterial STIs
Chairpersons: Carolyn Deal, National Institute of Allergy and Infectious Diseases, USA and Kate Seib, Griffith University, Australia
Location: MR 8+15

001.1 Genetic similarity of gonococcal homologs to meningococcal outer membrane proteins of serogroup B vaccine
- Henju Marjuki, Centers for Disease Control and Prevention, USA

001.2 Genetic, structural, and surface antigenic variation of *Treponema pallidum*’s OMPeome: Steps towards a global syphilis vaccine
- Kelly Hawley, Connecticut Children’s Medical Center, USA

001.3 Engineering hybrid bacterial transferrin receptor-based vaccines to confer broad protection against *Neisseria gonorrhoeae*
- Scott Gray-Owen, University of Toronto, Canada

001.4 Rabbit immunization with *B. burgdorferi* expressing *T. pallidum* TprK and Tp0435 as a novel vaccine design for syphilis
- Lorenzo Giacani, University of Washington, USA

001.6 A meningococcal native outer membrane vesicle vaccine as a platform for presenting conserved gonococcal antigens
- Gregory Moe, UCSF Benioff Children's Hospital Oakland, USA

001.6 Meningococcal vesicle vaccines deleted for major outer membrane proteins enhance gonococcal clearance in a murine model
- Kathryn Matthias, US Food and Drug Administration, USA

002 Oral Presentation Session 2
Extragenital bacterial STIs: Epidemiology, natural history, testing and antimicrobial resistance
Chairpersons: Jackie Sherrard, Bucks Healthcare NHS Trust, UK and Remco Peters, Anova Health Institute and University of Pretoria, South Africa
Location: MR 13

002.1 What Is the optimal testing strategy for oropharyngeal *Neisseria gonorrhoeae* in women visiting STI clinics?
- Christian Hoebe, Public Health Service South Limburg, Maastricht University Medical Center (MUMC+), The Netherlands
002.2 Oropharyngeal and genital gonorrhoea among heterosexuals who report sexual contact with partners with gonorrhoea
- Eric Chow, Monash University, Australia

002.3 Antimicrobial resistance in pharyngeal Neisseria gonorrhoeae infection: A cross-sectional study in men who have sex with men
- Hester Allen, Public Health England, UK

002.4 Incidence and duration of pharyngeal and rectal gonorrhea and chlamydia among high-risk men who have sex with men (MSM)
- Lindley Barbee, University of Washington, USA

002.5 Inflammatory cytokines in rectal gonorrhea/chlamydia infection and treatment: Towards STI control as HIV prevention for MSM
- Jesse Clark, UCLA Geffen School of Medicine, USA

002.6 Exogenous Mycoplasma genitalium infections amongst men who have sex with men
- Rosie Latimer, Monash University, Australia

10:45 - 12:15
Break

12:15 - 13:45

003 Oral Presentation Session 3
Persistence and resistance
Chairpersons: Anna Maria Geretti, University Of Liverpool, UK and Ranmini Kularatne, National Institute for Communicable Diseases, South Africa
Location: MR 9

003.1 Natural history of genital and oral herpes simplex virus-1 (HSV-1) shedding after first episode genital HSV-1 infection
- Christine Johnston, University of Washington, USA

003.2 Detection of glycosylated Treponema pallidum proteins: Relevance for diagnostic assays and importance for infection
- Alloysius Gomez, University of Victoria, Canada

003.3 The European gonococcal antimicrobial surveillance programme findings 2017
- Michaela Day, Public Health England, UK

003.4 Modelling intervention strategies for preventing spread of extensively drug resistant gonorrhoea strains among Australian MSM
- Qibin Duan, University of New South Wales, Sydney, Australia

003.5 Utility of real-time whole genome sequencing in partner notification and control of Neisseria gonorrhoeae infection
- Ling Yuan Kong, Leeds Teaching Hospitals NHS Trust, UK

003.6 Vaginal bacteria and risk of incident and persistent infection with high risk sub-types of human papillomavirus
- Kayla Carter, University of Washington, USA

13:45 - 14:20

PL04.1 Plenary 4
Chairperson: Janet Wilson (IUSTI President-Elect), Leeds Teaching Hospitals NHS Trust, UK
2019 IUSTI Prestigious Lecture - Revising STI treatment guidelines in times of rapidly evolving antimicrobial resistant STIs
Jørgen Jensen, Statens Serum Institut, Denmark
14:20 - 14:55  
**PL05.1 Plenary 5**  
Chairperson: Maria Amelia de Sousa Mascena Veras, Faculdade De Ciências Médicas Da Santa Casa De São Paulo, Brazil  
**Priorities for research and programmes for trans communities**  
Tonia Poteat, University of North Carolina, USA

14:55 - 15:30  
**PL06.1 Plenary 6**  
Chairperson: Sevgi Aral, CDC, USA  
**Mathematical modelling, a luxury or a necessity in STD control?**  
Geoff Garnett, Bill & Melinda Gates Foundation, USA

15:30 - 16:15  
**Coffee Break**  
Location: Exhibit Hall A

16:15 - 17:45  
**S05 Symposium 5**  
Community engagement, mobilization and empowerment  
Chairpersons: Maryam Shahmanesh, Institute for Global Health, University College London, UK and Igor Toskin, WHO, Switzerland  
Location: MR 2+3  
S05.1 Working with community to control HIV/STI: A U.S. local health department perspective  
- Matthew Golden, University of Washington, USA  
S05.2 Mobilising for health and rights: A history of sex worker activism in India  
- Smarajit Jana, Sonagachi Research and Training Institute, India  
S05.3 Mobilization and empowerment of sex workers: Can self-help groups bring about sustained change?  
- Primrose Matambanadzo, CeSHHAR, Zimbabwe  
S05.4 #SaveSexy: A gamified approach to harnessing the power of community activism for HIV testing promotion  
- Benedict Bernabe, Red Whistle, Philippines

16:15 - 17:45  
**S06 Symposium 6**  
Improved models and tools for STI infections  
Chairpersons: Nicholas Thomson, Wellcome Sanger Institute, UK and Lorenzo Giacani, University of Washington, USA  
Location: MR 9  
S06.1 Use of cervical explants to study gonococcal pathogenesis  
- Daniel Stein, University of Maryland, USA  
S06.2 T. pallidum in vitro growth  
- Steven Norris, University of Texas, USA  
S06.3 Pigtailed macaque model of STIs  
- Dorothy Patton, University of Washington, USA  
S06.4 Chlamydia, trichomonas and syphilis infections in macaques: Effects on simian HIV acquisition  
- Sundaram Ajay Vishwanathan, Center for Disease Control and Prevention, USA
**S07 Symposium 7**

Sexual health at the intersection of substance use and social inequality

*Chairpersons: Mark Pakianathan, The London School of Hygiene & Tropical Medicine, UK and Vincent Cornelisse, Kirketon Road Centre, Australia*

*Location: Ballroom*

- **S07.1** The North American overdose crisis: How structural violence, prohibition and stigma have paralyzed our response
  - Mark Tyndall, BC Centre for Disease Control, Canada

- **S07.2** Chemsex and new STI/HIV diagnoses among gay, bisexual and other men who have sex with men attending sexual health clinics
  - Aseel Hegazi, St George’s University Hospital Foundation Trust, UK

- **S07.3** Challenges in defining Chemsex. Answers for surveillance from EMIS-2017
  - Axel Schmidt, London School of Hygiene & Tropical Medicine, UK

- **S07.4** Review of sexualized drug use associated with sexually transmitted infections (STI) in men who have sex with men (MSM)
  - Fiona Guerra, Public Health Ontario, Canada

**004 Oral Presentation Session 4**

Antimicrobial resistance in STI pathogens

*Chairpersons: Jo-Anne Dillon, University Of Saskatchewan, Canada and Tariq Sadiq, St George's, University of London, UK*

*Location: MR 1*

- **004.1** Novel pathway to ceftriaxone resistance in clinical isolates of *N. gonorrhoeae* via point mutations in the RNA polymerase
  - Yonatan Grad, Harvard T.H. Chan School of Public Health, USA

- **004.2** Phylogenomic analysis reveals persistence of *Neisseria gonorrhoeae* clades with reduced susceptibility to cephalosporins
  - Jesse Thomas, US Centers for Disease Control and Prevention, USA

- **004.3** Prioritizing novel drug targets based on genomics and proteomics approach in *Neisseria gonorrhoeae*
  - Daman Saluja, University of Delhi, India

- **004.4** *Mycoplasma genitalium parC* and *gyrA* mutations associated with moxifloxacin and sitafloxacin treatment failure
  - Gerald Murray, The Royal Women’s Hospital, Australia

- **004.5** Point-of-care magnetofluidic assay cartridge for *Neisseria gonorrhoeae* detection and antimicrobial resistance determination
  - Alexander Trick, Johns Hopkins University, USA

- **004.6** Prediction of available drug targets of *Neisseria gonorrhoeae* based on codon usage parameter
  - Uma Chaudhry, Bhaskaracharya College of Applied Sciences, University of Delhi, India

**005 Oral Presentation Session 5**

Female genital infections, immunology and microbiome

*Chairpersons: Rebecca Brotman, University of Maryland School of Medicine, USA and Yaw Adut Sarkodie, Kwame Nkrumah University of Science and Technology, Ghana*

*Location: MR 13*

- **005.1** Lower genital tract predictors of acute endometritis among women with signs and symptoms of pelvic inflammatory disease (PID)
  - Sharon Hillier, University of Pittsburgh and Magee-Womens Research Institute, USA
005.2 Characterizing the impact of penile-vaginal sex on HIV-susceptible CD4+ T Cell subsets in the female genital tract
- Avid Mohammadi, University Of Toronto, Canada

005.3 The combined contraceptive vaginal ring increases Th17-related cytokines in the genital tract: A randomized crossover trial
- Iyaloo Konstantinus, University of Cape Town, South Africa

005.4 The effect of the combined oral contraceptive pill on the vaginal microbiota of women treated for bacterial vaginosis
- Larissa Ratten, Monash University, Australia

005.5 A case control study to examine the cervico-vaginal microbiota associated with pelvic inflammatory disease
- Sally Sweeney, Family Planning New South Wales, Australia

005.6 Cervicovaginal metabolic profiling reveals the interplay between HPV, microbiota and inflammation in cervical carcinogenesis
- Melissa Herbst-Kralovetz, University of Arizona, USA

16:15 - 17:45

**006 Oral Presentation Session 6**
**STI/HIV treatment efficacy and effectiveness**
*Chairpersons: Jonathan Ross, University of Birmingham, UK and Catriona Bradshaw, Melbourne Sexual Health Centre, Australia*
*Location: MR 11+12*

006.1 Gentamicin for pharyngeal gonorrhea: A single-arm, non-blinded clinical trial
- Lindley Barbee, University of Washington, USA

006.2 In vitro combination testing and selection of resistance to zoliflodacin combined with six antimicrobials for *N. gonorrhoeae*
- Magnus Unemo, World Health Organization Collaborating Centre for Gonorrhoea and Other STIs, Örebro University, Sweden

006.3 Efficacy of resistance guided therapy for *Mycoplasma genitalium* using doxycycline followed by azithromycin or moxifloxacin
- Duygu Durukan, Monash University, Australia

006.4 Efficacy and cost-effectiveness of qHPV vaccine with imiquimod or podophyllotoxin for patients with anogenital warts (HIPvac)
- Richard Gilson, University College London, UK

006.5 Do treatment rates suffer in a low-touch screening model? New York City sexual health clinics, 2017-2018
- Kelly Jamison, New York City Department of Health and Mental Hygiene, USA

006.6 Reduction in adherence to antiretroviral therapy during postpartum: Findings from a prospective cohort study
- Anthony Ajayi, University of Fort Hare, South Africa

16:15 - 17:45

**007 Oral Presentation Session 7**
**Bugs, behaviour and beyond: New challenges for STI control among gay, bisexual and other men who have sex with men**
*Chairpersons: Nigel Field, University College London, UK and Chris Bourne, Centre For Population Health, Australia*
*Location: MR 8+15*

007.1 Multiple lineages of multiresistant shigella in Australia
- Deborah Williamson, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Australia
007.2 Use of whole-genome sequencing to identify sexual transmission of shigella in men who have sex with men in England
- Holly Mitchell, University College London, UK

007.3 Sexually transmissible enteric infections in men who have sex with men: Preliminary findings from a cross-sectional study
- Holly Mitchell, University College London, UK

007.4 Incidence of sexual behaviors and relationship to the urethral microbiota among men who have sex with men (MSM) in Seattle
- Laura Chambers, University of Washington, USA

007.5 The index case's partnership status is important in predicting the likelihood of persistence of introduced XDR NG among MSM
- Ben Hui, University of New South Wales, Sydney, Australia

007.6 A RCT to facilitate psychosocial care among high risk MSM in Amsterdam, a SYNdemic BASISed INtervention (Syn.bas.In Study)
- Roel Achterbergh, Public Health Service of Amsterdam, The Netherlands

17:45 - 19:00

PS01 Poster Viewing Session
Location: Exhibit Hall A

TUESDAY, JULY 16, 2019

07:00 - 08:00

CCS02 Clinical Case Series
Clinical cases from experts
Chairpersons: Julie Dombrowski, University of Washington, USA and Kees Rietmeijer, Rietmeijer Consulting, USA
Location: MR 8+15

CCS02.1 Dequalinium chloride vaginal tablets for recalcitrant Trichomonas vaginalis (TV): A case report
- Deborah Goode, Leeds Teaching Hospitals Trust, UK

CCS02.2 Penile intraepithelial neoplasia: Myriad presentations and intractable course
- Somesh Gupta, All India Institute of Medical Sciences, India

CCS02.3 Persisting urethritis in an immunocompromised patient
- William Geisler, University of Alabama at Birmingham, USA

08:15 - 08:50

PL07.1 Plenary 7
Chairperson: Thomas Quinn, NIH, USA
Global trends in HIV in the era of combination prevention – what progress have we made towards elimination?
Wafaa El-Sadr, Columbia University, USA

08:50 - 10:00

PL08 Plenary 8
#MeToo movement, systems of power and sexual health and wellbeing: The widening of the #MeToo movement
Moderator: Jacky Jennings, Johns Hopkins School of Medicine, USA

Panel:
- Rebecca Thurston, University of Pittsburgh, USA
- Irin Carmon, New York Magazine & CNN Contributor, USA
Welcome by Elder, Coast Salish Nations
Chairperson: Ameeta Singh, University of Alberta, Canada

Coffee Break
Location: Exhibit Hall A

S08 Symposium 8
“Elders teach and youth reach”: Indigenous conversations on sexual health
Chairpersons: Elder Roberta Price, Indigenous Co-Lead for the Family Medicine Residency Program, Canada and Larissa Wahpooseyan, Youthco, Canada
Location: MR 2+3

The idea for this symposium was developed through discussion with Elders from the Aboriginal Health Elders Advisory Council at Vancouver Coastal Health. This Council includes Elders from the Coast Salish peoples on whose land this conference is held, specifically the Sḵwx̱wú7mesh (Squamish), Sel̓íl̓witulh (Tselel-Waututh), and xʷməθkʷəy̓əm (Musqueam) Nations, and from Nations from the Four Directions.

The Aboriginal Health Elders Advisory Council will be leading this symposium in partnership with the Yuúsnewas program at YouthCO HIV & Hep C Society. The Yuúsnewas program is an Indigenous youth-led program that centres Indigenous teachings in conversations about sexual health and harm reduction. Through workshops and cultural activities, this team of educators creates spaces for all Indigenous young people to develop solutions to the impacts of HIV and Hep C stigma on youth in what is now called British Columbia.

Support:
Organization of this symposium is supported by members of the Conference nə́c̓aʔmat ct Indigenous Sexual Health Committee. Financial support for this symposium is provided by the BC Centre for Disease Control, First Nations Health Authority, Indigenous Services Canada, and the Vancouver Foundation.

S09 Symposium 9
Prevention and care cascades
Chairpersons: Rebecca Guy, Kirby Institute, Australia and Nathan Lachowsky, University of Victoria / CBRC, Canada
Location: MR 11+12

S09.1 The relationship between demographics, health needs and the HIV care cascade outcomes: From infection to viral suppression
- Abigail Kroch, Ontario HIV Treatment Network (OHTN), Canada

S09.2 Cascade of HIV prevention: A powerful tool to improve the implementation of DREAMS combination prevention in rural South Africa
- Maryam Shahmanesh, Institute for Global Health, University College London, UK

S09.3 Application of a cascade approach for guiding prevention of congenital syphilis
- Patricia Garcia, Universidad Peruana Cayetano Heredia, Peru

S09.4 Cascades and other approaches to guide PrEP programming
- Sinead Delany-Moretlwe, Wits Reproductive Health and HIV Institute,

S10 Symposium 10
STIs in low and middle-income countries: Resurgent infections and evolving control measures
Chairpersons: Craig Cohen, UCSF, USA and Teodora Wi, World Health Organization, Switzerland
Location: MR 8+15

S10.1 High rates of curable STIs in low and middle income countries
- Connie Celum, University of Washington, USA
S10.2 Building STD clinical infrastructure in LMIC – role of general vs. specialized infrastructure
- Ligang Yang, Southern Medical University, China

S10.3 Cervical cancer prevention in LMICS: Are we on the path to elimination?
- Megan Huchko, Duke University, USA

S10.4 Self-care interventions for sexual and reproductive health and rights
- Manjulaa Narasimhan, World Health Organization, Switzerland

10:45 - 12:15

S11 Symposium 11
Research on the vaginal microbiome: Advances & controversies
Chairpersons: Jeanne Marrazzo, University of Alabama at Birmingham, USA and Sharon Hillier, University of Pittsburgh School of Medicine, USA
Location: MR 1

S11.1 Introduction to the vaginal microbiome preconference symposium
- Jeanne Marrazzo, University of Alabama at Birmingham School of Medicine, USA

S11.2 Lessons learned from the pre-meeting symposium on characterizing the vaginal microbiota through a blinded multi-laboratory collaboration
- Jen Balkus, University of Washington, USA

S11.3 The vaginal microenvironment prior to incident STI
- Rebecca Brotman, University of Maryland School of Medicine, USA

S11.4 Role of the genital tract microbiome in sexual and reproductive health: Report from the Keystone Symposium in Cape Town, 2018
- Janneke van de Wijgert, University of Liverpool, UK and University Medical Center Utrecht, The Netherlands

10:45 - 12:15

O08 Oral Presentation Session 8
Getting real with implementing PrEP 1: Gay, bisexual and other men who have sex with men
Chairpersons: Susan Blank, NYC Dept Of Health & Mental Hygiene, USA and Gilbert Yang, Skin/STD Clinic, Philippines
Location: Ballroom

O08.1 Pre-exposure prophylaxis in Brazil: Opportunities and challenges for men who have sex with men, Brazil, 2018
- Diego Calixto, Ministry of Health of Brazil, Brazil

O08.2 Sexual behaviour, risk and sexually transmitted infections before and after the introduction of the PrEP impact trial
- Louis MacGregor, University of Bristol, UK

O08.3 Rates of chlamydia and gonorrhea testing and positivity before and after initiation of PrEP among MSM in US private settings
- Guoyu Tao, Centers for Disease Control and Prevention, USA

O08.4 Influence of HIV-status and PrEP use on high STI prevalences in MSM in Germany, 2018
- Klaus Jansen, Robert Koch Institute, Germany

O08.5 Trends in bacterial STI incidence and impact of PrEP use among MSM attending Western Sydney Sexual Health Centre (2013-2018)
- David Lewis, Western Sydney Local Health District, Australia

O08.6 Frequency and determinants of switching between daily or event-driven PrEP and discontinuing each regimen in Amsterdam MSM
- Liza Coyer, Public Health Service of Amsterdam, The Netherlands
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 - 12:15</td>
<td><strong>O09 Oral Presentation Session 9</strong>&lt;br&gt;Epidemiology and surveillance to inform practice and policy&lt;br&gt;<em>Chairpersons: Viviane Bremer, Robert Koch-institute, Germany and Hannelore Götz, Public Health Service Rotterdam-Rijnmond, The Netherlands</em>&lt;br&gt;<em>Location: MR 13</em>&lt;br&gt;- 009.1 The Netherlands chlamydia cohort study: Pregnancies in women with and without a previous chlamydia infection&lt;br&gt;  - Bernice Hoenderboom, National Institute for Public Health and the Environment, The Netherlands&lt;br&gt;- 009.2 Declines in chlamydia-associated PID at SSHS in England since 2007: What might this tell us about chlamydia control?&lt;br&gt;  - Paddy Horner, University of Bristol, UK&lt;br&gt;- 009.3 Potential <em>Neisseria gonorrhoeae</em> outbreak in heterosexuals younger than 25 revealed three clusters by culture-free genotyping&lt;br&gt;  - Brian Van Der Veer, Maastricht University Medical Center (MUMC+), The Netherlands&lt;br&gt;- 009.4 HIV and HCV among clients of female sex workers in Dnipro, Ukraine&lt;br&gt;  - Marissa Becker, University of Manitoba, Canada&lt;br&gt;- 009.5 Hepatitis C incidence rate among people who inject drug (PWID) in British Columbia from 2000 to 2015&lt;br&gt;  - YiQiao Li, British Columbia Center for Disease Control, Canada&lt;br&gt;- 009.6 Development of an integrated data mart for surveillance of sexually transmitted and bloodborne infections (STIBBI)&lt;br&gt;  - Jason Wong, BC Centre for Disease Control, Canada</td>
</tr>
<tr>
<td>12:15 - 13:45</td>
<td><strong>ASTDA Awards Luncheon</strong>&lt;br&gt;<em>Location: Ballroom C (West Building)</em></td>
</tr>
<tr>
<td>13:45 - 14:20</td>
<td><strong>PL09.1 Plenary 9</strong>&lt;br&gt;<em>Chairperson: William Geisler, University of Alabama at Birmingham, USA</em>&lt;br&gt;<em>Understanding chlamydia pathogenesis</em>&lt;br&gt;Kevin Hybiske, University of Washington, USA</td>
</tr>
<tr>
<td>14:20 - 14:55</td>
<td><strong>PL10.1 Plenary 10</strong>&lt;br&gt;<em>Chairperson: Sinead Delany-Moretlwe, Wits Reproductive Health and HIV Institute, South Africa</em>&lt;br&gt;<em>The global HIV response at 40</em>&lt;br&gt;David Wilson, World Bank, USA</td>
</tr>
<tr>
<td>14:55 - 15:30</td>
<td><strong>PL11.1 Plenary 11</strong>&lt;br&gt;<em>Chairperson: King Holmes, University of Washington, USA</em>&lt;br&gt;<em>Global health legacies, sustainable development goals, and implications for sexual &amp; reproductive health</em>&lt;br&gt;David Peters, Johns Hopkins University, USA</td>
</tr>
<tr>
<td>15:30 - 16:15</td>
<td><strong>Coffee Break</strong>&lt;br&gt;<em>Location: Exhibit Hall A</em></td>
</tr>
</tbody>
</table>
**SCIENTIFIC PROGRAM (TUESDAY)**

**S12 Symposium 12**
New approaches for STI vaccines  
*Chairpersons: Anna Wald, University of Washington, USA and Sami Gottlieb, World Health Organization, Switzerland*  
*Location: MR 2+3*

S12.1 Progress towards a gonorrhea vaccine  
- Kate Seib, Griffith University, Australia  

S12.2 A tri-antigen protective syphilis vaccine design that enhances treponemal clearance and inhibits pathogen dissemination  
- Lorenzo Giacani, University of Washington, USA  

S12.3 Therapeutic vaccination to treat HPV disease: Lessons learned from high grade intraepithelial lesions  
- Margaret Madeleine (STI & HIV 2019 World Congress Scholarship Recipient), Fred Hutchinson Cancer Research Center, USA  

S12.4 A mucosal *Chlamydia trachomatis* vaccine stimulates protective memory T cells  
- Michael Starnbach, Harvard University, USA

**S13 Symposium 13**
Controversies in clinical STI care  
*Chairpersons: Matthew Golden, University of Washington, USA and Christopher Fairley, Monash University, Australia*  
*Location: MR 11+12*

S13.1 Does azithromycin have a future in the treatment of gonorrhoea and chlamydial infection?  
- Jane Hocking, University of Melbourne, Australia  

S13.2 Should enteric infections in MSM always be treated?  
- Mark Pakianathan, The London School of Hygiene & Tropical Medicine, UK  

S13.3 Do rectal bacterial STIs in women matter? Who should we test and when?  
- Christine Khosropour, University of Washington, USA  

S13.4 HPV vaccination in MSM: Who should be vaccinated and is there a role for vaccination of older and/or HIV-positive MSM in preventing initial, persistent and recurrent HPV and related diseases?  
- David Templeton, University of Sydney, Australia

**S14 Symposium 14**
Sexual networks and STI transmission: From modelling to practice  
*Chairpersons: Katy Turner, University of Bristol, UK and Laith Abu-Raddad, Weill Cornell Medicine, Qatar*  
*Location: Ballroom*

S14.1 Sexual contact networks, STI transmission and the effectiveness of interventions: Insights from mathematical modelling  
- Christian Althaus, University of Bern, Switzerland  

S14.2 Use of whole genome sequencing to explore transmission between sexual networks in an STI outbreak  
- Helen Fifer, Public Health England, UK
O10 Oral Presentation Session 10
Getting real with implementing PrEP 2
Chairpersons: Bradley Stoner, St. Louis STD/HIV Prevention Training Center, USA and Catherine O’Connor, Kirby Institute, Australia
Location: MR 8+15

O10.1 HIV pre-exposure prophylaxis (PrEP) indications and uptake vary by race, gender and insurance in a large clinic network
- Maria Pyra, Howard Brown Health, USA

O10.2 Impact of HIV-PrEP for female-sex-workers on community-wide awareness, uptake and perceptions in a rural-area KwaZulu-Natal
- Natsayi Chimbindi, Africa Health Research Institute (AHRI), South Africa

O10.3 High curable STI prevalence and incidence among young African women initiating PrEP in HPTN 082
- Sinead Delany-Moretlwe, University of the Witwatersrand, South Africa

O10.4 Scaling up HCV screening and treatment for eliminating HCV among MSM in UK in the era of HIV pre-exposure prophylaxis
- Louis MacGregor, University of Bristol, UK

O10.5 Patterns of HIV pre-exposure prophylaxis care one year after initiating PrEP, Baltimore City, Maryland 2015-2018
- Linxuan Wu, Johns Hopkins University School of Medicine, USA

O10.6 A longitudinal analysis of men who have sex with men’s condom use and attitudes during HIV antiretroviral prevention scale-up
- Nathan Lachowsky, University of Victoria, Canada

O11 Oral Presentation Session 11
Improving the equity and effectiveness of sexual health care
Chairpersons: Elizabeth Foley, Solent NHS Trust, UK and Peter Saxton, University of Auckland, New Zealand
Location: MR 1

O11.1 An update on the performance of STI services for gay and bisexual men across 40 cities: Preliminary results from EMIS-2017
- Jason Doran, London School of Hygiene & Tropical Medicine, UK

O11.2 How do the sexual networks of men who have sex with men in one mid-Atlantic city differ by race/ethnicity?
- Jessica Wagner, Johns Hopkins University School of Medicine, USA

O11.3 “You feel invisible”: A qualitative exploration of young LGBT+ people’s attitudes towards STI/HIV testing in primary care
- Lorraine McDonagh, University College London, UK

O11.4 Trans & gender diverse people’s experiences of sexual health care are associated with sexual health screening uptake
- Denton Callander, New York University, USA
O12  Oral Presentation Session 12
Understanding relationships and partner strategies for STI control
Chairpersons: John Saunders, University College London, UK and Matthew Hogben, Centers for Disease Control and Prevention, USA
Location: MR 13

012.1 Exploring relationship duration among gay and bisexual men: A longitudinal event-level analysis
- Kiffer Card, University of Victoria, Canada

012.2 Partnership context and consistent condom use among young African American men
- Megan Clare Craig-Kuhn, Tulane University School of Public Health and Tropical Medicine, USA

012.3 Epidemiological impact of expedited partner therapy for men who have sex with men: A modeling study
- Kevin Weiss, Emory University, USA

012.4 Effects of enhanced STI partner notification counselling in Cape Town: Randomized controlled trial
- Catherine Mathews, South African Medical Research Council, South Africa

012.5 Partner notification outcomes for chlamydia/gonorrhea cases diagnosed through clinics vs GetCheckedOnline in British Columbia
- Arina Zamanpour, British Columbia Centre for Disease Control, Canada

012.6 Contact tracing vs patient-delivered partner treatment for African American heterosexual men with chlamydia
- Patricia Kissinger, Tulane School of Public Health and Tropical Medicine, USA

17:45 - 19:00

PS02 Poster Viewing Session
Location: Exhibit Hall A

19:30 - 22:00 Congress Dinner (Ticketed Event)
Location: Ballroom C + D (West Building)

WEDNESDAY, JULY 17, 2019

07:00 - 08:00

CCS03 Clinical Case Series - Cases from the clinic
Chairpersons: David Hawkins, Chelsea and Westminster Hospital, UK and Laura Bachmann, Centers for Disease Control and Prevention, USA
Location: MR 8+15

CCS03.1 Rapid PrEP reinitiation in a patient with ongoing risk
- Negusse Ocbamichael PA-C, STD Clinic/Public Health-Seattle & King County at Harborview, USA

CCS03.2 Neonatal HSV: Could this transmission have been prevented?
- Elizabeth Foley, Solent NHS Trust, UK

CCS03.3 Zoon balanitis in HIV-infected patient
- Mauro Ramos, Ambulatório de Dermatologia Sanitária, Brazil
**S15 Symposium 15**

New approaches to STI diagnosis and prevention

*Chairpersons: Laura Sycuro, University of Calgary, Canada and Ameeta Singh, University of Alberta, Canada*

*Location: Ballroom*

- **S15.1** Four *Treponema pallidum* proteins detected in urine from syphilis-infected individuals using mass spectrometry  
  - Chris Kenyon, Institute of Tropical Medicine, Belgium

- **S15.2** CRISPR Diagnostics: Expanding the nucleic acid detection toolbox by harnessing microbial diversity  
  - Jonathan Gootenberg, Massachusetts Institute of Technology, USA

- **S15.3** Reducing the global burden of infectious diseases through precision infection management (PIM)  
  - Ian Lewis, University of Calgary, Canada

- **S15.4** Combatting HIV with nanomaterials  
  - Kim Woodrow, University of Washington, USA

---

**PL12.1 Plenary 12**

*Chairperson: Magnus Unemo, WHO CC for STIs, Örebro University Hospital, Sweden*

**Overview on the development of point-of-care tests for detection of antimicrobial resistance – challenges and opportunities**

*Johan Melendez, Johns Hopkins University, USA*

---

**PL13.1 Plenary 13**

*Chairperson: David Lewis, Western Sydney Sexual Health Centre/University of Sydney, Australia*

**The role of key population-led health services in addressing the challenge of STI and HIV**

*Rena Janamnuaysook, The Thai Red Cross AIDS Research Centre, Thailand*

---

**D01 Debate**

Among men who have sex with men, pharyngeal infection contributes more to population levels of gonorrhea transmission than urethral infection, rectal infection, or both?

*Chairperson: Kyle Bernstein, Centers for Disease Control and Prevention, USA*

**Speaker(s):**

- **D01.1 For the motion:** Kit Fairley, Monash University, Australia
- **D01.2 Against the motion:** Hunter Handsfield, University of Washington, USA

---

**Coffee Break**

*Location: Exhibit Hall A*

---

**S15 Symposium 15**

New approaches to STI diagnosis and prevention

*Chairpersons: Laura Sycuro, University of Calgary, Canada and Ameeta Singh, University of Alberta, Canada*

*Location: Ballroom*

- **S15.1** Four *Treponema pallidum* proteins detected in urine from syphilis-infected individuals using mass spectrometry  
  - Chris Kenyon, Institute of Tropical Medicine, Belgium

- **S15.2** CRISPR Diagnostics: Expanding the nucleic acid detection toolbox by harnessing microbial diversity  
  - Jonathan Gootenberg, Massachusetts Institute of Technology, USA

- **S15.3** Reducing the global burden of infectious diseases through precision infection management (PIM)  
  - Ian Lewis, University of Calgary, Canada

- **S15.4** Combatting HIV with nanomaterials  
  - Kim Woodrow, University of Washington, USA
S16  Symposium 16
Anatomical sites of infection: Biomedical, modeling, behavioral, and programmatic considerations for STI prevention
Chairpersons: Thomas Gift, Centers For Disease Control And Prevention, USA and Parinita Bhattacharjee, University of Manitoba, Canada
Location: MR 2+3

- S16.1 Anatomical sites of infection: Biomedical considerations for STI prevention
  - Jane Hocking, University of Melbourne, Australia

- S16.2 Modeling considerations related to multi-site infection
  - Ian Spicknall, Centers for Disease Control and Prevention, USA

- S16.3 Anatomical sites of infection: Behavioural considerations for STI prevention
  - Catherine Mercer, University College London, UK

- S16.4 Designing an approach to deal with extragenital sexually transmitted infections: Do we have the data we need?
  - Jeanne Marrazzo, University of Alabama, USA

S17  Symposium 17
Clinical issues in women's health and STI
Chairpersons: Gina Ogilvie, University of British Columbia, Canada and Anne Rompalo, Johns Hopkins University School of Medicine, USA
Location: MR 11+12

- S17.1 HPV screening – new evidence and current state of the art
  - Suzanne Garland, The Royal Women's Hospital, Australia

- S17.2 Treatment of bacterial vaginosis: How, when and how much?
  - Caroline Mitchell, Harvard University, USA

- S17.3 Screening women for bacterial STIs: Should we scale-back?
  - Jonathan Ross, University of Birmingham, UK

- S17.4 Prematurity and STI – value of screening and treatment
  - Deborah Money, University of British Columbia, Canada

S18  Symposium 18
Regional responses to global HIV/STI trends (IUSTI Special Symposium)
Chairpersons: Charotte Gaydos, Johns Hopkins University, USA and Kaushal Verma, Indian Institute of Science, India
Location: MR 13

- S18.1 An update on the status of HIV/STIs in IUSTI's five regions
  - Francis Ndowa, Skin & GU Medicine Clinic, Harare, Zimbabwe

- S18.2 Bridging the gap - best practice global examples of integration of HIV and STI services
  - Janet Wilson, National Health Service, UK

- S18.3 Improving the sexual and reproductive health of women living with HIV
  - Angelica Espinosa Miranda, Universidade Federal do Espirito Santo, Brazil

- S18.4 Engaging culturally and linguistically diverse populations in HIV/STI services: Challenges and opportunities
  - Shailendra Sawleshwarkar, University of Sydney, Australia
10:45 - 12:15

**O13 Oral Presentation Session 13**

**Working towards sexual health equity: Understanding context**  
*Chairpersons: Dennis Fortenberry, Indiana University School of Medicine, USA and Airi Põder, Tartu University Clinics Foundation (Clinic of Dermatology), Estonia*  
*Location: MR 1*

- **O13.1** Factors associated with safer sex efficacy among Northern and indigenous youth in the Northwest Territories, Canada  
  - Carmen Logie, University of Toronto, Canada

- **O13.2** Mixed methods analysis: Role of parents, peers and perceived severity of sexual health outcomes among Native American youth  
  - Lauren Tingey, Johns Hopkins University, USA

- **O13.3** High prevalence of cervico-vaginal infections among female adolescents in four urban regions of Panama  
  - Amanda Gabster, Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama

- **O13.4** Patterns of drug use among MSM in Amsterdam and sexually transmitted infections, The Netherlands: A cluster analysis  
  - Roel Achterbergh, Public Health Service of Amsterdam, The Netherlands

- **O13.5** Reaching home-based female sex workers with preventive sexual health care services in The Netherlands  
  - Charlotte Peters, South Limburg Public Health Services, The Netherlands

- **O13.6** Precarious legal immigration status linked to client condom refusal among sex workers in Metro Vancouver (2010-2018)  
  - Bronwyn McBride, Centre for Gender and Sexual Health Equity, Canada

10:45 - 12:15

**O14 Oral Presentation Session 14**

**Improving the access and impact of STI testing**  
*Chairpersons: Angelika Stary, Outpatients Centre for STI, Austria and Sunil Sethi, PGIMER, India*  
*Location: MR 8+15*

- **O14.1** Optimizing screening for chlamydia: Is there a role for screening heterosexual men?  
  - Minttu Rönn, Harvard T.H. Chan School of Public Health, USA

- **O14.2** Can community *Chlamydia trachomatis* screening of young heterosexual men help identify infected networks?  
  - Patricia Kissinger, Tulane School of Public Health and Tropical Medicine, USA

- **O14.3** Disparities in access to HIV point-of-care testing: The non-urban Canadian context  
  - Jacqueline Gahagan, Dalhousie University, Canada

- **O14.4** Implementation of point of care gonorrhoea and chlamydia testing in an STD clinic PrEP program, San Francisco, 2017-2018  
  - Stephanie Cohen, San Francisco Department of Public Health, USA

- **O14.5** *Chlamydia trachomatis* testing: A national evaluation of internet based self-sampling in Sweden  
  - Björn Herrmann, Uppsala University Hospital, Sweden

- **O14.6** mAfrica: Zennele, a mobile-phone enabled HIV testing and linkage to care pathway for young people in rural South Africa  
  - Maryam Shahmanesh, University College London, UK
10:45 - 12:15  
**O15 Oral Presentation Session 15**  
Understanding perceptions and beliefs: Improving STI/HIV interventions and outcomes  
Chairpersons: Lynn Barclay, American Sexual Health Association, USA and Charlotte Bell, Royal Adelaide Hospital, Australia  
Location: MR 9  

- O15.1 “A PrEP user is someone who has a lot of bareback”: A qualitative study of acceptability of PrEP in MSM in Lebanon  
  - Ismael Maatouk, Clemenceau Medical Center, Lebanon  
- O15.2 Interested? Why or why not? STI clinic client perceptions of bacterial STI vaccines in British Columbia, Canada  
  - Kara Plotnikoff, University of British Columbia, Canada  
- O15.3 Development of a scale measuring stigma towards alcohol abstinence among people living with HIV in Vietnam  
  - Kathryn Lancaster, The Ohio State University, USA  
- O15.4 Predictors of incorrect HIV care initiation beliefs among people living with HIV/AIDS in Chókwè District, Mozambique  
  - Christine Hara, Public Health Institute, Mozambique  
- O15.5 Syphilis risk perceptions among repeatedly infected men who have sex with men in Beirut, Lebanon  
  - Ismael Maatouk, Clemenceau Medical Center, Lebanon  
- O15.5 Women’s approaches to involving others in making HIV trial enrollment decisions while pregnant in the US and Malawi  
  - Kristen Sullivan, University of North Carolina at Chapel Hill, USA

12:15 - 13:45  
**Break**

13:45 - 15:15  
**S19 Symposium 19**  
Global public health approaches to gonorrhea prevention and the threat of antibiotic resistance  
Chairpersons: Rupert Kaul, University of Toronto, Canada and Helen Fifer, Public Health England, UK  
Location: MR 11+12  

- S19.1 Perspectives from North America  
  - Karen Schlanger, Center for Disease Control and Prevention, USA  
- S19.2 Perspectives from Brazil and Latin America  
  - Adele Schwartz Benzaken, Tropical Medicine Foundation, Manaus, Amazonas  
- S19.3 Perspectives from Thailand  
  - Pachara Sirivongrangson, Thailand Ministry of Public Health, Thailand  
- S19.4 Public health approaches to gonorrhea prevention and the threat of antibiotic resistance – perspectives from Europe  
  - Otilia Mårdh, European Centre for Disease Prevention and Control (ECDC), Sweden

13:45 - 15:15  
**S20 Symposium 20**  
Criminalization, the law and sexual health  
Chairpersons: Helen Ward, Imperial College London, UK and Michel Alary, CHU de Québec - Université Laval, Canada  
Location: Ballroom  

- S20.1 Understanding how laws and policies affect HIV prevention practices: A theoretical approach  
  - Morten Skovdal, University of Copenhagen, Denmark
S20.2 Intersectionality, criminalisation and sexual health  
- Carmen Logie, University of Toronto, Canada

S20.3 The health impacts of sex work criminalization: A review of the evidence  
- Lucy Platt, London School of Hygiene & Tropical Medicine, UK

S20.4 Criminalisation of HIV transmission in the era of U=U  
- Michael Brady, Kings College Hospital/Terrence Higgins Trust, UK

13:45 - 15:15

S21 Symposium 21
Building a human infrastructure for STI prevention: Beyond community engagement, consultation and advisory boards
Chairpersons: Deborah Money, University of British Columbia, Canada and Gail Bolan, Centers for Disease Control and Prevention (CDC), USA
Location: MR 2+3

S21.1 Youth and community based research  
- Sarah Flicker, York University, Canada

S21.2 Addressing anti-LGBT stigma and medical mistrust through a data-informed approach to community engagement  
- Errol Fields, Johns Hopkins University, USA

S21.3 Authentic and successful community engagement for STI/HIV prevention, screening and treatment in rural and urban settings  
- Scott Rhodes, University of North Carolina, USA

S21.4 Spurring innovation in improving community engagement for STI prevention  
- Weiming Tang, University of North Carolina Project-China, China

O16 Oral Presentation Session 16
Host-pathogen interactions
Chairpersons: Juan Salazar, UCONN School of Medicine, USA and Lyle McKinnon, University of Manitoba, Canada
Location: MR 9

O16.1 Therapeutic effect of indoleamine 2,3-dioxygenase (IDO) inhibitor in the male genital inflammation  
- Shin Ohira, Kawasaki Medical School, Japan

O16.2 Mapping regions of host attachment in the *T. pallidum* adhesin Tp0751; Function-informed vaccine design  
- Sean Waugh, University of Victoria, Canada

O16.3 Cytokine immune response against natural human papillomavirus infection among men in Kisumu, Kenya  
- Raphael Ondondo, Masinde Muliro University of Science and Technology, Kenya

O16.4 Structural similarity of *Treponema pallidum* protein Tp0225 with human toll-like receptor 2  
- Simon Houston, University of Victoria, Canada

O16.5 Targeting complement receptor 3 on primary human cervical cells has the potential to cure *Neisseria gonorrhoeae* infection  
- Jennifer Edwards, The Research Institute at Nationwide Children’s Hospital and The Ohio State University, USA

O16.6 Basic science aids syphilis vaccine development: Bloodstream spreading by the syphilis spirochete *Treponema pallidum*  
- Karen Lithgow, University of Victoria, Canada
13:45 - 15:15

**O17 Oral Presentation Session 17**

Screening and vaccination

*Chairpersons: Basil Donovan, Kirby Institute, Australia and Marc Steben, INSPQ, Canada*

*Location: MR 1*

O17.1 HPV FOCAL 48 month exit results by age for women HPV or LBC negative at baseline screening
- Gina Ogilvie, University of British Columbia, Canada

O17.2 Women's experiences with primary human papillomavirus (HPV) testing for cervix screening: HPV FOCAL exit survey results
- Laurie Smith, BC Cancer, Canada

O17.3 Declining rates of cervical intraepithelial neoplasia after introduction of the HPV vaccine in British Columbia, Canada
- Robine Donken, BC Children's Research Institute, Canada

O17.4 Impact of the human papillomavirus immunization program on rates of anogenital warts in British Columbia, Canada 2000-2017
- Christine Lukac, University of British Columbia, Canada

O17.5 Declining trends in anogenital warts since HPV vaccine introduction in a large urban health system, 2013-2017
- Linda Niccolai, Yale School of Public Health, USA

O17.6 Parents'/healthcare providers' knowledge, attitude and perception of school-based HPV vaccination program in Lagos, Nigeria
- Adebola Adejimi, College of Medicine, University of Lagos, Nigeria

13:45 - 15:15

**O18 Oral Presentation Session 18**

Pills of white mercury: Syphilis prevalence, screening and prevention

*Chairpersons: Troy Grennan, BC Centre for Disease Control, Canada and Pingyu Zhou, Shanghai Skin Disease Hospital, China*

*Location: MR 13*

O18.1 Prevalence of active syphilis among transwomen in São Paulo, Brazil
- Beatriz Paiatto, Faculdade de Ciências Médicas da Santa Casa de São Paulo, Brazil

O18.2 Estimating disease burden of maternal syphilis and associated adverse pregnancy outcomes in China
- Yajie Wang, Dermatology Hospital of Southern Medical University, China

O18.3 Development of a syphilis serum repository for research and evaluation of syphilis diagnostics tests in the United States
- Mayur Shukla, Centers for Disease Control and Prevention, USA

O18.4 Evaluation of routinized syphilis screening with HIV viral loads among men living with HIV
- Ann Burchell, St. Michael's Hospital, Canada

O18.5 HIV seropositivity and early syphilis stage predictive of ocular syphilis diagnosis in British Columbia, Canada: 2010-2018
- Hasan Hamze, University of British Columbia, Canada

O18.6 Prenatal care entry among pregnant women with syphilis who use methamphetamines: A key to congenital syphilis prevention
- Rosalyn Plotzker, California Department of Public Health, USA
13:45 - 15:15  O19  Oral Presentation Session 19  
**Models, networks and transmission dynamics: New insights for programs**
*Chairpersons: David Regan, University of New South Wales, Australia and Peter White, Imperial College London, UK*
*Location: MR 8+15*

- O19.1 Model-based study design for estimation of route-specific gonorrheal transmission probabilities  
  - Ethan Romero-Severson, Los Alamos National Laboratory, USA

- O19.2 Bridging of *Neisseria gonorrhoeae* across diverse sexual networks in the HIV PrEP era  
  - Deborah Williamson, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Australia

- O19.3 Partner services for gonorrhea can decrease new HIV among MSM in King County, Washington: A mathematical modeling study  
  - Gui Liu, University of Washington, USA

- O19.4 Molecular epidemiology of HIV among foreign-born residents of King County, Washington, USA; Using HIV surveillance data  
  - Diana Tordoff, University of Washington, USA

- O19.5 The influence of risk group turnover in STI/HIV epidemics: Mechanistic insights from transmission modeling  
  - Jesse Knight, St. Michael’s Hospital, Canada

- O19.6 Professional injectors, injection networks, and HIV: Case studies from five cities in Pakistan  
  - Laura Thompson, University of Manitoba, Canada

15:15 - 15:45  
**Coffee Break**
*Location: Exhibit Hall A*

**LOCATION: BALLROOM**

15:45 - 16:45  
**K02.1  Closing Keynote Lecture**
*Chairpersons: James Blanchard, University of Manitoba, Canada and Henry de Vries, Amsterdam University Medical Centers, The Netherlands*

**MAKING SCIENCE WORK TO DELIVER EFFECTIVE PROGRAMMES AT SCALE**
*Charlotte Watts, UK Department of International Development, UK*

16:45 - 18:00  
**Closing Ceremony**
Monday, July 15, 2019
17:45 - 19:00 PS01 Poster Viewing Session
Location: Exhibit Hall A

P004 - The nationwide antimicrobial resistance surveillance system of sexually transmitted infections - South Korea, 2017-2018
Chang Hee Han, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Republic of Korea

P005 - Gonorrhea in the era of AMR, diagnostic needs for improved antimicrobial stewardship in low and middle income countries
Cecilia Ferreyra, FIND, Switzerland

P006 - "First test along then together" - the practice of couple's HIV testing in Ethiopia
Tewodros Getachew Hailermariam, The University of New South Wales, Australia

P007 - Uptake of couples HIV testing and counselling in Sub-Saharan Africa: A systematic review and meta-analysis
Tewodros Getachew Hailermariam, The University of New South Wales, Australia

P008 - Diagnostic accuracy of Xpert MTB/RIF in detecting pulmonary tuberculosis among people living with HIV in western Nigeria
Saheed Usman, APIN Public Health Initiatives, Nigeria

P012 - A process evaluation of an incentivized home-based intervention to test and start (HITS) in rural KwaZulu-Natal, South Africa
Oluwafemi Adeagbo, Africa Health Research Institute, South Africa

P013 - Screening practices related to inconclusive Neisseria gonorrhoea and Chlamydia trachomatis nucleic acid amplification testing
Cherie Blair, University of California, Los Angeles, USA

P014 - Validating a clinical prediction rule for chlamydia and gonorrhoea infection among online testers in British Columbia, Canada
Aidan Ablona, BC Centre for Disease Control, Canada

P015 - Introduction of chlamydia and gonorrhea opt-out testing in a short-term correctional facility in Alberta, Canada
Petra Smyczek, Alberta Health Services, Canada

P017 - Effect of time change on adolescent and young people accessibility to AFYHC in Akure, Ondo state Nigeria
Onesimus Aiwanfo, Federal University of Technology Akure, Nigeria

P018 - Pay-it-forward gonorrhea and chlamydia testing among Chinese men who have sex with men: A cluster randomized controlled trial
Tiane Zhang, University of North Carolina Project-China, China

P019 - Implementing home-sampling strategies to engage young heterosexuals in Chlamydia trachomatis re-testing and peer-referral
Nicole Dukers-Muijriers, Public Health Service South Limburg, Netherlands

P020 - Urisponge™ facilitate urine collection and transportation for the detection of STD with the AnyplexTM II STI-7 assay
Santina Castriciano, Copan Italia Spa, Canada

P021 - Use of non-FDA cleared assays for detection of STIs in children being evaluated for suspected sexual abuse
Margaret Hammerschlag, State University of New York Downstate Medical Center, USA

P022 - Antenatal testing for curable STIs compared to syndromic management in Botswana: A cost-effectiveness study
Adriane Wynn, UCSD, USA

P023 - A mixed-methods analysis of a pay-it-forward gonorrhea/chlamydia testing program among men who have sex with men in China
Wenting Huang, University of North Carolina at Chapel Hill Project-China, China

P024 - Targeted point-of-care testing compared to syndromic management of urogenital infections in Rwandan women
Janneke Van De Wijgert, University Medical Center Utrecht, Netherlands

P025 - Automation and optimization strategies in a molecular lab result in an improved workflow for STI surveillance studies
Carsten Tiemann, Krone Laboratory / LABCON-OWL, Germany

P026 - Frequency of STD testing services among commercially-insured patients with high risk sexual behaviors
Sagar Kumar, Centers for Disease Control and Prevention, USA

P027 - Safety and effectiveness of same-day screening and treatment among youth in Los Angeles, California
Erin Keizur, UCLA, USA

P029 - Multi-target PCRs - the new multi-tool of STI diagnostics
Carsten Tiemann, Krone Laboratory / LABCON-OWL, Germany

P030 - Pilot implementation of a home-care program for chlamydia, gonorrhea and syphilis testing in HIV positive MSM
Nicole Dukers-Muijriers, Public Health Service South Limburg, Netherlands

P031 - Using intervention mapping to develop a home-care program for men who have sex with men to get themselves tested for HIV/STI
Nicole Dukers-Muijriers, Public Health Service South Limburg, Netherlands

P032 - Alone but supported with an innovative HIV self-testing app: Qualitative results from a large cohort study in South Africa
Ricky Janssen, Maastricht University, Netherlands

P033 - Differentiation of common genital ulcer disease pathogens using sequential or parallel molecular testing
Chris McGowin, Roche Diagnostics Corp, USA

P034 - HIV self-testing and potential linkage to care among men who have sex with men in China: A cross-sectional online survey
Cheng Wang, Social Enterpreneurship to Spur Health(SESH) Team, China

P035 - Impact of mass media exposure in getting HIV testing among urban women in Nepal
Bikesh Bajracharya, Support to the Health Sector Programme, Nepal

P036 - Predictors of lost to follow-up in a “test and treat” programme among women with high-risk sexual behaviour in Kampaala, Uganda
Onesmus Kamacooko, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Uganda

P038 - Comparison of Anyplex™II STI-7 v1.1 to Allplex™ CT/NG/MG/TV for the detection of STI from urine collected with UriSponge™
Santina Castriciano, Copan Italia Spa, Canada

P039 - A central reference laboratory for antimicrobial resistant Neisseria gonorrhoeae in the US Department of Defense June Early, Infectious Disease Clinical Research Program, USA

P040 - Making sense of HIV self-testing: Social representation in young Nigerians narratives for promoting HIV self-testing
Chisom Obiezu-Umeh, Saint Louis University, USA

P041 - How is the value of point-of-care tests for STIs negotiated in the context of a nationalised health system?
Agata Pacho, St George's, University of London, UK

P043 - Regional differences in STI testing barriers among online testers in British Columbia, Canada
Mark Gilbert, BC Centre for Disease Control, Canada

P044 - Regional differences in use of GetCheckedOnline and client characteristics across British Columbia, Canada
Aidan Ablona, BC Centre for Disease Control, Canada
P045 - Is chlamydia testing in general practice sustained when financial incentives or audit + feedback are removed: A cluster RCT
Jane Hocking, University of Melbourne, Australia

P046 - Ensuring quality-assured and personalized online self-testing within a market-driven context
Hanna Bos, Soa Aids Nederland, Netherlands

P047 - The three Rs: recalls, reminders and retesting for chlamydia – views of GPs and young adults
Alaina Vaisey, University of Melbourne, Australia

P048 - Improving ‘home-based’ STI/HIV self-sampling and boosting sample return rates
Paul Flowers, University of Glasgow, UK

P049 - STI testing and documentation via a phone application (app): Experience with the safe app
Kenneth Fife, SAFE Health, USA

P050 - Sexual Health London online testing: A review of service users and outcomes
Ryan Kinsella, Preventx, UK

P051 - Accuracy of sexually transmitted infections testing on self-collected vaginal samples versus cervical samples
Clementina Cocuzza, University of Milano-Bicocca, Italy

P052 - HIV case finding and linkage to care in Eleme local government area, Rivers state
Atochi Emenike, Pathfinder International, Nigeria

P053 - Detection of sexually transmitted pathogens from sediment of first-void urine in patients from greater Zagreb Area
Jasmina Vranes, Institute of Public Health “Dr. Andrija Stampa”, Croatia

P055 - London Sexual Health Programme – Developing innovative solutions to open access sexual health services
Ryan Kinsella, Preventx, UK

P056 - The acceptability of different HIV testing options among young men living in Vancouver, Canada: A qualitative study
Caroline Mniszak, BC Centre on Substance Use, Canada

P057 - The Brazilian strategy for HIV self-tests free distribution in public health
Pâmela Gaspar, Ministry of Health of Brazil, Brazil

P058 - Design and performance of the alinity m STI assay for the detection of CT, NG, TV, and MG
Kevin Nelson, Abbott Molecular, USA

P059 - Quantitative detection of bacteria associated with BV in urine versus swab samples using droplet digital PCR
Deshanta Naicker, Nelson R Mandela School of Medicine, South Africa

P060 - Performance of 3-in-1 pooled samples from anal, rectal, and throat of GeneXpert® CT/NG in Bali, Indonesia
Irvin Romcyo, FHI360-LINKAGES, Indonesia

P061 - A mobile clinic model to care for women engaging in exchange sex who are opiate dependent and living unhoused in Seattle
Jenell Stewart, University of Washington, USA

P067 - Drug use during sex among Dutch swingers and associated sexual risk behavior: A hidden phenomenon?
Christian Hoebe, Public Health Service South Limburg, Maastricht University Medical Center (MUMC+), Netherlands

P069 - Do cannabis use and social support mediate the relationship between intersectional stigma and bodily pain and functioning?
Carmen Logie, University of Toronto, Canada

P070 - Determination of antibiotic susceptibility and efficacy by VITA-PCR
Nicole Lima, University of New South Wales, Australia

P071 - Police harassment and HIV/STI risk behaviors among a sample of people who inject drugs on the U.S.-Mexico border
Oscar Beltran, Programa Compañeros, A.C., Mexico

P073 - From silos to buckets: A qualitative study of how sexual health clinics can address mental health & substance use needs
Travis Salway, BC Centre for Disease Control, Canada

P074 - STI and HIV infections among MSM reporting exposure to gonorrhea or chlamydia: implications for expedited partner therapy
Julia Schillinger, Centers for Disease Control and Prevention, USA

P076 - Do prescriptions for expedited partner therapy get filled? Findings from a multi-jurisdictional evaluation,
Julia Schillinger, Centers for Disease Control and Prevention, USA

P077 - Piloting an algorithm to guide clinical treatment decisions for syphilis notified partners in Rotterdam, the Netherlands
Hannelore Götz, 1 Public Health Service Rotterdam Rijnmond; 2 Erasmus MC University Medical Center Rotterdam; 3 National Institute for Public Health and the Environment (RIVM), Netherlands

P078 - Barriers and facilitators to expedited partner therapy: a survey of family physicians in British Columbia, Canada
Jason Wong, BC Centre for Disease Control, Canada

P079 - Using theory and evidence to optimise an accelerated partner therapy intervention in a chlamydia partner notification trial
Paul Flowers, University of Glasgow, UK

P080 - Investigating the effects of accelerated partner therapy on chlamydia transmission in Britain: a mathematical modeling study
Christian Althaus, University of Bern, Switzerland

P083 - Designing online HIV information, testing and clinical care pathways to address users’ expectations and emotions
Jo Gibbs, University College London, UK

P084 - Geographical proximity as barrier in sexual health clinic utilization, even in infrastructure rich countries
Denise Twisk, Municipality of Rotterdam / Public Health Service Rotterdam-Rijnmond / Erasmus Medical Center, Netherlands

P085 - Relative contribution of general practices and sexual health centres in STI consultations in the Netherlands
Hannelore Götz, 1 Public Health Service Rotterdam Rijnmond; 2 Erasmus MC University Medical Center Rotterdam; 3 National Institute for Public Health and the Environment (RIVM), Netherlands

P086 - Social bonds as a strategy of practical assistance for sex worker healthcare
Ana Amélia Bones, UFCSPA, Brazil

P087 - Providers’ views on barriers and facilitators of bacterial STI testing among gbMSM living with or at risk for HIV
Charlie Guiang, St. Michael’s, University of Toronto, Canada

P088 - Using electronic screening and feedback with adolescents to decrease sexual health risks in the emergency department
Siobhan Thomas-Smith, Seattle Children’s Hospital/University of Washington School of Medicine, USA

P089 - Evaluating online and clinic-based STI screening services: A case study of Umbrella Sexual Health Services, UK
Louise Jackson, University of Birmingham, UK

P090 - Understanding young people’s priorities for sexually transmitted infection (STI) screening
Louise Jackson, University of Birmingham, UK

James Matthias, Centers for Disease Control and Prevention, USA
P092 - Herpes simplex virus type 1 epidemiology in Latin America and the Caribbean: systematic review and meta-analyses
Manale Harfouche, Weill Cornell Medicine-Qatar, Qatar

P093 - Performance of four diagnostic assays for detecting herpes simplex virus type 2 antibodies in Middle East and North Africa
Soha Dargham, Weill Cornell Medicine-Qatar, Qatar

P094 - An assessment of risk factors for HSV-2 infection in Malawian women using two classifications for the Herpesselect 2 test
Payal Chakraborty, The Ohio State University, USA

P095 - Age disparity and sociodemographic correlates of herpes simplex virus type 2 (HSV-2) seropositivity in South India
Makella Coudray, Florida International University, USA

P096 - Vulvar Zoster
Christine Remar Concepcion, University of the Philippines, Philippines

P099 - Risk of acquiring HIV infection among exposed infants in selected primary health care facilities in Ibadan Oyo State Nigeria
Aishat Usman, AFRICAN FIELD EPIDEMIOLOGY NETWORK, Nigeria

P100 - Bidirectional association between Human Immunodeficiency Virus and psoriasis: Systematic review of cohort studies
Yi-Yu Chen, Taiwan

P103 - Optimization of data audits to achieve epidemic control and quality of care in Kajado Central sub-county PRECIOUS Mbabazi, NATIONAL AIDS &STI CONTROL PROGRAMME, Kenya

P107 - Socio-cultural factors influencing condom use intentions among African migrant youth in South Africa
Johannes John-Langba, University of Kwazulu-Natal, South Africa

P108 - Prevalence of alexithymia among a cohort of well-controlled HIV infected and normal children
Ragas Dental College and Hospital, Chennai, India

P113 - Risk behaviors following Hepatitis C treatment among gay and bisexual men living with HIV in Melbourne, Australia
Brendan Harney, Burnet Institute, Australia

P115 - Socio-demographic profile of HIV seropositivity in a tertiary care North Indian hospital: A ten year retrospective study
Nikhil Sharma, Guru Nanak Dev University, India

P120 - Treatment outcomes in HIV care among children and adult in high volume ART sites in Rivers State, Nigeria
Atochi Emenike, Nigeria

P123 - HIV seropositivity and early syphilis stage predictive of ocular syphilis diagnosis in British Columbia, Canada:
Hasan Hamze, University of British Columbia, Canada

P124 - Attitudes and beliefs regarding HIV and AIDS among immigrants in Mopani District, South Africa
Hilda Shilubane, University of Venda, South Africa

P125 - Low rate of HIV testing among prisoners in Iran: Findings from nationwide repeated behavioral surveys
Mohammad Karamouzian, BC Centre on Substance Use, Canada

P127 - Disparities between HIV testing levels and the self-reported HIV-negative status of sexually active college students
Edmond Pui Hang Choi, The University of Hong Kong, Hong Kong PRC

P128 - HIV+ women 50+ stigmatized and discriminated
Chantal Mukandoll, APAA(African In Partnership Against AIDS), Canada

P137 - Modelling factors determining Pakistan's heterogeneous HIV epidemic in people who inject drugs
Aaron Lim, University of Bristol, UK

P138 - High STI prevalence among HIV-exposed women planning for pregnancy in rural, southwestern Uganda
Pooja Chitneni, Brigham and Women's Hospital, USA

P139 - The racial impact of AIDS trends among women in Sao Paulo, Brazil
Carmen Silvia Domingues, STI/AIDS Reference Center - Sao Paulo State Program of STI/AIDS, Brazil

P140 - The rising HIV epidemic among key populations: An urgent need for a focused targeted prevention response in Pakistan
Baseer Achakzai, National AIDS Control Program, Pakistan

P141 - Factors associated with HIV-related stigma among individuals accessing antiretroviral therapy in British Columbia, Canada
Andrea Bever, BC Centre for Excellence in HIV/AIDS, Canada

P142 - Characteristics of HIV-1 pretreatment drug resistance and its impact on combined antiretroviral therapy in Beijing Ruolei Xin, Beijing Center for Disease Prevention and Control, China

P143 - Medication reviews for people living with HIV (PLWHiV) Bronagh McBrien, Manchester Foundation Trust, UK

P145 - An intra-familial transmission of HIV-1 CRF02_AG was reconstructed by molecular epidemiology
Chun Huang, Beijing Center for Disease Prevention and Control, China

P146 - Gender, sexual relationship power equity, and HIV-risk among sub-Saharan African youth: A comprehensive literature review
Angela Kaida, Simon Fraser University, Canada

P148 - Transcontinental dissemination of the major HIV-1 CRF01_AE lineages circulating in China
Ruolei Xin, Beijing Center for Disease Prevention and Control, China

P149 - EVolution: A text messaging powered intervention for connection, support and HIV eradication
Katie Plax, Washington University School of Medicine, USA

P151 - HIV epidemic among crack users in central Brazil: Epidemiological basis for interventions
Márcia Souza, Universidade Federal de Goias, Brazil

P152 - The epidemiology of HIV infection among young adults in Brazil
Natalia Kops, Hospital Moinhos de Vento, Brazil

P153 - Are parturient women on anti-retroviral therapy complying with the recommended six-months exclusive breastfeeding?
Anthony Ajayi, University of Fort Hare, South Africa

P154 - Diffuse skewing of Th17/Treg ratio in the anorectal mucosa of HIV+ MSM with HPV-associated dysplasia
Rupert Kaul, University of Toronto, Canada

P156 - Study on the effect of slamDC-mediated ADCC in HIV-1-infected patients
Wenqing Geng, the First Affiliated Hospital, China Medical University, China

P157 - Crowdsourcing methods to enhance HIV and sexual health services: A qualitative scoping review of evidence
Weiming Tang, UNC Project-China, China

P159 - Influence of HIV status and opioid misuse on STI risk and infection: Results of a pilot study
Wiley Jenkins, Southern Illinois University School of Medicine, USA

P161 - Adopting a political economy approach to HIV research: A case study of ongoing conflict in Ukraine
Nicole Herpai, Canada

P162 - Unsuppressed viral load (VL) by HIV exposure category among people living with HIV in British Columbia (BC), Canada: 2005-2015
David Moore, BC Centre for Excellence in HIV/AIDS, Canada
P163 - HIV care and treatment services for female sex workers: utilisation of and satisfaction with the services in Kampala, Uganda
Gertrude Namale, MRC/UVRi & LSHTM, Uganda

P166 - Determinants of viral non-suppression among children in a HIV program in Kenya: A cross-sectional study
Douglas Gaitho, Christian Health Association of Kenya, Kenya

P167 - PCR detection of HIV proviral DNA in brain tissues from dead HIV/AIDS in Zambia
Lishi Bai, Beijing Center for Disease Prevention and Control, China

P168 - Multidrug resistant tuberculosis in TB/HIV co-infected patients in River’s State, Nigeria
Mary Alex-Wele, University of Port Harcourt teaching Hospital, Nigeria

P169 - Association between CXCR4 and TRAIL pathway expression in CD4 T lymphocytes from HIV+ ART-naive patients
Sarah Raktovich-Gonzalez, Universidad de Guadalajara, Mexico

P170 - Efavirenz based anti-retroviral regimens in paediatrics: A peek into neuropsychiatric and biochemical derangements
Purba Chakraborty, India

P171 - Zbtbs gene expression in CD4+ T cells and systemic pro-inflammatory cytokines in naive and treated HIV patients
Judith De Arcos Jimenez, Universidad de Guadalajara, Mexico

P172 - Association between short-chain fatty acids producing bacteria and CD4 T cells recovery in HIV positive patients
Mariana Ruiz Briseño, Universidad de Guadalajara, Mexico

P173 - Investigating varicella-zoster virus-specific T cells through the lenses of HIV
Carolina Moreira, University of Manitoba, Canada

P176 - HIV acquisition and antiretroviral therapy initiation in a youth cohort in Soweto and Durban, South Africa
Angela Kaida, Simon Fraser University, Canada

P179 - Community based local rapid HIV testing campaigns to expand HIV diagnostic coverage
Ana Amélia Bones, Brazil

P180 - Virtual academic detailing to improve quality of HIV health care
Ana Amélia Bones, UFCSPA, Brazil

P181 - Epidemiological information on HIV in the management of the cascade of care in health services
Ana Amélia Bones, UFCSPA, Brazil

P183 - Predictors of Chlamydia trachomatis and Neisseria gonorrhoeae asymptomatic infection in HIV patients
Cátia Caldas, Centro Hospitalar e Universitário de São João, Portugal

P184 - Vaginal microbiota associated with oncogenic HPV in a cohort of HPV-vaccinated women living with HIV
Elisabeth McClymont, University of British Columbia, Canada

P186 - Neisseria gonorrhoeae infections among people living with HIV on ART at STI clinic in Kumasi, Ghana
Thomas Agyarko-Poku, Suntreso Government Hospital, Ghana

P187 - Anal cancer and precursor lesions in HIV-infected persons: A clinical cohort study
Yuanfan Ye, University of Alabama at Birmingham, USA

P189 - Evaluation of Aptima HIV-1 quant assay performance using plasma and dried blood spots
Julie Nelson, University of North Carolina at Chapel Hill, USA

P190 - The role of helpline counseling in HIV status disclosure among sexual partners: A case study of toll free helpline in Uganda
Július Ssekinkuse, Communication for Development Foundation Uganda, Uganda

P191 - South Indian long-distance truck drivers still at high-risk for HIV/STI
Karl Krupp, Florida International University, USA

P192 - Healthcare worker related stigma and discrimination towards people living with HIV in one of the government hospital in Bohol.
Lydette Galimba, Gov.Celestino Gallares Memorial Hospital, Philippines

P195 - Creation of an HIV case definition to assess the quality of HIV care in the primary healthcare setting in Canada
Sarah Boyd, Memorial University Centre for Rural Health Studies, Canada

P196 - WIR-Center for Sexual Health and Medicine: A care model to counter HIV/STI in Germany
Norbert Brockmeyer, Walk In Ruhr - WIR - Center for Sexual Health, Germany

P198 - Dolutegravir rollout and expected prevalence of pretreatment drug resistance to antiretroviral therapy among Kenyan women
Horacio Duarte, University of Washington, USA

Jason Wong, BC Centre for Disease Control, Canada

P202 - Developing a database with sensitive health information: A profile of people living with HIV in Newfoundland and Labrador
Sarah Boyd, Memorial University Centre for Rural Health Studies, Canada

P204 - Serodiscordance and sex partner concurrency: evidence for racial disparities in HIV among gay and bisexual men (MSM)
Carla Tilchin, Johns Hopkins University School of Medicine, USA

P205 - HIV Non-B subtypes in San Francisco: Migration but little local transmission
Hong-Ha Truong, University of California, San Francisco, USA

P206 - The specific contribution of each data source in a population-based administrative data cohort from Manitoba, Canada
Souradet Shaw, University of Minnesota, Canada

P207 - Burden of ophthalmia neonatorum among babies of PLHIV at a district hospital in Kumasi, Ghana
Thomas Agyarko-Poku, Suntreso Government Hospital, Ghana

P208 - Testing and treating genital and extra genital bacterial infections in HIV infected patients: Lessons learned
Cátia Caldas, Centro Hospitalar e Universitário de São João, Portugal

P209 - Productive impact of assisted referrals and incentivized enrollment on the uptake of HIV services in Lagos state, Nigeria
Felix Iwuala, Association for Reproductive and Family Health (ARFH), Nigeria

P210 - Alinity m HIV-1 assay: Design and performance
Jeffrey Wuitschick, Abbott Molecular, USA

P211 - Reproductive outcome and fetal growth in HIV-infected pregnant women at a university hospital in Vitória, Brazil
Angela Miranda, Universidade Federal do Espirito Santo, Brazil

P212 - Psychosocial factors affecting the caregivers of pediatric HIV patients in returning for treatment
Kelsey Buehler, Touro University, USA

P216 - Gender-based violence and the associated psychosocial and mental health issues among Filipino HIV-positives
Evangelina Castronuevo-Ruga, De La Salle University-Dasmarias, Philippines
P217  “Stigma and Level of Care Among Health Care Providers to HIV/AIDS patients”
Felisse Julien Jegonia, Phillipine College Of Physicians, Philippines

P218  Determining the Neurocognitive status and functional ability to screen for HIV-Associated Neurocognitive Disorder (HAND)
Ritika Agarwal, Chandra Laxmi Hospital, India

P219  Profile of patients who underwent rapid STI tests at a health unit in the Brazilian capital city with the highest HIV rate Ana Amélia Bones, UFCSPA, Brazil

P220  Opportunities and challenges to the rituals of care that circumvent misdiagnosis amongst rapid HIV testers in Zimbabwe Morten Skovdal, University of Copenhagen, Denmark

P222  Living with HIV/AIDS in adolescence: factors for adherence to therapeutics.
Shirley Coelho, Centro Estadual Especializado em Diagnostico, HIV/AIDS e Hepatites Virais, Brazil

P223  Prevalence of Reproductive Tract Infections and HIV on pregnant women in some areas in Indonesia, 2016-2017 Luxi Pasaribu, National Institute of Health Research and Development, Indonesia

P225  Practical cognitive screening for patients with HIV Gwen Levitt, District Medical Group, USA

P226  Self-esteem, body image, and subculture identification among gay, bisexual, and other men who have sex with men Kiffer Card, University of Victoria, Canada

P227  Perceived stress and socioeconomic factors associated with vaginal microbiota in the Longitudinal Study of Vaginal Flora Rodman Turpin, University of Maryland, USA


P233  Genital tract infection of women with and without tubal pathology Svetlana Dubrovina, Rostov Medical State University, Russian Federation

P235  Vaginal and rectal M. genitalium (MG), C. trachomatis (CT), and N. gonorrhoeae (GC) Co-Infection Among Women in Seattle, WA
Christine Khosropour, University of Washington, USA

P237  Enzyme complexes of alcohol metabolism protect against liver injury in animal models fed acute alcohol and anti-HIV drugs Cheng Ji, University of Southern California, USA

P239  Genital HSV-2 suppression is not associated with alterations in the vaginal microbiome: a one-way, cross-over study Christine Johnston, University of Washington, USA

P241  Detection of Y-chromosomal DNA correlates with last unsafe sexual exposure Petra Wolffs, Maastricht University Medical Center (MUMC+), Netherlands

P242  Co-infections with cytomegalovirus (CMV) and sexually transmitted infections (STIs) in pregnant women Swetha Pinninti, University of Alabama at Birmingham, USA

P243  High prevalence of Ureaplasma spp. in women visiting an STI clinic although no azithromycin resistance was discovered Inge Van Loo, Maastricht University Medical Center, Netherlands

P245  Integration of HIV testing with tuberculosis and sexually transmitted infections at a tertiary care hospital in Delhi Tanisha Bharara, Dr Baba Saheb Ambedkar Hospital and Medical College, India

P246  Community perceptions, experiences and preferences for partner notification services in North Carolina Humberto Gonzalez Rodriguez, UNC-CH Gillings School of Global Public Health, USA

P247  Partner notification for syphilis in Chile: Realities from two regional health services - a qualitative case study Jane Tomnay, The University of Melbourne, Australia

P248  STI risk reduction strategies among individuals with multiple sex partners and perceived partner non-monogamy in the US Casey Copen, Centers for Disease Control and Prevention, USA

P249  What works in partner notification for sexually transmitted infections, including HIV? Systematic review and meta-analysis Nicola Low, University of Bern, Switzerland

P250  Interim analysis of individual risk factors, sexual networks, and STI risk in a military population Eric Garges, USUHS, USA

P251  Developing partner notification outcomes for bacterial STI by sex-partner type: International perspectives Claudia Estcourt, Glasgow Caledonian University, UK

P252  Predictability of Prevalence of Sexually Transmitted Infection on Complex Sexual Network Ryoosuke Omori, Hokkaido University, Japan

P253  HPV vaccine knowledge and acceptability among MSM in Lebanon: A qualitative study Ismael Maatouk, Clemenceau Medical Center, Lebanon

P254  Barriers to sexual assault disclosure within sexual health services: A mixed method/population study Jane Meyrick, University of the West of England, UK

P257  Patterns and correlates of gender-based violence (GBV) in rural and urban South African communities Saheed Usman, APIN Public Health Initiatives, Nigeria

P259  Seeking clickthroughs: Using cell phone applications in preventing STDs Rachel Kachur, Centers for Disease Control and Prevention, USA

P260  Risk perception, safer sex practices, and PrEP enthusiasm: Exploring PrEP with black and minority ethnic women in the UK Sarah Nakasone, USA

P262  PrEP utilization among young transgender women, transgender men, and MSM in an urban community-based setting Doreen Dankerlui, Henry Ford Health System, USA

P264  Community perspectives on bacterial STI testing for gay, bisexual and other men who have sex with men in Toronto, Canada Dionne Gesink, U of Toronto, Canada

P265  CD4 count as parameter to estimate the time of infection in HIV positive men having sex with men and its social implications Patrick Eustaquio, LoveYourself, Inc., Philippines

P270  Health rights: LGBTIQ community Tyrone Havnar, Zimbabwe

P271  A community perspective on the immediate prescribing of antiretroviral therapy at time of a HIV diagnosis (ARTATD) David Crawford, Positive Life NSW, Australia

P272  Research to resource: Booklet for people living with HIV associated neurocognitive disorder (HAND) David Crawford, Positive Life NSW, Australia

P273  Understanding the mental health issues and service needs of the transgender community in Delhi, India Ramita Iyer, Singapore
P274 - Leveraging multi-level monitoring to achieve stakeholder buy-in: Descriptive lessons from key population mapping in Nigeria
Chukwuebuka Chukwukadibia Ejecam, Centre for Global Public Health, University of Manitoba (Nigeria Country Office), Nigeria

P275 - Towards the management of HIV/AIDS patients in pentecostal churches in Uganda: A case of Eden and Bethel churches in Kampala
Rebecca Nantalo Namige, Vamutu Women Group, Uganda

P276 - A national action plan to advance the sexual and reproductive health and rights of women living with HIV in Canada
Angela Kaida, Simon Fraser University, Canada

P277 - Reducing HIV self-testing barriers in black African communities using collect: A PHE HIV innovation fund project
Louise Logan, Public Health England, UK

P278 - Strategies developed by ministry of health of Brazil to increase HIV diagnosis since 2012
Pämela Gaspar, Ministry of Health of Brazil, Brazil

P279 - Development and validation of sexually transmitted infections decision modelling software in cooperation with policy makers
John Saunders, UCL, UK

P280 - Use of mobile healthcare units in rapid test events in combating sexually transmitted infections
Ana Amélia Bones, Brazil

P281 - Reaching out to MSM who fled for war and LGBT oppression for HIV and STI testing, HBO vaccination and counselling
Hanna Bos, Soa Aids Nederland, Netherlands

P283 - The Alberta 2016-2020 STBBI Operational Strategy and Action Plan: collective impact to address the provincial STI outbreak
Cari Egan, Alberta Health Services, Canada

P285 - Factors associated with mother-to-child HIV transmission in western Nigeria: Importance of 90-90-90 goals in the elimination
Saheed Usman, APIN Public Health Initiatives, Nigeria

P288 - Sexually transmitted infections among pregnant women in rural Mysore, India
Sandra Kiplagat, Florida International University, USA

P290 - Temporal discounting and engagement in care among HIV-infected pregnant and breastfeeding women
Jessica Londeree Saleska, Ohio State University College of Public Health, USA

P291 - Impact of PMTCT service uptake on outcome of care among women attending anti natal care in Nigeria
Chidiebere Ezeokfor, National Agency for the Control of AIDS, Nigeria

P295 - Prevalence of STIs among Nepalese women population
Prasanna Uperti, Prabhat Kiran Sewa Samaj (NGO, NPO), Nepal

P299 - Epidemiology of sexually transmitted infections at Gabriel Toure Teaching Hospital, Bamako, Mali
Ibrahim Téguéét, Mali

P300 - Neighborhood violent crime and HIV transmission risk: A temporal and spatial exploration of their association
Aruna Chandran, Johns Hopkins University School of Medicine, USA

P302 - Achieving the third 90: Keeping pregnant and breastfeeding women living with HIV virally suppressed in western Nigeria
Ibiwumi Usman, Kids & Teens Resource Centre, Nigeria

P304 - Achieving the third 90: Keeping adolescents living with HIV virally suppressed in rural Nigeria in the era of test and treat
Saheed Usman, APIN Public Health Initiatives, Nigeria

P305 - Poor adherence predictors and factors associated with treatment failure among HIV seropositive patients in western Nigeria
Ibiwumi Usman, Kids & Teens Resource Centre, Nigeria

P306 - Vaccine development & AMP; Participation in sub-Saharan Africa: How willing are young people in Western Nigeria?
Saheed Usman, APIN Public Health Initiatives, Nigeria

P307 - Linkage to HIV care from sexual health center Rotterdam: Temporal entrance to care, but worrying loss to follow-up in migrants
Hannelore Götz, 1 Public Health Service Rotterdam Rijnmond; 2 Erasmus MC University Medical Center Rotterdam; 3 National Institute for Public Health and the Environment (RIVM), Netherlands

P308 - Timing of initiation of HIV treatment and level of adherence among pregnant women under option B+ programme in Nigeria
Olumuyiwa Omonaiye, Deakin University, Australia

P309 - Going deeper - MSM peer cliques and not peer groups promotes behaviour change in HIV prevention intervention in Nigeria
Lawrence Ukponahiungi, Edo State Agency for the Control of HIV and AIDS, Nigeria

P311 - Examining interactions with online outreach workers for gay, bisexual and other men who have sex with men
David Brennan, University of Toronto, Canada

P312 - Evaluation of an antiretroviral therapy (ART) interruption alert and referral system in British Columbia (BC), Canada
Jon Kremer, BC Centre for Excellence in HIV/AIDS, Canada

P313 - The role of temporal discounting in a conditional cash transfer intervention to improve engagement in HIV-care
Jessica Londeree Saleska, Ohio State University College of Public Health, USA

P314 - Identifying key stakeholders and their roles in the integration of POCTs for STIs into clinical services
Agata Pacho, St George’s, University of London, UK

P316 - Structure-based drug design for Neisseria gonorrhoeae, Chlamydia trachomatis, and Mycoplasma genitalium
Kayode Ojo, University of Washington, USA

P317 - Implementation of continuous quality initiative for improving key indicators in HIV treatment cascade in western Nigeria
Saheed Usman, APIN Public Health Initiatives, Nigeria

P318 - The implications of effective school-based prevention for risk of STD acquisition
Kathleen Ethier, Centers for Disease Control and Prevention, USA

P319 - Randomized Controlled Trial of 1% and 5% 5-Fluorouracil Compared to 90% Trichloroacetic Acid for Anogenital Wart Treatment
Ika Anggraini, Universitas Indonesia, Indonesia

P320 - Incentive testing and treatment for STBBI in hard to reach populations in Edmonton, Alberta, Canada
Petra Smyczek, Alberta Health Services, Canada

P321 - The sexual and reproductive health needs of the hard to reach populations in Uganda
SAMUEL Mukasa, Uganda Martyrs University, Uganda

P322 - A Brief Clinic-Based Peer-to-Peer Education Intervention to Improve Prevention Practices Among Sexual Minority Men
Nathan Lachowsky, University of Victoria, Canada

P323 - Unexpected rising trend of sexually transmitted infections in Bangkok, Thailand
Alisa Tattakorn, BMA, Thailand

P324 - How do the psychosocial characteristics of women attending sexual health services differ from those attending primary care?
Natalie Edelman, University of Brighton, UK
P326 - Syndemic patterns of risk for sexually transmitted infections
Ashley Hill, Texas A&M University, USA

P327 - Pattern of sexually transmitted infections in the interior part of Sindh Province of Pakistan
Mour Khan, Chandka Medical College & SMBB Medical University, Pakistan

P328 - Sexual health care: Professional development for rural practitioners
Siobhan Bourke, The University of Melbourne, Australia

P329 - Stress, post-traumatic stress disorder, and sexual and reproductive health in a nationally-representative sample of US women
Joy Scheidell, NYU School of Medicine, USA

P330 - The sexual and reproductive health needs of hard to reach groups in Uganda
SAMUEL Mukasa, Uganda Martyrs University, Uganda

P331 - Quantitative evaluation of an innovation contest to enhance a sexual health campaign in China
Ye Zhang, Kirby Institution, University of New South Wales, Australia

P334 - Acceptance of contraceptive vaginal ring among women with bacterial vaginosis and their male partners in Kenya
Jeanne Marrazzo, University of Alabama at Birmingham, USA

P335 - E-devices usage in order to promote mHealth for young key population: HackHealth outcomes
Diego Calixto, Ministry of Health of Brazil, Brazil

P336 - The sexual health knowledge, attitudes and behaviour of women living with HIV in Banten Province, Indonesia
Dyah Juliastuti, The University of Queensland, Australia

P337 - A study on how sexual empowerment under mixed-gender dyads influences sexual health among women in India
Raman Mishra, International Institute for Population Sciences, India

P338 - Prevalence and mucosal impact of STIs in young women from Mombasa, Kenya with varying exposure to sex work
Lyle McKinnon, University of Manitoba, Canada

P339 - Factors of risky sexual behavior among long-haul truckers in a Southern Nigerian town
Paul Okojie, Liberty University, USA

Patricia Dittus, Centers for Disease Control and Prevention, USA

P341 - Trends in condom use among a nationally representative sample of women and men with opposite-sex partners in the U.S.
Patricia Dittus, Centers for Disease Control and Prevention, USA

P343 - Primary outcomes from implementing a behavioral counseling intervention program in four federally qualified health centers
Kathryn Brookmeyer, Centers for Disease Control and Prevention, USA

P345 - Correlates of consistent condom use among urban adolescents attending high-school in Panama
Indira Ranaweera, University of South Florida, USA

P346 - Psychosocial factors associated with chlamydia retesting among young people in the UK
Lorraine McDonagh, University College London, UK

P347 - Does HPV vaccine initiation influence sexual behaviour? Findings from the second Australian study of health and relationships
Anna Yeung, St. Michael's Hospital, Canada

P348 - Intracluster correlations of STI and sexual behaviour outcomes: Estimates from a community-based cluster RCT
Jane Hocking, University of Melbourne, Australia

P349 - Sexual behavior and STI risk among MSM and transgender women participating in a study of timing of antiretroviral therapy
Michalina Montaño, University of Washington, USA

P350 - What is the optimum method for collecting robust data to understand a nation's sexual health needs?
Catherine Mercer, University College London, UK

P351 - Down to test: Music festivals to improve attitudes & social norms to STI testing & condoms in high-risk young people
Chris Bourne, NSW Health, Australia

P352 - STD, HIV, and pregnancy testing behaviors among internet and mobile dating application users and non-users, 2016
Matthew Hoben, Centers for Disease Control and Prevention, USA

P353 - Social apps and the evolving risk environment: A cross-sectional survey among men who attend STDs clinics in Guangdong, China
Changchang Li, Dermatology Hospital of Southern Medical University, China

P356 - HIV-related stigma and discrimination in Western Nigeria: Experiences of people living with HIV and rights issues
Ibiwumi Usman, Kids & Teens Resource Centre, Nigeria

P357 - Interlinking stigma, violence and STI/HIV among injecting drug users in India
Santosh Sharma, International Institute for Population Sciences, India

P360 - Improving health care worker understanding of LGBTQ+ patients through storytelling and empathy
Errol Fields, Johns Hopkins University, USA

P361 - Prevalence of bacterial vaginosis among women attending Sexual Health Clinics in New York City, 2017-2018
Alissa Davis, Columbia University, USA

P363 - Combined oral and topical antibiotic therapy for male partners of women with bacterial vaginosis: A pilot study
Erica Plummer, Monash University, Australia

P364 - Gardnerella vaginalis clade distribution is associated with behaviours and Nugent score in women who have sex with women
Erica Plummer, Monash University, Australia

P365 - Microbial risk factors for acquisition of symptomatic bacterial vaginosis (BV)
May Beamer, Magee-Womens Research Institute, USA

P366 - An evaluation of the BD MAX™ vaginal panel compared to the Nugent Score for diagnosis of bacterial vaginosis (BV)
Lisa Cosentino, Magee-Womens Research Institute, USA

P367 - Hormonal contraception and risk of STIs and bacterial vaginosis in South African adolescents: a randomized trial
Christina Bale, University of Cape Town, South Africa

P368 - Low prevalence of vaginal dysbiosis in Kenyan adolescent girls
Anna Wald, University of Washington, USA

P369 - Incidence of vaginal infections in Kenyan women randomized to continuous or cyclic contraceptive ring (CVR)
Jeanne Marrazzo, University of Alabama at Birmingham, USA

P370 - Prevalence of chlamydia, gonorrhoea, M. genitalium and T. vaginalis in the general population of Slovenia, 2016-2017
Irena Klavz, National Institute of Public Health, Slovenia

P371 - Effect of metronidazole treatment on recurrent and persistent bacterial vaginosis: A pilot study
Makella Coudray, Florida International University, USA

P372 - Bacterial vaginosis and high-risk human papillomavirus coinfection among African American women in the United States
Purnima Madhivanan, Florida International University, USA
P423 - Pre-exposure prophylaxis as an alternative to PEP for electives. Survey assessing medical students’ knowledge and beliefs
Zayn Majeed, GKT School Of Medical Education, UK

P424 - High prevalence and incidence of bacterial STIs in young women at high risk of HIV prior to PrEP scale-up in Kenya
Jenell Stewart, University of Washington, USA

P425 - Capturing missed opportunities for PrEP prescription in patients diagnosed with other STIs
Stephanie McLaughlin, New York University, USA

P426 - Risk factors associated with Gonorrhea infection among PrEP patients in a Montreal clinic
Réjean Thomas, Clinique médicale l’Actuel, Canada

P427 - SUPPlex: Appearance and performance-enhancing supplements use in people on pre-exposure ProphylaXis
Isaac Bogoch, University Health Network, Canada

P428 - HIV Incidence, and pre- and post-exposure prophylaxis (PrEP and PEP) among PEP users at New York City sexual health clinics
Preeti Pathela, New York City Department of Health and Mental Hygiene, USA

P429 - Does HIV pre-exposure prophylaxis (PrEP) initiation in sexual health clinics impact subsequent HIV risk?
Preeti Pathela, New York City Department of Health and Mental Hygiene, USA

P430 - Predictors of interest in switching from daily to on-demand HIV pre-exposure prophylaxis (PrEP) among Australians
Vincent Cornelisse, Melbourne Sexual Health Centre, Australia

P431 - Effect of targeted intervention on condom use and among men who have sex with men (MSM) taking PrEP in Nairobi, Kenya
Maureen Akolo, Partners for Health and Development in Africa, Kenya

P432 - High prevalence and incidence of curable STIs among young women initiating PrEP in a township in South Africa
Katherine Gill, Desmond Tutu HIV Foundation, South Africa

P433 - Low HIV incidence among women diagnosed with syphilis or gonorrhea does not support PrEP recommendations, King County, WA
Anna Berzkalns, Public Health – Seattle & King County, WA

P434 - Substance use patterns and HIV prevention among gay and bisexual men in the 2014-2015 sex now survey
Kifer Card, University of Victoria, Canada

P435 - Use of condoms for the prevention of sexually transmitted infections (STIs) among HIV pre-exposure prophylaxis (PrEP) users
Benjamin Bavinton, University of New South Wales, Sydney, Australia

P436 - Barriers to adherence to HIV treatment among adolescents and youth enrolled in ARV in two district hospitals in rural Rwanda
Naome Nyirahabimana, Partners In Health/Inshuti mu Buzima (Rwanda), Rwanda

P437 - Gay, bisexual and other men who have sex with men prefer sexual health clinic nurses over family physicians for PrEP delivery
Darrell Tan, St. Michael’s Hospital, Canada

P438 - Insurance coverage, financial strain, and adherence to pre-exposure prophylaxis among gay/bisexual men in the United States
Tyler Wray, Brown University School of Public Health, USA

P439 - Assessment of potential pre-exposure prophylaxis (PrEP) compliance in intravenous drug users accessing outreach services
Jane Champion, University of Texas at Austin, USA

P440 - Assessment of potential pre-exposure prophylaxis (PrEP) compliance in intravenous drug users accessing outreach services
Jane Champion, University of Texas at Austin, USA

P441 - Implementing pre-exposure prophylaxis for HIV: Experiences in a health department based STI clinic
Andrea Lewis, Wake Forest Baptist Medical Center, USA

P442 - Eligibility for and use of HIV pre-exposure prophylaxis among Australian gay and bisexual men over time
Benjamin Bavinton, University of New South Wales, Sydney, Australia

P443 - A case series of pre-exposure prophylaxis failures in men using event-based-dosing in London, UK
Naomi Fitzgerald, Guy’s and St Thomas’ NHS Trust, UK

P444 - Anxiety about HIV and use of HIV pre-exposure prophylaxis among gay and bisexual men
Peter Saxton, University of Auckland, New Zealand

P445 - Use of antibiotic prophylaxis for sexually transmitted infections among gay and bisexual men in Australia
Vincent Cornelisse, Melbourne Sexual Health Centre, Australia

P446 - Awareness and acceptability of pre-exposure prophylaxis among MSM: Results from Scotland’s gay bar survey
Jamie Francis, Glasgow Caledonian University, UK

P447 - Are we enrolling men who have sex with men with greatest HIV acquisition risk in a pre-exposure prophylaxis program?
Errol Fields, USA

Errol Fields, USA

P450 - Prep use, STD acquisition and sexual risk behavior
Amy Burrell, Chase Breton Health Services, USA

P452 - A Nurse-Led HIV Pre-Exposure Prophylaxis Program at Cool Aid Community Health Centre for Men Who Have Sex with Men
Karen Lundgren, Cool Aid Community Health Centre, Canada

P453 - Incidence and Predictors of Urethral and Rectal Chlamydia and Gonorrhea among Men Who Have Sex with Men Taking PrEP in Kenya
Supriya Mehta, University of Illinois at Chicago, USA

P454 - Emergency Department (ED)-Based HIV Pre-Exposure Prophylaxis (PrEP) Referral Program—Using EDs as a Portal for PrEP Services
Zezhou Zhao, Johns Hopkins University, USA

P455 - Awareness, Knowledge and Willingness to use HIV PrEP among MSM and TG People in Bali, Indonesia
Irvin Romyco, FH1360-LINKAGES, Indonesia

P457 - A single dose of behaviour change: The impact of testing on behaviour and chlamydia transmission
Daphne Van Wees, Netherlands

P458 - Genital Chlamydia trachomatis and Mycoplasma genitalium among infertile women in University College Hospital, Ibadan
Tinuade Ajani, Babcock University Teaching Hospital, Nigeria

P459 - Towards a universal tool for estimating chlamydia prevalence from surveillance data: A systematic comparison of models
Jonathan Roberts, Imperial College London, UK

P460 - Assessment of tubal factor infertility attributable to chlamydia with Pgp3 serology
Gloria Anyalechi, Centers for Disease Control and Prevention, USA

P461 - Bacterial load of chlamydia in the oropharynx and saliva among gay and bisexual men with untreated oropharyngeal chlamydia
Kate Maddaford, Alfred Health, Australia

P462 - Re-testing for chlamydia in the National Chlamydia Screening Programme in Bristol, England: An analysis of surveillance data
Katherine Davis, Imperial College London, UK
P463 - Participation and retention of women in a prospective multicenter study on Chlamydia trachomatis infections (FemCure)
Nicole Dukers-Muijrers, Public Health Service South Limburg, Netherlands

P464 - Treatment failure in rectal Chlamydia trachomatis azithromycin treated women driven by high viable bacterial load (FemCure)
Nicole Dukers-Muijrers, Public Health Service South Limburg, Netherlands

P465 - Chlamydia-screening for women under the age of 25 years in Germany – how are we doing?
Martyna Gassowski, Robert Koch-Institute, Germany

P466 - High prevalence of extragenital Chlamydia trachomatis (CT) in heterosexual women: validation of pooled samples
Selena Singh, UK

P467 - Factors associated with anorectal chlamydial or gonorrhoea test positivity in women – a systematic review and meta-analysis
Andrew Lau, University of Melbourne, Australia

P468 - The association of symptoms with viable vaginal or rectal Chlamydia trachomatis load: Multicenter cohort study
Nicole Dukers-Muijrers, Public Health Service South Limburg, Netherlands

P469 - Spontaneous resolution to negative and non-viable status of vaginal and rectal Chlamydia trachomatis infection (FemCure)
Nicole Dukers-Muijrers, Public Health Service South Limburg, Netherlands

P470 - Screening rates and follow-up of Chlamydia trachomatis and Neisseria gonorrhoeae infections during pregnancy
Annie-Claude Labbé, Hôpital Maisonneuve-Rosemont, CIUSSS de l’Est-de-l’Île-de-Montréal, Canada

P471 - Lymphogranuloma venerum in Quebec, Canada: five years of epidemiological survey, 2013-2017
Karine Blouin, Institut National de Santé Publique du Québec, Canada

P472 - Do chlamydia testing patterns in New Zealand explain the high diagnosis rates?
Peter Saxton, University of Auckland, New Zealand

P473 - Epidemiology of Chlamydia trachomatis in Ontario and implications for changes to practice guidelines
Gayane Hovhannisyan, Niagara Public Health Department, Canada

P474 - Cases of Lymphogranuloma venerum in Chicago, IL, July 2016 – April 2017
Irina Tabidze, Chicago Department of Public Health, USA

P475 - Chlamydia trachomatis and Neisseria gonorrhoeae: Prevalence and factors associated among women with HIV in São Paulo, Brazil
Validir Pinto, Municipal Health Secretariat of São Paulo, Brazil

P476 - Prevalence of chlamydia and gonorhoea among youth in Los Angeles and New Orleans receiving frequent testing
Erin Keizur, UCLA, USA

P477 - Prenatal screening and treatment of Chlamydia trachomatidis infection to prevent adverse pregnancy outcomes - a pilot study
Changchang Li, Dermatology Hospital of Southern Medical University, China

P478 - Is chlamydia and gonorrhoea testing associated with pregnancy outcomes? A retrospective data-linkage cohort study
Torington Callan, University of Technology Sydney, Australia

P479 - Immunoprofiling of Chlamydia trachomatis combining whole-proteome microarrays and high-throughput multiplex serology
Katrin Hufnagel, German Cancer Research Center (DKFZ), Germany

P480 - Enhanced prevalence of Chlamydia trachomatis DNA in clinical samples of patients with STIs co-infection
Valentina Feodorova, Federal Research Center for Virology and Microbiology, Branch in Saratov, Russian Federation

P481 - Patients with repeat Chlamydia trachomatis and Neisseria gonorrhoeae are different compared to those with single infections
Nicole Dukers-Muijrers, Public Health Service South Limburg, Netherlands

P482 - Women visiting general practitioners have higher Chlamydia trachomatis bacterial loads than women visiting the STI clinic
Nicole Dukers-Muijrers, Public Health Service South Limburg, Netherlands

P483 - A lower genital Chlamydia trachomatis bacterial load is associated with coinfections with Neisseria gonorrhoeae and HIV
Nicole Dukers-Muijrers, Public Health Service South Limburg, Netherlands

P484 - The impact of Chlamydia trachomatis NAAT detection probability on test-of-cure results
Peta Wolffs, Maastricht University Medical Center (MUMC+), Netherlands

P485 - Predictors of loss-to-follow-up among HIV infected MSM on treatment at a (trusted) community health centre in Lagos, Nigeria
Adebola Adejimi, College of Medicine, University of Lagos, Nigeria

P486 - Population structure of Lymphogranuloma venerum in Belgium: Surveillance data from 2010 until 2017
Iirth De Baetselier, Institute of Tropical Medicine, Belgium

P487 - A novel rapid real-time PCR test for the detection of Chlamydia trachomatis in patient samples
Clare Cornwell, QuantuMDx, UK

P488 - Putting the U.S. Army’s rising rates of chlamydia and gonorrhea in perspective: A comparison with U.S. trends
Nikki Jordan, Army Public Health Center, USA

P489 - Chlamydia trachomatis -specific gene transcripts as a more accurate marker for infection status
Peta Wolffs, Maastricht University Medical Center (MUMC+), Netherlands

P490 - LGV in patients attending an STI outpatient clinic in Berlin: An urban emergence with high proportion of HIV-coinfections
Heiko Jessen, Praxis Jessen2 + Kollegen, Germany

P491 - Determining recommended chlamydia and gonorrhea treatment using linked medical claims, prescription and laboratory data
Guoyu Tao, Centers for Disease Control and Prevention, USA

P492 - Predicting Chlamydia reinfection in African American women using immunogenetic determinants in a Bayesian model
Kristin Olson, University of Alabama at Birmingham, USA

P493 - Determination of Chlamydia trachomatis organism load in men with Nongonococcal Urethritis (NGU)
James Williams, Indiana University School of Medicine, USA

P494 - Diagnosis and management of lymphogranuloma venerum (LGV) in a municipal STD Clinic, San Francisco, 2016-18
Stephanie Cohen, San Francisco Department of Public Health, USA

P495 - HIV, STIs and sexual health screening in men who have sex with men in Lebanon: A retrospective study
Ismael Maatouk, Clemenceau Medical Center, Lebanon

P496 - Syphilis risk perceptions among repeatedly infected men who have sex with men in Beirut-Lebanon
Ismael Maatouk, Clemenceau Medical Center, Lebanon

P497 - A meta-synthesis of men who have sex with men (MSM)’s experiences and perceptions of Human Papillomavirus (HPV) vaccination
Lewis Clarke, Edinburgh Napier University, UK
**P499** - Human papillomavirus detection in residual samples from STI tests in men who have sex with men
Richard Gilson, University College London, UK

**P500** - Barriers and opportunities for partner services related to syphilis among men who have sex with men in Anchorage, Alaska
Laura Quilter, Centers for Disease Control and Prevention, USA

**P501** - Low prevalence of high-risk anal HPV in young gay and bisexual males after the universal HPV vaccination program in Australia
Eric Chow, Monash University, Australia

**P503** - Trends in awareness and use of PrEP among HIV-negative men who have sex with men in Vancouver, Toronto, and Montreal
Heather Armstrong, University of British Columbia, Canada

**P505** - The impact of gonorrhea vaccination in men who have sex with men on prevalence and resistance: mathematical modelling study
Janneke Heijne, National Institute for Public Health and the Environment (RIVM), Netherlands

**P507** - Disclosure of same-sex behavior and extragenital STI testing among men who have sex with men — American Men's internet survey
Alex De Voux, Centers for Disease Control and Prevention, USA

**P508** - Hepatitis C reinfection rates after cure or clearance among HIV-infected and uninfected men who have sex with men
Maryam Darvishian, British Columbia Centre for Disease Control, Canada

**P509** - Use of internet/mobile dating apps to find sex partners among a nationally representative sample of men who have sex with men
Rachel Kachur, Centers for Disease Control and Prevention, USA

**P510** - Chemsex among men who have sex with men in a mixed urban-non-urban area and associations with sexually transmitted infections
Christian Hoebe, Public Health Service South Limburg, Maasstricht University Medical Center (MUMC+), Netherlands

**P511** - Surveillance of Lymphogranuloma venereum among men who have sex with men attending STI clinics in Alberta, Canada, 2018
Petra Smyczek, Alberta Health Services, Canada

**P512** - Quantifying sexual mixing by HIV status and pre-exposure prophylaxis (PrEP) use among men who have sex with men (MSM) with men
Jesse Knight, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Canada

**P513** - Convection mixing and the social geography of partner selection among sexual minority men in Toronto, Canada
Dionne Gesink, University of Toronto, Canada

**P516** - Low immunity to hepatitis A amongst men who have sex with men attending a large sexual health clinic in Melbourne, Australia
Lenka Vodstrcil, Monash University, Australia

**P517** - Do sexual practices differ by age among gay and bisexual men? A cross-sectional study in Melbourne, Australia
Eric Chow, Monash University, Australia

**P518** - Sexual practices and healthcare use of men who have sex with men only and men who have sex with men and women
Alaina Vaisey, University of Melbourne, Australia

**P519** - Does sexual mixing increase the likelihood of acquiring HIV and STIs among needle exchange participants in Vancouver, Canada?
Lenka Vodstrcil, Monash University, Australia

**P520** - HPV infections and flat penile lesions of the penis in men who have sex with men
Maarten Schim Van Der Loeff, Public Health Service Amsterdam, Amsterdam University Medical Center (UMC), Netherlands

**P521** - Increases in the estimated number of reported gonorrhoea cases among men who have sex with men (MSM): The role of testing
Emily Weston, US Centers for Disease Control and Prevention, USA

**P522** - Disparities in HIV/STI testing and diagnosis among urban and non-urban US men who have sex with men from 2013 to 2017
Maria Zlotorzynska, Emory University Rollins School of Public Health, USA

**P523** - Urethral microbiota in idiopathic nononococcal urethritis (NGU) in men who have sex with men and men who have sex with women
Sujatha Srinivasan, Fred Hutchinson Cancer Research Center, USA

**P524** - Gays, government and big data: Should routine health records include sexual orientation?
Peter Saxton, University of Auckland, New Zealand

**P525** - Prevalence of Mycoplasma genitalium by anatomical site in men who have sex with men: A systematic review and meta-analysis
Rosie Latimer, Melbourne Sexual Health Centre, Australia

**P526** - Hepatitis C reinfection rates after cure or clearance among HIV-infected and uninfected men who have sex with men in Tokyo
Daisuke Mizushima, National Center for Global Health and Medicine, Japan

**P527** - HIV testing uptake among young men who have sex with men in Myanmar: Self-efficacy and HIV testing behavior
Minh Pham, Burnet Institute, Australia

**P528** - Rates of primary and secondary syphilis among men who have sex with men by HIV status — 24 states, 2011–2015
Jeremy Grey, Centers for Disease Control and Prevention, USA

**P529** - Early sexual debut and non-consensual sex among Chinese men who have sex with men: A multi-city cross-sectional study
Weiming Tang, UNC Project-China, China

**P530** - Addressing underserved men who have sex with men (MSM): Advancing the sexual health approach for MSM in Vancouver, Canada
Nathan Lachowsky, University of Victoria, Canada

**P531** - Chemsex and STI clinic use among MSM: results from a large online survey in England
Paula Blomquist, Public Health England, UK

**P532** - The sexual behaviour and health of heterosexual-identifying men who have sex with men: A systematic review
Tyrone Curtis, University College London, UK

**P533** - Hepatitis A vaccine uptake among men who have sex with men in a targeted vaccination program in Melbourne in 2018
Lenka Vodstrcil, Monash University, Australia

**P534** - Chemsex & Amp; sexual consent: A quantitative study on sexualized drug use in men who have sex with men and non-consensual sex
Martijn Van Rooijen, Public Health Service of Amsterdam, Netherlands

**P535** - High HIV incidence among men who have sex with men in eight Chinese cities: Results from a cohort study
Weiming Tang, UNC Project-China, China

**P539** - Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae among MSM in Morocco
Ámina Hançali, Institut National d’Hygiène, Morocco

**P540** - HPV (sero) prevalence among young MSM visiting the STI clinic: Opportunities for targeted HPV vaccination
Petta Woestenberg, RIVM, Netherlands
PS41 - To pool or not to pool STI samples in MSM using PrEP? Results of the CohMSM-PrEP Study (ANRS 12369 - Expertise France)
Irith De Baetselier, Institute of Tropical Medicine, Belgium

PS42 - Prevalence of STIs among MSM initiating PrEP in West-Africa (CohMSM-PrEP ANRS 12369 - Expertise France)
Irith De Baetselier, Institute of Tropical Medicine, Belgium

PS43 - Cost-effectiveness of pre-exposure prophylaxis in MSM with event-driven and daily regimens
Maarten Reitsema, RIVM, Netherlands

PS44 - Trends in recreational drug use and associations with CAS, HIV and STI among HIV-negative MSM in Amsterdam between 2008-2017
Liza Coyer, Public Health Service Amsterdam, Netherlands

PS45 - Trends in HIV infection and AIDS in men who have sex with men (MSM): Adults compared to young people in Sao Paulo, Brazil
Carmen Silvia Domingues, STI/AIDS Reference Center - Sao Paulo State Program of STI/AIDS, Brazil

PS46 - “STIs are everyone’s responsibility”: A new conceptual model of sexual health among gay and bisexual men
Denton Callander, New York University, USA

PS47 - Relationship length of gay male couples and sexually transmitted infections
Silver Vargas, Universidad Peruana Cayetano Heredia, Peru

Gretchen Snoeyenbos Newman, University of Washington, USA

PS49 - What is the optimal testing strategy for oropharyngeal Neisseria gonorrhoeae in MSM visiting STI clinics?
Christian Hoebe, Public Health Service South Limburg, Maastricht University Medical Center (MUMCH), Netherlands

PS50 - High awareness but low uptake of HPV vaccine among GBMSM in Ontario, Canada: Results from the #iCruise Study
Anna Yeung, St. Michael's Hospital, Canada

PS51 - Extragenital gonorrhea positivity among men who have sex with men – STD Surveillance Network, 2015–2017
Winston Abara, CDC, USA

PS52 - Extragenital Chlamydia in Men Who Have Sex with Men – STD Surveillance Network, the deep South
Paul St. Clair, USA

PS53 - Initiating a sexual network study among men who have sex with men: A mixed-methods pilot study
JaNelle Ricks, The Ohio State University, USA

PS54 - Adherence and sexually transmitted infections among MSM receiving care in a community-based HIV PrEP clinic in the deep South
Winston Abara, CDC, USA

PS55 - Monitoring HIV and syphilis co-infection among men who have sex with men in Brazil, 2009-2016
MARK Guimaraes, Brazil

PS56 - History of STI therapy and willingness of prep among HIV-negative MSM cohort in Japan
Masao Takano, National Center for Global Health and Medicine, Japan

PS57 - “Flux NZ”: An online national cohort investigating HIV, STI and drug-related practices among New Zealand gay and bisexual men
Peter Saxton, University of Auckland, New Zealand

PS58 - Sexual health, syndemics and assets among men who have sex with men: Secondary analysis of multi-national surveys
Paul Flowers, University of Glasgow, UK

PS59 - Incarceration, stress and sexual risk-taking: An inter-sectional analysis of black men who have sex with men in the deep south
Denton Callander, New York University, USA

PS60 - HIV preventative behaviour during last sex with a non-steady partner – self-reported data from 113,000 MSM from 66 countries
Ulrich Marcus, Robert Koch-Institut, Germany

PS61 - Developing surveillance tools to measure MSM’s HIV infection risk in the era of complex biobehavioural prevention strategies
Jamie Frankis, Glasgow Caledonian University, UK

PS62 - Health seeking behaviour and acceptability of online outreach efforts among MSM using sex-seeking apps/websites
David Brennan, University of Toronto, Canada

PS63 - MSM predictive modeling within a large, linked database of laboratory, surveillance, and administrative healthcare records
Travis Salway, BC Centre for Disease Control, Canada

PS64 - Outcomes of anal HPV screening in HIV+ men who have sex with men attending high resolution anoscopy clinic in Canada
Angel Chu, Alberta Health Services, Canada

PS65 - Personalized cognitive counseling (PCC) to reduce HIV risk following rectal gonorrhea/chlamydia diagnosis among MSM in Peru
Jesse Clark, UCLA Geffen School of Medicine, USA

PS66 - The uptake of non-occupational HIV postexposure prophylaxis among MSM: A systematic review and meta-analysis
Zhenyu Wang, School of Public Health, Sun Yat-sen University, China

PS67 - Factors influencing gay and queer men’s acceptability of integrating substance use care within sexual healthcare settings
Caroline Mniszak, BC Centre on Substance Use, Canada

PS68 - Positivity of syphilis, rectal gonorrhea and rectal chlamydia among MSM PrEP users in Baltimore City, Maryland
Christina Schumacher, Johns Hopkins School of Medicine, USA

PS69 - Seroadaptive behaviors influenced by partner-level and environmental-level factors among IPREX participants
Hong-Ha Truong, University of California, San Francisco, USA

PS70 - Demographic, healthcare, and psychosocial factors related to STI diagnosis in a sample of young MSM: The P18 cohort study
Stephanie McLaughlin, USA

PS71 - Prevalence of extragenital gonorrhea and chlamydia among venue-attending men who have sex with men – San Francisco, 2017
Trang Nguyen, San Francisco Department of Public Health, USA

PS72 - High prevalence of anal human papillomavirus infection in HIV-Infected males having sex with males in Turkey
Alper Gunduz, Sisili Etflaf Training and Research Hospital, Turkey

PS73 - Geographic effects of incarceration on multiple partnerships and STI among black men who have sex with men
Maria Khan, New York University School of Medicine, USA

PS74 - Rectal and pharyngeal M. genitalium among Men who have Sex with Men (MSM): Results from a Longitudinal Cohort Study
Lindley Barbee, University of Washington, USA

PS75 - Prevalence and Risk Factors of Anal Human papillomavirus (HPV) Infections among MSM in Bali, Indonesia
Irvin Romyco, FHI360-LINKAGES, Indonesia

PS76 - Developing surveillance tools to measure MSM’s HIV infection risk in the era of complex biobehavioural prevention strategies
Irvin Romyco, FHI360-LINKAGES, Indonesia

PS77 - Associations between penile-rectal intercourse and oral sex and viral STIs in the United States, 2011-2015
Melissa Habel, Centers for Disease Control and Prevention, USA

PS78 - Drivers of sexual health knowledge for two-spirit, gay, bi and/or native men who have sex with men (gbMSM)
Harlan Pruden, BCCDC, Canada

PS79 - Prevalence and correlates of syphilis and HIV infection among adolescents of the Comarca Ngäbe-Buglé, Panama
Amanda Gabster, Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama
P622 - The use of Seegene's Allplex™MG & AzIR assay for the detection of Mycoplasma genitalium and macrolide resistance in Wales
Andrew Barratt, Room 166, 6th floor Main Building, University Hospital of Wales, UK

P623 - Post-transcriptional regulation of genes by non-coding RNA in Neisseria gonorrhoeae, an obligate human pathogen
Pooja Tanwer, University of Delhi, India

P624 - Culture for urethral gonorrhoea from asymptomatic men positive for Neisseria gonorrhoeae by urine Aptima Combo 2 testing
Melanie Bisssessor, Melbourne Sexual Health Centre, Australia

P625 - Trends in symptomatic presentation among reported gonorrhea cases, STD Surveillance Network (SSuN), 2010 – 2017
Mark Stenger, U.S. Centers for Disease Control and Prevention, USA

P626 - Neisseria Gonorrhoea as an Unrecognized Cause of Preseptal Cellulitis
Paul Adamson, UCLA - David Geffen School of Medicine, USA

P627 - Changing of molecular characterization of gonococcal isolates in Guangdong, China: In a background of a rising epidemic
He-ping Zheng, Dermatology Hospital of Southern Medical University, Guangdong Center for STD Control & Prevention, China

P628 - The impact of including throat and rectal swabs for chlamydia and gonorrhoea testing online in British Columbia, Canada
Aidan Ablona, BC Centre for Disease Control, Canada

P629 - Gonorrhoea acquisition after infection with the US NmNG urethritis clade: a prospective, chart-based study
Abigail Norris Turner, Ohio State University, USA

P630 - Estimating the potential impact of realistic vaccination strategies against antibiotic resistant Neisseria gonorrhoeae
Lilith Whittles, Imperial College London, UK

P631 - Cases of gonorrhoea with multiple anatomic sites of infection in Canada, 2016 to 2017
Pam Sawatzky, Public Health Agency of Canada, Canada

P632 - Regional differences in gonorrhoea antimicrobial resistance patterns in the Netherlands
Maartje Visser, National Institute for Public Health and the Environment (RIVM), Netherlands

P633 - Low gonorrhoea antimicrobial resistance and culture positivity rates in general practice: A pilot study
Maartje Visser, National Institute for Public Health and the Environment (RIVM), Netherlands

P634 - Surveillance for disseminated gonococcal infections, active bacterial core surveillance (ABCs) – United States, 2015 – 2018
Emily Weston, US Centers for Disease Control and Prevention, USA

P635 - The Enhanced Gonococcal Antimicrobial Surveillance Program (EGASP) in the Philippines, 2018
Emily Weston, US Centers for Disease Control and Prevention, USA

P636 - High diversity of Neisseria gonorrhoeae in Germany revealed by molecular typing using NG-MAST (2014-17)
Klaus Jansen, Robert Koch Institute, Germany

P637 - Neisseria gonorrhoeae genomic diversity in high risk groups in Switzerland
Helena Seth-Smith, University Hospital Basel, Switzerland

P638 - Surveillance of gonococcal infection treatment failures 2015-2018 in Québec, Canada
Sylvie Venne, Quebec Health Ministry, Public Health direction, Canada

P639 - Molecular markers to predict cefixime decreased susceptibility of Neisseria gonorrhoeae: A global review
Xiaomeng Deng, David Geffen School of Medicine, USA

P640 - Targeting Murl protein to combat drug resistance in Neisseria gonorrhoeae using homology modeling and drug docking studies
Ravi Kant, University of Delhi, New Delhi, India

P641 - Gonococcal antimicrobial susceptibility from the Thailand Enhanced Gonococcal Antimicrobial Surveillance Program, 2015 – 2018
Pachara Sirivongrangson, Department of Disease Control, Thailand Ministry of Public Health, Thailand

P642 - Whole genome sequencing of N. gonorrhoeae deconvolutes sexual behaviour, population structure and transmission in Singapore
Mathew Beale, Wellcome Sanger Institute, UK

P643 - Adverse pregnancy and neonatal outcomes associated with Neisseria gonorrhoeae: A systematic review and meta-analysis
Dianne Egli-Gany, University of Bern, Switzerland

P644 - Analyzing the genomes of Neisseria gonorrhoeae isolates using a novel integrated bioinformatic pipeline: Gen2Epi
Nidhi Parmar, University of Saskatchewan, Canada

P645 - Peruvian gonococcal strains reveal novel NG-MAST types and false-positive β-lactamase isolates with blaTEM gene mutations
Adriana Le Van, Uniformed Services University of the Health Sciences, USA

P646 - Agent-based modelling study of antimicrobial resistant Neisseria gonorrhoeae transmission
Katy Turner, University of Bristol, UK

P647 - Effective monotherapy due to high rate of azithromycin resistance in Neisseria gonorrhoeae infection in men in South Africa
Remco Peters, University of Pretoria, South Africa

P648 - Factors associated with Neisseria gonorrhoeae azithromycin resistance in the Quebec sentinel network, 2015-2017
Karine Blouin, Institut National de Santé Publique du Québec, Canada

P649 - Variations in time to clinical presentation for patients with uncomplicated genital gonorrhoea
Jonathan Ross, University Hospital NHS Foundation Trust, UK

P650 - Randomized clinical trial comparing gentamicin+ azithromycin vs. ceftriaxone+ azithromycin for rectal and pharyngeal gonorrhoea
Magnus Unemo, World Health Organization Collaborating Centre for Gonorrhoea and Other STIs, Faculty of Medicine of Health, Örebro University, Sweden

P651 - Elucidating the effect of esculetin against glutamate racemase – a novel drug target of Neisseria gonorrhoeae
Alka Pawar, University of Delhi, India

P652 - Use of specimens submitted for Neisseria gonorrhoeae molecular testing to enhance surveillance in a Canadian arctic territory
Ameeta Singh, University of Alberta, Canada

P653 - Modeling the impact of partially efficacious gonorrhoea vaccines
Shaheen Seedat, Weill Cornell Medicine-Qatar, Qatar

P654 - Clonal spread of azithromycin resistant Neisseria gonorrhoeae in Canada, 2014-2017
Irene Martin, National Microbiology Laboratory, Canada

P655 - Molecular epidemiology associated with resistance in Neisseria gonorrhoeae isolates from south Brazil during 2008-2016
Magaly Parmelee, Federal University of Santa Catarina, Brazil

P656 - GyrA and ParC mutations in fluoroquinolone-resistant Neisseria gonorrhoeae isolates from Kenya
Mary Kivata, US Army Medical Research Directorate-Africa, Kenya
P657 · High azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in Shenzhen(2010-2017), China
Feng Wang, Shenzhen Center for Chronic Disease Control, China

P658 · Did minimum inhibitory concentrations in N. gonorrhoeae isolates change in Germany since 2014? Thalea Tamminga, Robert-Koch-Institute, Germany

P659 · Improved typability using culture-free genotyping of Neisseria gonorrhoeae compared to routine culture-derived surveillance Brian Van Der Veer, Maastricht University Medical Centre, Netherlands

P660 · Extra-genital ciprofloxacin-resistant Neisseria gonorrhoeae infections among sexual-health clinic users in Lima, Peru
Silver Vargas, Universidad Peruana Cayetano Heredia, Peru

P662 · Cell envelope damage of N. gonorrhoeae after 15-min beta-lactam exposure enables rapid antimicrobial susceptibility testing Emily Savela, California Institute of Technology, USA

P663 · Sharp increase of ciprofloxacin resistance of Neisseria gonorrhoeae in Yaoundé, Cameroon
Tania Crucitti, Centre Pasteur du Cameroun, Cameroon

P664 · In vitro evaluation of gepotidacin, an oral antimicrobial against multidrug-resistant Mycoplasma genitalium Jørgen Jensen, Statens Serum Institut, DK, Denmark

P665 · Rapid sequence typing for antimicrobial resistance surveillance in Neisseria gonorrhoeae using whole genome sequencing S Tariq Sadig, St George's University of London, UK

P666 · Increased resistance to extended-spectrum cephalosporins in Neisseria gonorrhoeae isolates in Nanjing, China (2013-2018)
Xiaohong Su, Institute of Dermatology, Chinese Academy of Medical Sciences, China

P667 · Guiding Neisseria gonorrhoeae management by molecular detection of ciprofloxacin resistance by SpeeDx ResistancePlus GC assay
Seb Cotton, Royal Infirmary Edinburgh, UK

P668 · Transfer of high-level macrolide resistance in Neisseria gonorrhoeae
Said Abdellati, Institute of Tropical Medicine, Belgium

P669 · Clinically isolated thiamine auxotrophs of Neisseria gonorrhoeae indicate increased susceptibility to host innate defenses
Nelson Dozier, Uniformed Services University of the Health Sciences, USA

P670 · Internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain found in China Shaochun Chen, National Center for STD Control, China CDC Institute of Dermatology Chinese Academy of Medical Sciences & Peking Union Medical College, China

P671 · Distribution of antimicrobial resistance in Neisseria gonorrhoeae – 5 years of German Gonococcal Resistance Network (GORENET)
Klaus Jansen, Robert Koch Institute, Germany

P672 · Genetic pathway to high level azithromycin resistance in Neisseria gonorrhoeae Said Abdellati, Institute of Tropical Medicine, Belgium

P673 · In-vitro activity of SMT-571 and comparators against clinical isolates and reference strains of Neisseria gonorrhoeae Paul Meo, Summit Therapeutics, UK

P675 · Two recent cases of extensively drug-resistant (XDR) gonorrhoea in the UK linked to a European party destination Paddy Horner, University of Bristol, UK

P676 · Azithromycin resistance among Neisseria gonorrhoeae cases in King County, Washington, USA, 2017-2018
Christina Thibault, Public Health - Seattle & King County, USA

P677 · Prescribed treatments for Neisseria gonorrhoeae infections and treatment failures in the Quebec sentinel network, 2015-2017
Fannie Defay, Institut National de santé publique, Canada

P678 · An effective gonococcal lipooligosaccharide (LOS) vaccine: We know enough to make one
Mac Griffiss, Crapaud Bio, Inc., USA

P679 · Neisseria gonorrhoeae (GC) culture positivity by indication for culture and anatomic site, Seattle, Washington, 2017-2018
Christina Thibault, Public Health - Seattle & King County, USA

P680 · Oropharyngeal gonorrhoea in the absence of urogenital gonorrhoea in a sexual network of males and females.
Vincent Cornelisse, Melbourne Sexual Health Centre, Australia

P681 · Importation of ciprofloxacin resistant Neisseria gonorrhoea into the UK: A public health challenge
Martina Furegato, St George's, University of London, UK

P682 · Efficacy of Securidaca longipendulculata Fresen (Polygalaceae) against standard isolates of Neisseria gonorrhoeae Meshack Omolo, UNIVERSITY OF NAIROBI, Kenya

P683 · Racial and ethnic disparities related to Neisseria gonorrhoea among U.S. military active duty service members June Early, Infectious Disease Clinical Research Program, USA

P684 · Gonorrhea sequence types in non-cultured specimens from a provincially representative sample in British Columbia Canada, 2018
Amalia Plotogea, Public Health Agency of Canada, Canada

P685 · Evaluation of Extranegative Swabs for Simultaneous Neisseria Gonorrhoeae Culture and Nucleic Acid Amplification Testing
Olusegun Soge, University of Washington, USA

P686 · The Enhanced Surveillance of Antimicrobial-Resistant Gonorrhea (ESAG) in Canada Irene Martin, National Microbiology Laboratory, Canada

P687 · Sexual network and genotypic analysis of an outbreak of gonorrhea in Winnipeg, Canada
Souradet Shaw, University of Manitoba, Canada

P689 · Turning gonorrhea against HIV: Latent HIV ‘shock-and-kill’ using a gonococcal-derived metabolite
Scott Gray-Owen, University of Toronto, Canada

P690 · Establishment of the gonorrhea mouse model for pre-clinical testing of antibiotics that follow the FK driver fauc/MIC Kristie Connolly, F. Edward Hebert School of Medicine, Uniformed Services of the Health Sciences, USA

P691 · Widespread use of high-dose ceftriaxone therapy for uncomplicated gonorrhea without reported Ceftriaxone treatment failure
Yan Han, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, China

P692 · Gentamicin susceptibility to Neisseria gonorrhoeae in Malawi after twenty-five years of sustained use
Jane Chen, University of North Carolina at Chapel Hill, USA

P693 · Neisseria gonorrhoeae In-vitro susceptibilities to Ceftriaxone, Cefixime and Azithromycin in GISP Isolates, 1987 – 2017
Ellen Kersh, Centers for Disease Control and Prevention, USA

P694 · Case-based enhanced gonorrhoea surveillance, Chicago, IL, 2018
Irina Tabidze, Chicago Department of Public Health, USA

P695 · Epidemiology of key STIs among female sex workers in the Middle East and North Africa: systematic review and meta-analyses
Laith Abu-Raddad, Weill Cornell Medicine-Qatar, Qatar
<table>
<thead>
<tr>
<th>Poster Program</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>P715</td>
<td>Violence and associated factors among female sex workers: analysis from a cross-sectional study in Guangdong, China</td>
</tr>
<tr>
<td>P716</td>
<td>HIV prevalence in at-risk adolescent girls and young women in Kenya across locations associated with sex work</td>
</tr>
<tr>
<td>P717</td>
<td>Using ethnography for planning and improving the quality of HIV prevention interventions for female sex workers in Nigeria</td>
</tr>
<tr>
<td>P718</td>
<td>Risk and place: the association between hotspot typology and determinants of HIV risk among female sex workers in Ukraine</td>
</tr>
<tr>
<td>P719</td>
<td>Prevalence and type-specific distribution of oncogenic human papillomavirus among female sex workers in Cotonou, West Africa</td>
</tr>
<tr>
<td>P720</td>
<td>Evaluating syphilis partner notification outcomes in Nigeria</td>
</tr>
<tr>
<td>P721</td>
<td>Evaluating the use of rapid syphilis testing among female sex workers in Benin, 2008-2018</td>
</tr>
<tr>
<td>P722</td>
<td>An Unusual Constellation of Symptoms: Outpatient Diagnosis of Neurosyphilis with No History of Prior Syphilis Symptoms</td>
</tr>
<tr>
<td>P723</td>
<td>A conditional pay-for-performance program to Improve Syphilis Screening in Chinese STD Clinics: A Pilot Intervention</td>
</tr>
<tr>
<td>P724</td>
<td>Frequency and characteristics of biologic false positive tests for syphilis, reported in Florida and New York City, 2013-2017</td>
</tr>
<tr>
<td>P725</td>
<td>James Matthews, Centers for Disease Control and Prevention, USA</td>
</tr>
<tr>
<td>P726</td>
<td>Syphilis – do we see the end of the steep rise in cases in Germany?</td>
</tr>
<tr>
<td>P727</td>
<td>Klaus Jansen, Robert Koch Institute, Germany</td>
</tr>
<tr>
<td>P728</td>
<td>Kendra Cuffe, Centers for Disease Control and Prevention, USA</td>
</tr>
<tr>
<td>P729</td>
<td>Kristal Aaron, University of Alabama at Birmingham, USA</td>
</tr>
<tr>
<td>P730</td>
<td>Treponema pallidum-platelet interactions and relevance to treponemal invasion</td>
</tr>
<tr>
<td>P731</td>
<td>The demography of congenital syphilis elimination in the United States</td>
</tr>
<tr>
<td>P732</td>
<td>The demography of congenital syphilis elimination in the United States</td>
</tr>
<tr>
<td>P733</td>
<td>Prevalence of self-reported syphilis among Brazilian young adults: Findings from a nationwide Survey</td>
</tr>
<tr>
<td>P734</td>
<td>Jane Chen, University of North Carolina at Chapel Hill, USA</td>
</tr>
<tr>
<td>P735</td>
<td>What do guys know about syphilis anyways?</td>
</tr>
<tr>
<td>P736</td>
<td>Evaluation of the provincial infectious syphilis partner notification program in British Columbia, Canada</td>
</tr>
<tr>
<td>P737</td>
<td>Christine Lukac, BC Centre For Disease Control, Canada</td>
</tr>
<tr>
<td>P738</td>
<td>Evaluating syphilis partner notification outcomes in seven jurisdictions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Program</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>P696</td>
<td>HIV among female sex workers and clients in the Middle East and North Africa: Subregional differences and epidemic potential</td>
</tr>
<tr>
<td>P697</td>
<td>Feasibility of HPV self-collection for cervix screening in under-screened street entrenched women</td>
</tr>
<tr>
<td>P698</td>
<td>Comprehensive healthcare intervention for female sex workers in Ethiopian STI clinics: experience from Mekelle University</td>
</tr>
<tr>
<td>P699</td>
<td>Role of management in enhancing efficiency of female sex workers HIV programs in Nigeria</td>
</tr>
<tr>
<td>P700</td>
<td>Unintended pregnancy among female sex workers in Mekelle City, Northern Ethiopia: A cross-sectional study</td>
</tr>
<tr>
<td>P701</td>
<td>Time trends in prevalence and incidence of HIV, gonorrhea and chlamydia among female sex workers in Benin, 2008-2018</td>
</tr>
<tr>
<td>P702</td>
<td>Characterizing HIV-associated vulnerabilities among women engaged in transactional sex to design programs in Ukraine</td>
</tr>
<tr>
<td>P703</td>
<td>Pregnancy intention and prevalence according to HIV status among female sex workers in Mali</td>
</tr>
<tr>
<td>P704</td>
<td>Bacterial sexually transmitted infections among women who inject drugs and exchange sex in King County, Washington</td>
</tr>
<tr>
<td>P705</td>
<td>Low gonorrhea and chlamydia testing rate among female sex workers in Guangdong province: A cross-sectional analysis</td>
</tr>
<tr>
<td>P706</td>
<td>Understanding the correlates of STI-HIV co-infections among female sex workers in Kitui</td>
</tr>
<tr>
<td>P707</td>
<td>Women's encounters with venue-based HIV risk contexts in Abuja, Nigeria</td>
</tr>
<tr>
<td>P708</td>
<td>Abnormal cervical screening test and sexually transmitted infections in West Africa's female sex workers</td>
</tr>
<tr>
<td>P709</td>
<td>Epidemiology of abnormal cervical cytology in female sex workers in Mali, West Africa</td>
</tr>
<tr>
<td>P710</td>
<td>“You need a cash buffer”: Male sex work and condom use in the era of HIV pre-exposure prophylaxis</td>
</tr>
<tr>
<td>P711</td>
<td>“Need a cash buffer”: Male sex work and condom use in the era of HIV pre-exposure prophylaxis</td>
</tr>
<tr>
<td>P712</td>
<td>High prevalence of condomless anal intercourse among female sex workers in Iran</td>
</tr>
<tr>
<td>P713</td>
<td>HIV testing and undiagnosed fraction among adolescent girls and young women by engagement in sex work in Mombasa, Kenya</td>
</tr>
<tr>
<td>P714</td>
<td>Violence and associated factors among female sex workers: analysis from a cross-sectional study in Guangdong, China</td>
</tr>
<tr>
<td>P715</td>
<td>HIV prevalence in at-risk adolescent girls and young women in Kenya across locations associated with sex work</td>
</tr>
<tr>
<td>P716</td>
<td>Using ethnography for planning and improving the quality of HIV prevention interventions for female sex workers in Nigeria</td>
</tr>
<tr>
<td>P717</td>
<td>Risk and place: the association between hotspot typology and determinants of HIV risk among female sex workers in Ukraine</td>
</tr>
<tr>
<td>P718</td>
<td>Prevalence and type-specific distribution of oncogenic human papillomavirus among female sex workers in Cotonou, West Africa</td>
</tr>
<tr>
<td>P719</td>
<td>An Unusual Constellation of Symptoms: Outpatient Diagnosis of Neurosyphilis with No History of Prior Syphilis Symptoms</td>
</tr>
<tr>
<td>P720</td>
<td>A conditional pay-for-performance program to Improve Syphilis Screening in Chinese STD Clinics: A Pilot Intervention</td>
</tr>
<tr>
<td>P721</td>
<td>Frequency and characteristics of biologic false positive tests for syphilis, reported in Florida and New York City, 2013-2017</td>
</tr>
<tr>
<td>P722</td>
<td>James Matthews, Centers for Disease Control and Prevention, USA</td>
</tr>
<tr>
<td>P723</td>
<td>Syphilis – do we see the end of the steep rise in cases in Germany?</td>
</tr>
<tr>
<td>P724</td>
<td>Klaus Jansen, Robert Koch Institute, Germany</td>
</tr>
<tr>
<td>P725</td>
<td>Kendra Cuffe, Centers for Disease Control and Prevention, USA</td>
</tr>
<tr>
<td>P726</td>
<td>Kristal Aaron, University of Alabama at Birmingham, USA</td>
</tr>
<tr>
<td>P727</td>
<td>Treponema pallidum-platelet interactions and relevance to treponemal invasion</td>
</tr>
<tr>
<td>P728</td>
<td>The demography of congenital syphilis elimination in the United States</td>
</tr>
<tr>
<td>P729</td>
<td>The demography of congenital syphilis elimination in the United States</td>
</tr>
<tr>
<td>P730</td>
<td>Prevalence of self-reported syphilis among Brazilian young adults: Findings from a nationwide Survey</td>
</tr>
<tr>
<td>P731</td>
<td>Jane Chen, University of North Carolina at Chapel Hill, USA</td>
</tr>
<tr>
<td>P732</td>
<td>What do guys know about syphilis anyways?</td>
</tr>
<tr>
<td>P733</td>
<td>Christine Lukac, BC Centre For Disease Control, Canada</td>
</tr>
<tr>
<td>P734</td>
<td>Evaluating syphilis partner notification outcomes in seven jurisdictions</td>
</tr>
<tr>
<td>P735</td>
<td>Anna Cope, Centers for Disease Control and Prevention, USA</td>
</tr>
</tbody>
</table>
P738 - No bejel among Treponema pallidum isolates diagnosed as syphilis from Surinam, Antillian and Dutch clients in Amsterdam
Helene Zondag, Public Health Service Amsterdam, Netherlands

P739 - Novel rapid test for improved diagnosis of active syphilis at the point of care
Minh Pham, Burnet Institute, Australia

P740 - Improving Syphilis Diagnosis and Treatment in an Urban Population Through Routine Emergency Department Screening
Kimberly Stanford, University of Chicago, USA

P741 - Detection of Treponema pallidum DNA at various body locations
Silvia Nieuwenburg, Public Health Service Amsterdam, Netherlands

P742 - Using lottery incentives to attract sexually risky Chinese men who have sex with men to prevent syphilis
Weiming Tang, UNC Project-China, China

P743 - Clinical Profiles of 58 Hospitalized HIV-Negative Patients with Neurosyphilis in a General Hospital in China
Minzhi Wu, The fifth people’s hospital of Suzhou, China

P744 - The pregnancy syphilis cascade of care: “95-95-95” goals for reducing of congenital syphilis in the state of Sao Paulo, Brazil
Carmen Silvia Domingues, STI/AIDS Reference Center - Sao Paulo State Program of STI/AIDS, Brazil

P745 - Maternal to child transmission prevention program for syphilis and HIV in Brazil: Missed opportunities
Angelica Miranda, Universidade Federal do Espirito Santo, Brazil

P746 - Characteristics of chlamydia/gonorhea infections associated with a subsequent syphilis diagnosis in British Columbia, Canada
Theodora Consolacion, BC Centre for Disease Control, Canada

P747 - Syphilis diagnostic test of STANDARD™ Q Syphilis Ab using fingerprint whole blood and serum on high risk populations
Rahma Lubis, Faculty of Medicine Universitas Indonesia/dr. Cipto Mangunkusumo National Hospital, Jakarta, Indonesia, Indonesia

P748 - A comparison of Treponema pallidum molecular typing systems: MLST vs. ECDC
Sharon Sahi, University of Washington, USA

P749 - Evaluation of a syphilis awareness campaign for gay, bisexual and other MSM (gbMSM): did we reach our targeted audience?
Jason Wong, BC Centre for Disease Control, Canada

P750 - Under sensitive non- treponemal tests: Implications for syphilis management
John Scythes, Community Initiative for AIDS Research, Canada

P751 - Monitoring the evaluation of congenital syphilis cases in the state of Sao Paulo, 2007 to 2017
Carmen Silvia Domingues, STI/AIDS Reference Center - Sao Paulo State Program of STI/AIDS, Brazil

P752 - Quantitation of cytokines in rabbits following tri-antigen vaccine cocktail immunization and T. pallidum challenge
Charmie Godornes, University of Washington, USA

P753 - Treponema pallidum stimulated macrophage-derived exosomal mir-146a-5p decreased monocyte transendothelial migration
Qian-Qiu Wang, Institute of Dermatology, Chinese Academy of Medical Sciences, China

P754 - Risk factors for primary and secondary syphilis among females in Chicago, 2010-2017
Kimberly Stanford, University of Chicago, USA

P755 - An evaluation of the provincial ‘Syphistory’ campaign in British Columbia, Canada
Venessa Ryan, BC Centre For Disease Control, Canada

P756 - Use of a rapid syphilis test for syphilis diagnosis among patients presenting to an STI clinic in North Carolina, USA
Arlene Seña, University of North Carolina at Chapel Hill, USA

P757 - Evaluation of the fully automated Bio-Rad Bionex 2200 Syphilis Total & RPR antibody detection assay
Vincent Boissonneault, Canada

P758 - Sensitivity and specificity of the quantitative test for TPPA and RPR for diagnosis of congenital syphilis in neonates
Xiangdong Gong, Institute of Dermatology, Chinese Academy of Medical Sciences, China

P759 - Tip of the iceberg? An unusual syphilis outbreak among young Dutch heterosexuals indicating a larger epidemic
Anne-Marie Niekamp, South Limburg Public Health Service, Netherlands

P760 - Is kissing safe? Detection of Treponema pallidum in oral swabs from patients with syphilis
Lauren Tantalo, University of Washington, USA

P761 - Attenuation of syphilis infection following immunization of rabbits with a trivalent antigen cocktail
Barbara Molinari, University of Washington, USA

P762 - Getting to the bottom of it: Sexual positioning and syphilis stage at diagnosis among men who have sex with men
Vincent Cornelisse, Melbourne Sexual Health Centre, Australia

P763 - Use of a rapid syphilis test for syphilis diagnosis
Minh Pham, Burnet Institute, Australia

P764 - Tip of the iceberg? An unusual syphilis outbreak among young Dutch heterosexuals indicating a larger epidemic
Anne-Marie Niekamp, South Limburg Public Health Service, Netherlands

P765 - A systematic review on alternative treatments for maternal syphilis
Aishwarya Ralich, UCLA David Geffen School of Medicine, USA

P766 - Slings and arrows of syphilis surveillance: The department of defense experience with administrative case finding
Eric Larsen, USUHS, USA

P767 - Getting to the bottom of it: Sexual positioning and syphilis stage at diagnosis among men who have sex with men
Vincent Cornelisse, Melbourne Sexual Health Centre, Australia

P768 - Characteristics of chlamydia/gonorhea infections associated with a subsequent syphilis diagnosis in British Columbia, Canada
Theodora Consolacion, BC Centre for Disease Control, Canada

P769 - Monitoring the evaluation of congenital syphilis cases in the state of Sao Paulo, 2007 to 2017
Carmen Silvia Domingues, STI/AIDS Reference Center - Sao Paulo State Program of STI/AIDS, Brazil

P770 - Quantitation of cytokines in rabbits following tri-antigen vaccine cocktail immunization and T. pallidum challenge
Charmie Godornes, University of Washington, USA

P771 - Treponema pallidum stimulated macrophage-derived exosomal mir-146a-5p decreased monocyte transendothelial migration
Qian-Qiu Wang, Institute of Dermatology, Chinese Academy of Medical Sciences, China

P772 - Risk factors for primary and secondary syphilis among females in Chicago, 2010-2017
Kimberly Stanford, University of Chicago, USA

P773 - An evaluation of the provincial ‘Syphistory’ campaign in British Columbia, Canada
Venessa Ryan, BC Centre For Disease Control, Canada

P774 - Evaluation of the fully automated Bio-Rad Bionex 2200 Syphilis Total & RPR antibody detection assay
Vincent Boissonneault, Canada

P775 - Sensitivity and specificity of the quantitative test for TPPA and RPR for diagnosis of congenital syphilis in neonates
Xiangdong Gong, Institute of Dermatology, Chinese Academy of Medical Sciences, China

P776 - Tip of the iceberg? An unusual syphilis outbreak among young Dutch heterosexuals indicating a larger epidemic
Anne-Marie Niekamp, South Limburg Public Health Service, Netherlands

P777 - Is kissing safe? Detection of Treponema pallidum in oral swabs from patients with syphilis
Lauren Tantalo, University of Washington, USA

P778 - Attenuation of syphilis infection following immunization of rabbits with a trivalent antigen cocktail
Barbara Molinari, University of Washington, USA

P779 - Getting to the bottom of it: Sexual positioning and syphilis stage at diagnosis among men who have sex with men
Vincent Cornelisse, Melbourne Sexual Health Centre, Australia

P780 - Use of a rapid syphilis test for syphilis diagnosis
Minh Pham, Burnet Institute, Australia

P781 - A systematic review on alternative treatments for maternal syphilis
Aishwarya Ralich, UCLA David Geffen School of Medicine, USA

P782 - Jarisch-Herxheimer reaction in central nervous system among neurosyphilis patients: discontinuation of therapy or not?
Rui-Rui Peng, Sexually Transmitted Disease Institute, Shanghai Skin Disease Hospital, China

P783 - Clinical trial of Cefoxime for the Treatment of Early Syphilis - Preliminary results
Chrysosavant Stafylis, UCLA David Geffen School of Medicine, USA

P784 - Gastric syphilis: A case of gastric syphilis developed into neurosyphilis.
Lin Zhu, Shanghai Skin Disease Hospital, China

P785 - Increased detection rates of primary syphilis by PCR in a Provincial Laboratory
Prenilla Naidu, Provincial Laboratory for Public Health, Canada

P786 - Prevalence of bacterial sexually transmitted infections and co-infection with HIV among MSM and TW in Tijuana, Mexico
Claire Bristow, University of California San Diego, USA

P787 - Hepatitis C is not a problem for female transgenders in Goiânia, Central Brazil - preliminary data
Márcia Souza, Universidade Federal de Goias, Brazil

P788 - HIV epidemiology among men who have sex with men and transgender women in Myanmar: Data from community-based surveillance
Vanessa Veronese, CPOP, Australia
**Poster Program**

**P777** - Difference between transvestites and transwomen for HIV prevalence and risk behaviors  
Sheila Teles, Universidade Federal de Goias, Brazil

**P778** - HIV infection in transgender women from a region far from the epicenter of the HIV epidemic in Brazil – preliminary results  
Sheila Teles, Universidade Federal de Goias, Brazil

**P779** - Pre-exposure prophylaxis use among trans and gender diverse people: Characteristics and behaviour from the EPIC-NSW trial  
Benjamin Bavinton, University of New South Wales, Sydney, Australia

**P781** - Patterns of HIV and STI among transgender women in eastern and southern U.S.: Interim baseline findings from the LITE cohort  
Tonia Poteat, University of North Carolina School of Medicine, USA

**P783** - Factors associated with syphilis testing in transgender women in central-west Brazil  
Sheila Teles, Universidade Federal de Goias, Brazil

**P784** - Prevalence of STIs and HIV in transgender women and men. A systematic review  
Olivia Van Gerwen, University of Alabama at Birmingham, USA

Jesse Clark, UCLA Geffen School of Medicine, USA

**P787** - Trichomonas vaginalis positivity rates by HIV status among women in a clinical study  
Stephanie Taylor, Louisiana State University, USA

**P788** - Comparison of vaginal speculum and non-speculum specimens in the diagnosis of Trichomonas vaginalis  
Ibinabo Oboro, University of Port Harcourt teaching Hospital, Nigeria

**P789** - Bacterial vaginosis markers detected by BD MAX™ Vaginal Panel in relation to absence and presence of Trichomonas vaginalis  
Marie-Helene Tremblay, BD Life Sciences, Canada

**P790** - Determining the origins of repeat Trichomonas vaginalis infections using clinical versus genotype-informed criteria  
Patricia Kissinger, Tulane School of Public Health and Tropical Medicine, USA

**P791** - Assessment of urethritis etiology among HIV-infected men attending an STI clinic in LiLongwe, Malawi  
Mitch Matoga, UNC Project Malawi, Malawi

**P793** - Risk factors for incident non-gonococcal urethritis (NGU) in men who have sex with women (MSW) attending an STD clinic  
Emily Rowlinson, University of Washington, USA

**P794** - Signs and symptoms associated with single-pathogen nongonococcal urethritis in men  
Teresa Batteiger, Indiana University School of Medicine, USA

**P795** - Prevalence and Etiology of Post-azithromycin Persistent Nongonococcal Urethritis (NGU) Symptoms in Men  
Stephen Jordan, Indiana University School of Medicine, USA

**P796** - Reassessing the Gram stain smear (GSS) polymorphonuclear leukocyte (PMN) cutoff for diagnosing non-gonococcal urethritis (NGU)  
Gina Leipertz, University of Washington, USA

**P797** - Antibody response to *Mycoplasma genitalium* in longitudinally infected men with non-gonococcal urethritis  
Gwendolyn Wood, University of Washington, USA

**P799** - Accelerated HIV case finding and bridging enrolment gap for key populations in western Nigeria: A break-even in the 90-90-90  
Saheed Usman, APIN Public Health Intiatives, Nigeria

**P800** - Prevalence of curable sexually transmitted infections among refugees: Global systematic review and meta-analysis  
Ghina Mumtaz, American University of Beirut, Lebanon

**P802** - Size of female injecting drug users in 10 Nigerian states and implications for HIV/reproductive health  
Idoteyin Ezirim, National Agency for the Control of AIDS, Nigeria

**P803** - Assessing correct knowledge and positive attitude towards HIV/AIDS transmission homeless women in India  
MITHLESH Chourase, International Institute for Population Sciences, India

**P804** - Behavioral risk factors for sexually transmitted infections and health-seeking behavior of homeless women in Delhi, India  
MITHLESH Chourase, International Institute for Population Sciences, India

**P808** - Correlates of sexually transmitted infections symptoms among male prisoners in Iran, 2013: A nation-wide survey  
Mohammad Karamouzian, BC Centre on Substance Use, Canada

**P809** - Negotiating safer sexual relations with husband and associated STI/HIV vulnerabilities among married women in India  
Deepanjali Vishwakarma, International Institute for Population Sciences, India

**P810** - HIV/STI service coverage among key population in Nigeria - lessons from size estimation study in Abia and Taraba states  
Greg Ashefor, National Agency for the Control of AIDS, Nigeria

**P812** - Leveraging peak days/time at spots to improve key population HIV programs – size estimation study of 10 states in Nigeria  
Greg Ashefor, National Agency for the Control of AIDS, Nigeria

**P813** - Community-based health services delivery among key and priority populations - a case study in Uganda  
Geoffrey Mujisha, Most At-Risk Populations (MARP) Network Limited, Uganda

**P814** - Comprehensive healthcare interventions at Mekelle University STI and ART clinics for key population, northern Ethiopia  
Tesfay Gebrehiwot, Mekelle University, Ethiopia

**P815** - Factors associated with oncogenic human papilloma-virus prevalence among Australian women following vaccine introduction  
Sybil Lianne Bravo, University of the Philippines, Philippines

**P821** - Sexual behavior in adolescents before and after introduction of the HPV vaccination in Canada  
Robine Donken, University of British Columbia, Canada

**P822** - Factors associated with oncogenic human papilloma-virus prevalence among Australian women following vaccine introduction  
Dorothy Machalek, The Royal Women's Hospital, Australia

**P823** - Comparison of Copan UriSpongE™ to Colli-Pee for the collection of urine for HPV detection with molecular assays  
Santina Castriciano, Copan Italia Spa, Canada

**P824** - Accuracy of cervical cancer screening using a self-collected vial for HPV DNA testing among adult women in sub-Saharan Africa  
Ralph Sydney Mboumba Bouassa, Ecole Doctorale d'Infectiologie Tropicale, Gabon
P825 - HPV seroprevalence and seroconversion among HIV-positive men: Cohort study in South Africa
Admire Chikandiwa, Witts RHI, University of the Witwatersrand, South Africa

P826 - High prevalence of cervical HR-HPV in immigrant women originating from Sub-Saharan Africa and living in Orleans, France
Ralph Sydney Mboumba Bouassa, Ecole Doctorale d'Infectiologie Tropicale, Gabon

P827 - A very high prevalence of human papillomavirus in hidden population of swingers: A Dutch case-control study
Fleur Koene, Amsterdam UMC, Netherlands

P828 - Use of hormonal contraceptives and genital human papillomavirus infection: A national multicenter study
Marina Bessel, Hospital Moinhos de Vento, Brazil

P829 - Human papillomavirus types distribution in head and neck: A meta-analysis from infection to cancer
Yong Lu, School of Public Health, Sun Yat-sen University, Guangzhou, PR China, China

P830 - Feasibility of an online HPV self-collection screening program in Canada: digital health literacy in South Asian women
Sandy Zhang, Canada

P831 - Characteristics associated with HPV-related external genital lesions among young adults in Brazil
Marina Bessel, Hospital Moinhos de Vento, Brazil

P832 - Effectiveness of the quadrivalent HPV vaccine against HSIL and CIN: A data-linkage study
Robine Donken, University of British Columbia, Canada

P833 - HSV-2 serostatus and HPV incidence, persistence, and precancerous lesions in a cohort of HPV-vaccinated women living with HIV
Elisabeth McClymont, University of British Columbia, Canada

P834 - Epidemiology of human papillomavirus among women in Guangdong, China 2009-2017
Ganfeng Luo, Sun Yat-sen University, China

P835 - Quantitative oral HPV16 and HPV18 detection in patients attending dental clinics
Helen Stankiewicz Karita, University of Washington, USA

P836 - Trends in anogenital warts since introduction of human papillomavirus vaccines in Connecticut, USA
Linda Niccolai, Yale School of Public Health, USA

P837 - HPV16 / 18 vaccine: influence on the systemic and local TH1 / TH2 cytokine profile
Rose Luce Do Amaral, UNICAMP, Brazil

P838 - Associations of the vaginal microbiota with HPV infection and cervical dysplasia in South African women living with HIV
Janneke Van De Wijgert, University Medical Center Utrecht, Netherlands

P839 - A chemically modified β-lactoglobulin (JB01) is effective in treating HPV infection and preventing sexual transmission of HPV
Shibo Jiang, Fudan University, China

P840 - The HPV Screening and Vaccine Evaluation (HPV-SAVE) Study in men living with HIV: early pathologic and acceptability outcomes
Troy Grennan, BC Centre for Disease Control, Canada

P841 - Barriers to HPV vaccination among gay, bisexual, and other men who have sex with men (gbMSM) in Canada: A CIRN study
Ramandip Grewal, St. Michael's Hospital, Canada

P842 - Healthcare engagement and HPV vaccination among gay, bisexual, and other men who have sex with men (gbMSM): A CIRN study
Ramandip Grewal, St. Michael's Hospital, Canada

P843 - The transmission of HPV in the sexual networks of swingers, a multilevel network approach
Anne-Marie Niekamp, South Limburg Public Health Service, Netherlands

P844 - The burden of HPV and HSV-related anogenital diseases in a Southeastern US urban HIV clinic
Yuanfan Ye, University of Alabama at Birmingham, USA

P846 - Biomarkers of HIV exposure and condomless receptive anal sex in men who have sex with men using self-collected rectal swabs
Maria Lemos, Fred Hutchinson Cancer Research Center, USA

P848 - Revisiting enfuvirtide's mechanism and designing its analog with improved activity by targeting triple sites in gp41
Shibo Jiang, Fudan University, China

P850 - Gender identify and self-reported HPV vaccination among youth living with or at high-risk for HIV
Elizabeth Arnold, UT Southwestern Medical Center, USA

P851 - Performance disk diffusion method in identifying gonococcal resistance
Wenqi Xu, National Center for STD Control, Chinese Center for Disease Control and Prevention,Chinese Academy of Medical Sciences & Peking Union Medical College, China

P852 - Evaluation of PLEXPCR VHS For diagnosis of genital lesions
Litty Tan, SpeeDx Pty Ltd., Australia

P853 - Human factors engineering to drive the development of a next generation Colli-Pee home-based first-void urine collection
Vanessa Vankerckhoven, Novosanis N.V., Belgium

P854 - Interspecies chimeras: A tool to identify chlamydial virulence factors
Mark Fernandez, University Of Washington, USA

P855 - Multi-peptide ELISAs overcome cross-reactivity and inadequate sensitivity of Chlamydia trachomatis and C. pneumoniae serology
Bernhard Kaltenboeck, Auburn University, USA

P856 - Privacy and technology for young black men who have sex with men in the Southern US related to sexual care and research
Christina Muzny, University of Alabama at Birmingham, USA

P857 - Penile microbiome and urinary cytokines of Kenyan men who have sex with men and men who have sex with women
Supriya Mehta, University Of Illinois at Chicago, USA

P858 - 2018/2019 Surveillance update on Neisseria gonorrhoeae isolates
Meshack Omolo, University of Nairobi, Kenya

P859 - Genotyping gyrA and penA from remnant Neisseria gonorrhoeae positive Cepheid Xpert® clinical specimens
Sakina Qadir, University of California Los Angeles, USA

P861 - Novel mutation conferring high-level azithromycin resistance in Neisseria gonorrhoeae
Cau Pham, US Centers for Disease Control and Prevention, USA

P862 - Female sex workers and their attitude towards oral pre-exposure prophylaxis
Tinashe Mudzviti, University of Zimbabwe, Zimbabwe

P863 - Transgender women in Lebanon: A qualitative study to understand HIV/STIs risk
Ismael Maatouk, Clemenceau Medical Center, Lebanon
All Industry-Supported Symposia will be held at the Vancouver Convention Centre, East Building from Monday, July 15 to Wednesday, July 17.

**Monday, July 15**

**BD**

**Maintaining Vaginal Health: Complexities in Diagnosis and Management**

*Breakfast Symposium Supported by BD Diagnostic Systems*

- Diagnostics for Women with Discharge: Including Both Vaginal and Cervical Causes - **Barbara Van Der Pol**
- Clinical Management of Vaginal Syndromes - **Jeanne Marrazzo**

Open to all registered delegates
Breakfast will be served

---

**Roche**

**Mycoplasma genitalium and the Evolution of Clinical Practice: What Matters for the Clinician and Laboratorian**

*Lunch Symposium Supported by Roche*

- Understanding *Mycoplasma genitalium*: Epidemiology and Clinical Significance - **William M. Geisler**
- Clinical Performance of the Cobas TV/MG Assay for the Detection of *Mycoplasma genitalium* - **Barbara Van Der Pol**

Open to all registered delegates
Lunch will be served (first-come, first-served)

---

**Abbott**

**Achieving Precision Diagnostics for Sexually Transmitted Infections to Improve Public Health**

*Evening Symposium Supported by Abbott Molecular*

- Insights to Improve Operational Efficiencies in Molecular Testing for STIs - **Dr. Kevin Nelson**
- Innovative Approaches in STI testing and Precision Diagnostics - **Dr. Ajith Jospeh**

Appetizers and beverages will be served (first-come, first-served)

---

**Tuesday, July 16**

**Cepheid**

**Point of Care Molecular Testing and Improved Patient Outcomes**

*Breakfast Symposium Supported by Cepheid*

- Extragenital Testing for Chlamydial and Gonorrheal Disease: Study Review – **Claire C. Bristow**
- Improved Patient Care with STI Screening – **Pierre-Cédric B. Crouch**

Open to all registered delegates
Breakfast will be served (first-come, first-served)
Aptima Mycoplasma genitalium Evaluation Study
Breakfast Symposium Supported by Hologic

- Mycoplasma genitalium: History of the Discovery, Detection and Treatment of a Sexually Transmitted Pathogen – Charlotte A. Gaydos
- Mycoplasma genitalium Testing in the US: Results from a Prospective, Multi-Center Clinical study – Damon Getman

Open to all registered delegates
Breakfast will be served (first-come, first-served)

Aptima Vaginosis and Vaginitis Evaluation Study
Lunch Symposium Supported by Hologic

- Vaginitis and Vaginosis: Challenges in Diagnosis and Treatment – Jane R. Schwebke
- Clinical Performance of the Aptima BV and Aptima CV/TV Assays for Vaginitis and Vaginosis – Craig Clark

Open to all registered delegates
Lunch will be served (first-come, first-served)

We are a better way.

Life is full of questions. Consolidated molecular diagnostic testing on Cepheid’s GeneXpert® System delivers better answers. We are advancing healthcare with accurate, fast results whenever and wherever they are needed.

Please join us for a Cepheid Breakfast Symposium Point of Care Molecular Testing and Improved Patient Outcomes
Tuesday, 16 July 2019 from 07:00 to 8:00
Meeting Room 2+3

Come visit us at the Cepheid at Booth #203
## Board and Side Meetings

### Saturday, July 13

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 12:30</td>
<td>ISSTDR Board Meeting</td>
<td>(By Invitation Only)</td>
<td>MR 1</td>
</tr>
<tr>
<td>12:30 – 13:00</td>
<td>ISSTDR Board Member-IUSTI Executive Committee Lunch</td>
<td>(By Invitation Only)</td>
<td>Meeting Level South Foyer</td>
</tr>
<tr>
<td>13:00 – 18:00</td>
<td>IUSTI Executive Committee Meeting</td>
<td>(By Invitation Only)</td>
<td>MR 1</td>
</tr>
</tbody>
</table>

### Sunday, July 14

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 – 13:00</td>
<td>UCLA &amp; WHO Lunch</td>
<td>(By Invitation Only)</td>
<td>MR 20</td>
</tr>
<tr>
<td>16:00 - 17:00</td>
<td>STD Journal Assoc. Editors Meeting</td>
<td>(By Invitation Only)</td>
<td>MR 20</td>
</tr>
</tbody>
</table>

### Monday, July 15

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 - 08:00</td>
<td>ASTDA Young Investigator Mentor/Mentee Breakfast</td>
<td>Session: Meet the Editor!</td>
<td>MR 11+12</td>
</tr>
<tr>
<td></td>
<td>Supported by: <a href="https://www.msfglobal.org">Michael Smith Foundation</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 – 13:30</td>
<td>STI &amp; HIV World Congress 2021 - ISC/LSC Meeting</td>
<td>(By Invitation Only)</td>
<td>MR 13</td>
</tr>
<tr>
<td>12:30 - 14:00</td>
<td>NIH Meeting</td>
<td>(By Invitation Only)</td>
<td>MR 9</td>
</tr>
<tr>
<td>12:45 – 13:45</td>
<td>IUSTI General Assembly</td>
<td>(Members Only)</td>
<td>MR 1</td>
</tr>
<tr>
<td>18:15 – 19:15</td>
<td>IUSTI-Canada AGM</td>
<td>(Members Only)</td>
<td>MR 1</td>
</tr>
</tbody>
</table>

### Tuesday, July 16

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:00</td>
<td>Sexually Transmitted Infections Editorial Meeting</td>
<td>(By Invitation Only)</td>
<td>MR 13</td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td>ASTDA Young Investigator Mentor/Mentee Breakfast</td>
<td>Session: Meet the NIH!</td>
<td>MR 11+12</td>
</tr>
</tbody>
</table>
09:30 – 16:00  
Meetings – Government of Canada *(By Invitation Only)*  
*Location: MR 19*

Supported by:

12:15 – 13:45  
ASTDA Awards Luncheon  
*Location: Ballroom C (West Building)*

Supported by:

17:30 – 19:00  
Trade Commissioner Service Networking Reception *(By Invitation Only)*  
*Location: MR 19 + 20*

Supported by:

17:45 - 18:45  
2020 Bangkok Scientific Committee Meeting  
*Location: IUSTI Office - MR 4*

**Wednesday, July 13**

07:00 - 08:00  
ASTDA Young Investigator Mentor/Mentee Breakfast  
Session: Sexual Harassment in Sexual Health Professions: Breaking Silence and Making Solutions  
*Location: MR 11+12*

10:15 - 10:45  
Canadian Institutes of Health Research HIV/AIDS and STBBI Strategic Plan Consultation Session  
*Location: MR 19*

Supported by:

12:30 – 13:30  
*Mycoplasma genitalium* Global Surveillance Meeting *(By Invitation Only)*  
*Location: MR 9*

18:00 – 20:00  
2nd IUSTI Executive Meeting *(By Invitation Only)*  
*Location: MR 1*

18:00 – 20:30  
4th Annual Public Health Applications of *C. trachomatis* Serology (PHACTS) Meeting  
*Location: MR 13*
Saturday, July 13
19:30 – 22:00  Presidents’ Dinner (By Invitation Only)
Location: The Teahouse, Stanley Park

Sunday, July 14
19:30 – 21:00  Welcome Reception
Location: Exhibit Hall A

Monday, July 15
17:45 – 19:00  Poster Viewing
Location: Exhibit Hall A

19:30 – 22:00  Speakers’ Dinner (By Invitation Only)
Location: The Vancouver Club

Tuesday, July 16
17:45 – 19:00  Poster Viewing
Location: Exhibit Hall A

19:30 – 22:00  Congress Dinner (Ticketed Event)
Location: Ballroom C + D (West Building)
GENERAL INFORMATION

ABSTRACTS
Abstracts selected for the STI & HIV 2019 World Congress are presented in Oral and Poster Sessions. All abstracts approved for presentation will be published online in the journal of Sexually Transmitted Infections on July 14, 2019.

ATTIRE
Business casual is appropriate. Room temperature can vary in session rooms. We encourage attendees to dress in layers for their personal comfort.

BADGES
Your personalized badge is your admission card to the Congress. For organizational and security reasons, badges must be worn at the congress venue at all times.

CELL PHONES
As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.

CERTIFICATE OF ATTENDANCE
Congress attendees can request a ‘Certificate of Attendance’ by completing the Congress Evaluation Form available on the Congress website on the last day of the Congress. After completing the evaluation form you will be able to download your Certificate of Attendance.

CME ACCREDITATION AND CME CERTIFICATE
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of VCU Health Continuing Medical Education and International Conference Services, Ltd. VCU Health Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

VCU Health Continuing Medical Education designates this live activity for a maximum of 23 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Congress attendees can request a ‘CME Certificate’ by completing the Congress Evaluation Form available on the Congress website on the last day of the Congress. After completing the evaluation form you will be able to download your CME Certificate.

EMERGENCY SERVICES AND FIRST AID EMERGENCY NUMBER
In the event of a health, safety, or criminal emergency, dial 7500 from any of the house phones or +1 604 647 7500 from your mobile phone. The First Aid Office is located in the East Lobby next to the washrooms. Kindly note that the First Aid office is not staffed. For access please call the above-mentioned emergency numbers.

EVALUATION SURVEY
A Congress Evaluation Survey will be e-mailed to all delegates after the Congress. Please help us to improve the Congress by completing your Survey.

EXHIBITION
The exhibits are an integral part of the experience at the STI & HIV 2019 World Congress and will feature the latest in technology and research. The exhibits are located in East Exhibit Hall A, Street/Convention Level at the Vancouver Convention Centre, East Building.
GENERAL INFORMATION

EXHIBITION SHOW HOURS
Sunday, July 14 ..........  19:30 – 21:00 (Welcome Reception)
Monday, July 15 ..........  10:15 – 19:00
Tuesday, July 16 ......... 10:15 – 19:00
Wednesday, July 17 ...  10:15 – 15:45

JOIN THE CONVERSATION – STI & HIV 2019 WORLD CONGRESS OFFICIAL SOCIAL MEDIA ACCOUNTS
Share your experience and images from the STI & HIV 2019 World Congress with colleagues and friends via Facebook and Twitter. Follow our official social media feeds throughout the Congress: @ISSTDRIUSTI2019. We encourage you to tag your posts with #ISSTDRI2019 and #IUSTIWorld2019.

www.facebook.com/ISSTDRIUSTI2019
www.twitter.com/ISSTDRIUSTI2019

LOST AND FOUND
Lost and Found items should be returned/claimed at the Registration Desk.

LUNCHES
There are many food options available in and around the convention centre. The Coal Harbour Café is located on the street level next to the registration area in the East Building. There is a food court located at the Waterfront Centre across the street from the Vancouver Convention Centre, with a variety of options to suit all tastes.

NETWORKING BREAKS
Breaks will take place in the following locations and at the following times. Refreshments will be provided.

Monday, July 15
10:15 – 10:45
15:30 - 16:15
Exhibit Hall A, Street/Convention Level

Tuesday, July 16
10:15 – 10:45
15:30 - 16:15
Exhibit Hall A, Street/Convention Level

Wednesday, July 17
10:15 – 10:45
15:15 - 15:45
Exhibit Hall A, Street/Convention Level

MOBILE APP
Supported by:

Download the free STI & HIV 2019 World Congress mobile app for a convenient way to stay up-to-date via your phone or tablet. View the full scientific schedule, abstracts, exhibit information including floor plan, exhibitor bio, and general Conference and venue information on our easy to use app! The app is compatible with all iOS devices (iPhone,
iTouch and iPad) and all Android mobile devices. Timely updates on program or room changes will be distributed through the mobile app via notification alerts. You must enable notifications on your device to receive these alerts.

Search “STI HIV” in the App Store (for Apple) or Google Play Store (for Android).

PARKING
Parking is available in the Vancouver Convention Centre West and East Building.

Vancouver Convention Centre East
999 Canada Place

WestPark
• Enter at the foot of Howe Street, obtain ticket from dispenser and proceed to P1 or P2.
• Use Convention Centre/Hotel elevators (not World Trade Centre elevators).
• For Convention Level: press “G” for Registration, Ballrooms and Exhibits.
• For Meeting Rooms: press “M”.

POSTER VIEWING
East Exhibit Hall A, Street/Convention Level

All posters have been split into two groups: Monday and Tuesday. A different set of posters will be displayed on these days so be sure to visit the Exhibit & Poster Hall. Posters will be on display for the entire day, but presenters will be standing by their poster during the poster viewing sessions.

OFFICIAL POSTER VIEWING SESSIONS
Monday, July 15 .......... 17:45 – 19:00
Tuesday, July 16 .......... 17:45 – 19:00

POSTER VIEWING IN THE EXHIBIT HALL DURING COFFEE BREAKS
10:15 – 10:45
15:30 – 16:15

PUBLIC TRANSPORTATION
Vancouver is a walkable city and all Congress hotels are within a maximum of 20-minute walking distance.

REGISTRATION COUNTER HOURS
Located in the lobby of the Vancouver Convention Centre East Building, Street/Convention Level.

Saturday, July 13.............. 15:00 – 19:00
Sunday, July 14............... 07:30 – 20:00
Monday, July 15.............. 06:30 – 16:00
Tuesday, July 16............. 06:30 – 16:00
Wednesday, July 17......... 06:30 – 15:00

SMOKING
It is against the law to smoke in any indoor public place or worksite, including pubs, bars, restaurants, and shopping centres. Designated smoking rooms are non-existent, and public transit, transit shelters, taxis and work vehicles are also smoke-free.

In addition, there is a 3-metre non-smoking “buffer zone” around public and work place doorways, opening windows and air intakes including apartments and condominiums.
SPEAKER READY ROOM

MR 10 in the East Building (on Meeting Room Level) is the designated Speaker Ready Room. Only digital material will be allowed for oral presentation (PowerPoint files).

- All oral presenters are requested to check-in at the Speaker Ready Room a minimum of 24 hours prior to your scheduled presentation, to review and upload your PowerPoint presentation.
- Once you have uploaded your PowerPoint, you may still make changes to it up to 4 hours before your presentation.
- If for any reason you are unable to meet this schedule, please inform the STI & HIV 2019 World Congress Secretariat at STIHIV2019-Speakers@icsevents.com before the Congress.
- PowerPoint presentations cannot be uploaded in the session rooms.
- Computers will be available for you in the Speaker Ready Room for your final check.
- Once the presentation has been checked, the technical staff will be responsible for its delivery to the session rooms in preparation for your presentation.

Hours of Operation:
Saturday, July 13 .................. 15:00 – 19:00
Sunday, July 14 ................... 07:00 – 18:30
Monday, July 15 ................... 06:30 – 16:30
Tuesday, July 16 ................... 06:30 – 16:30
Wednesday, July 17 ............. 06:30 – 16:00

STAFF AND VOLUNTEERS

Supported by: Abbott

Volunteers are working throughout the Convention Centre and are happy to assist with any questions delegates may have regarding the Congress or the Convention Centre. Delegates can easily locate volunteers by their volunteer shirts.

WIRELESS INTERNET

The Congress is happy to provide delegates with complimentary Wi-Fi.

Network: STI & HIV 2019 World Congress
Password: STIHIV2019

DISCLAIMER

The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.
Vancouver Convention Centre, East Building Street / Convention Level

• Lobby
• Ballroom
• Exhibit Hall A

Vancouver Convention Centre, East Building Meeting Level / Level 1

• MR 1
• MR 2+3
• MR 8+15
• MR 9
• MR 10
• MR 11+12
• MR 13
• MR 14
• MR 19
• MR 20
STI & HIV 2019 WORLD CONGRESS
JULY 14 - 17, 2019
VANCOUVER CONVENTION CENTRE - EAST
HALL A

**Exhibitor Listing**

### Organization (Alphabetical)

<table>
<thead>
<tr>
<th>Organization</th>
<th>Booth #</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Molecular</td>
<td>404</td>
<td>Mayer Labs</td>
</tr>
<tr>
<td>BD Diagnostic Systems</td>
<td>105</td>
<td>Novosanis</td>
</tr>
<tr>
<td>bioLytical Laboratories Inc.</td>
<td>104</td>
<td>Pauktuutit Inuit Women Of Canada</td>
</tr>
<tr>
<td>Center for Disease Detection</td>
<td>408</td>
<td>Roche</td>
</tr>
<tr>
<td>Cepheid</td>
<td>203</td>
<td>SD Biosensor</td>
</tr>
<tr>
<td>Cembio Diagnostic Systems, Inc.</td>
<td>505</td>
<td>Seegene Inc.</td>
</tr>
<tr>
<td>Clinical Prevention Services - BC Centre For Disease Control</td>
<td>409</td>
<td>Shield Diagnostics</td>
</tr>
<tr>
<td>Copan</td>
<td>401</td>
<td>SpeeDx</td>
</tr>
<tr>
<td>EUROMMUN AG, a PerkinElmer Company</td>
<td>403</td>
<td>STEMCELL Technologies</td>
</tr>
<tr>
<td>GIANTmicrobes</td>
<td>412</td>
<td>Stichting World STI &amp; HIV</td>
</tr>
<tr>
<td>Hologic</td>
<td>300</td>
<td>Congress 2021</td>
</tr>
<tr>
<td>ImmunoPrecise Antibodies</td>
<td>504</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>IUSTI-Europe</td>
<td>100</td>
<td>Youth against AIDS</td>
</tr>
</tbody>
</table>

### Organization (Numerical)

<table>
<thead>
<tr>
<th>Organization</th>
<th>Booth #</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IUSTI-Europe</td>
<td>100</td>
<td>Novosanis</td>
</tr>
<tr>
<td>bioLytical Laboratories Inc.</td>
<td>104</td>
<td>Stichting World STI &amp; HIV</td>
</tr>
<tr>
<td>BD Diagnostic Systems</td>
<td>105</td>
<td>Congress 2021</td>
</tr>
<tr>
<td>SpeeDx</td>
<td>200</td>
<td>Center for Disease Detection</td>
</tr>
<tr>
<td>Spot On Sciences</td>
<td>201</td>
<td>Clinical Prevention Services - BC Centre For</td>
</tr>
<tr>
<td>STEMCELL Technologies</td>
<td>202</td>
<td>Disease Control</td>
</tr>
<tr>
<td>Cepheid</td>
<td>203</td>
<td>Shield Diagnostics</td>
</tr>
<tr>
<td>SD Biosensor</td>
<td>204</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>Roche</td>
<td>206</td>
<td>GIANTmicrobes</td>
</tr>
<tr>
<td>Hologic</td>
<td>300</td>
<td>ImmunoPrecise Antibodies</td>
</tr>
<tr>
<td>Seegene Inc.</td>
<td>400</td>
<td>Cembio Diagnostic Systems, Inc.</td>
</tr>
<tr>
<td>Copan</td>
<td>401</td>
<td>Mayer Labs</td>
</tr>
<tr>
<td>EUROMMUN AG, a PerkinElmer Company</td>
<td>403</td>
<td>Pauktuutit Inuit Women Of Canada</td>
</tr>
<tr>
<td>Abbott Molecular</td>
<td>404</td>
<td>Youth against AIDS</td>
</tr>
</tbody>
</table>
Insight to work smarter, not harder

simplicity / flexibility / efficiency

When you know where you’re going, you get there faster.
Transform your lab with the simplicity, flexibility and efficiency of the Molecular Work Area from Roche… proven performance with a clear path for sustainable sexual health testing now and for the future.

Come and learn more about Molecular Work Area and the broad menu it delivers at Booth 206

COBAS is a trademark of Roche.
©2019 Roche
Roche Molecular Diagnostics, Pleasanton, CA 94588 USA molecularworkarea.com MC--01379
**Exhibitor Biographies**

**Abbott Molecular | Booth #404**
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries. (abbott.com)

**BD Diagnostic Systems | Booth #105**
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. (bd.com)

**bioLytical Laboratories Inc. | Booth #104**
bioLytical Laboratories based in Richmond, BC, is a privately-owned Canadian company focused on the research, development, and commercialization of rapid, point-of-care in-vitro medical diagnostics using its proprietary INSTI® technology platform. The INSTI product line provides highly accurate test results in 60 seconds or less with over 99% accuracy. (insti.com)

**Center for Disease Detection | Booth #408**
Center for Disease Detection (CDD) is one of the nation’s leading laboratories, providing testing to customers in all 50 states as well as internationally. Founded in 1990, CDD services federal, state and local government agencies, STD clinics, and organizations dedicated to sexual health. (cddmedical.com)

**Cepheid | Booth #203**
Cepheid is a leading on-demand molecular diagnostics company that is dedicated to improving healthcare by developing fully-integrated systems and accurate yet easy-to-use molecular tests. The company is focusing on applications where rapid and actionable test results are needed most, in fields such as critical and healthcare-associated infections, sexual health, genetic diseases, virology and cancer. (cepheid.com)

**Chembio Diagnostic Systems, Inc. | Booth #505**
Chembio Diagnostic Systems, Inc. is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP® technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in 15-20 minutes. The novel DPP® technology offers broad market applications beyond infectious disease. (chembio.com)
Clinical Prevention Services – BC Centre For Disease Control | Booth #409
Clinical Prevention Services at the BC Centre for Disease Control (BCCDC) provides low-barrier, culturally safe services for diverse communities around the prevention, testing, diagnosis and treatment of STIs and HIV. STI and HIV services offered at the BCCDC include integrated care, provincial STI clinics, community sexual health services, and prevention interventions. (bccdc.ca)

Copan | Booth #401
With a rightful reputation for innovation, COPAN is the world leading manufacturer of collection and transport systems. In like manner, COPAN’s collaborative approach to pre-analytics has resulted in the development of FLOQSwabs®, ESwab®, UTM® and modular laboratory automation, WASP® and WASPLab®. (copangroup.com)

EUROIMMUN AG a PerkinElmer Company | Booth #403
EUROIMMUN is an international provider of medical laboratory products with a growing molecular genetic diagnostics portfolio. The company’s EUROArray platform provides multiplex detection of sexually transmitted pathogens, HPV or dermatophytes. Real-time PCR tests for Zika virus and HSV-1/2 and microarrays for genetic risk determination in many different diseases complete the portfolio. (euroimmun.com)

GIANTmicrobes | Booth #412
GIANTmicrobes are educational products based on health and biology. Our adorable Herpes, Syphilis, HIV, Chlamydia, Gonorrhea, HPV and other STDs are used globally by public health agencies, medical organizations, healthcare professionals and educators as an engaging and memorable way to get people talking about infectious diseases and important health topics. (giantmicrobes.com)

Hologic | Booth #300
A global champion of women’s health, Hologic is an innovative medical technology company that enables healthier lives everywhere, every day through The Science of Sure: Clinical superiority that delivers life-changing diagnostic, detection, surgical and medical aesthetic products rooted in science and driven by technology. (hologic.com)
**Exhibitor Biographies**

**ImmunoPrecise Antibodies | Booth #504**
ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody solutions; delivering the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials. Our comprehensive collection of discovery platforms include transgenic animals, B-cell selection, phage display, and hybridoma development. Our extensive experience with multiple transgenic platforms provides clients access to reliable and effective therapeutic human antibody selection, available through all ImmunoPrecise’s discovery platforms. (immunoprecise.com)

**IUSTI-Europe | Booth # 100**
The 33rd IUSTI-Europe Congress on Sexually Transmitted Infections will be held September 05 – 07, 2019 in Tallinn, Estonia. The meeting will take place in the historic venue of the Estonian National Opera in the heart of the medieval city. IUSTI-Europe 2019 Congress has been granted 11 European CME credits (ECMEC®s). (iusti2019.eu)

**Mayer Labs | Booth #507**
Featuring Kimono Condoms, Aqua Lube, and Today Contraceptive Sponge, institutional and retail accounts rely on Mayer Labs to produce the finest reproductive healthcare. ISO 13485 and MDSAP certified, and US FDA and Health Canada registered, Mayer Labs’ global sourcing, draws upon the finest manufacturing partnerships in Japan, India, Thailand, Korea, New York, and California to deliver the best in quality and user satisfaction. (mayerlabs.com)

**Novosanis | Booth #406**
Novosanis is a subsidiary of OraSure Technologies Inc (NASDAQ: OSUR) and an innovative developer and producer of medical devices. Our flagship device platform, Colli-Pee, is suited for volumetric and standardized collection of first-void urine improving the quality of diagnostics tests for infectious diseases and oncology. (novosanis.com)

**Pauktuutit Inuit Women Of Canada | Booth #508**
Pauktuutit is the national representative organization of Inuit women in Canada. We foster greater awareness of the needs of Inuit women, advocate for equality and social improvements, and encourage Inuit women’s participation in the community, regional and national life of Canada. (https://www.pauktuutit.ca/)
Roche | Booth #206
As the world leader in in-vitro diagnostics, Roche offers a broad portfolio of instruments and assays for the screening, diagnosis and prevention of infectious diseases. With an ongoing focus on patient needs and the depth and breadth of our comprehensive portfolio, Roche is your partner for improving patient outcome by offering a wide range of solutions to Microbiologists, Clinical Researchers and Infection Preventionists. Visit our booth for the latest molecular, PCR-based assays and proven immunochemistry innovations. (diagnostics.roche.com)

SD Biosensor | Booth #204
SD Biosensor is an IVD manufacturer based in Korea. It offers a large range of portfolio such as rapid diagnostic, glucometer, ELISA test, immunochromatography and fluorescence analyzer etc. Currently SD Biosensor is developing new POC MDx platform which makes SD Biosensor a total diagnostic provider from screening to confirmatory test. (sdbiosensor.com)

Seegene Inc. | Booth #400
Seegene is the world’s leading developer of multiplex molecular technologies and diagnostic products. Seegene’s innovative proprietary technologies enable the simultaneous detection, differentiation and quantification of multiple targets with high sensitivity, specificity and reproducibility and perform on unique streamlined automation solution. Seegene’s products, in particularly for sexually transmitted infections, provide accurate and comprehensive information on infected STI, BV and HPV pathogens. (seegene.com)

Shield Diagnostics | Booth #410
Shield Diagnostics’ mission is to provide clinicians with the ability to apply precision medicine to the most pressing bacterial infections. Our first rapid molecular test, Target-NG, evaluates Gonorrhea infections for antibiotic susceptibility to ciprofloxacin, as a rapid reflex to Gonorrhea & Chlamydia testing in our CLIA laboratory in San Jose, CA. (shielddx.com)

SpeeDx | Booth #200
SpeeDx specializes in innovative multiplex real-time polymerase chain reaction (qPCR) solutions for clinical diagnostics. SpeeDx has a portfolio of CE-IVD multiplex qPCR kits for detection of infectious disease pathogens and antimicrobial resistance markers. Resistance-guided therapy improves patient outcomes by empowering practitioners to make informed clinical decisions. (plexpcr.com)
Spot On Sciences | Booth # 201
Spot On Sciences develops and markets innovative devices that revolutionize collection and storage of biological fluids for medical research. HemaSpot™ devices enable collection of blood samples offering solutions for multiple markets including clinical research, biobanking, military field medicine and population studies. The company was founded to ultimately improve access to medical testing for home-bound, rural and economically disadvantaged patients by allowing easy sample collection and shipment. (spotonsciences.com)

STEMCELL Technologies | Booth #202
STEMCELL Technologies provides cell isolation products for studying HIV and other infectious diseases. Our cell separation technologies, EasySep™, RosetteSep™ and SepMate™ facilitate rapid human blood processing. SepMate™ registered as an IVD device, isolates PBMC in just 15 minutes. RoboSep™ fully automates EasySep™ cell isolation, minimizing sample handling and eliminating cross-contamination. (stemcell.com)

Stichting World STI & HIV Congress 2021 | Booth #407
Herewith we would like to welcome you to the 24th STI & HIV World Congress 2021, to be held from 18 until 21 July 2021 in Amsterdam, The Netherlands. The organisers have chosen “Sexual diversity and the city” as the conference theme, and they aim to address diversity, health and sexuality in the urban context. Amsterdam is a very popular destination and very easy to travel to. #sexualdiversityandthecity (stihiv2021.org)

World Health Organization | Booth #411
WHO has a vision for the attainment of the highest possible standard of sexual and reproductive health for all people. It strives for a world where all people’s rights to enjoy sexual and reproductive health and gender equality are promoted and protected, and all people, including adolescents and other underserved and marginalized populations, have access to comprehensive sexual and reproductive health information and services. (who.int/reproductivehealth)

Youth against AIDS | Booth #509
In a world impacted by major technological and social disruptions “Youth against AIDS” goes new ways to face the HIV & STI epidemic among young generations. “Youth against AIDS” is convinced that great innovations are necessary to meet the needs of the young target group, and to become a close partner in young peoples lives. “Youth against AIDS” builds networks to create innovation in prevention and to create a major change in young peoples individual health management. (youth-against-aids.org)
“Over 60% of the current world population live in urbanised settings, places where a large portion of the STI epidemic is also focussed. At the same time, urban environments offer networks, infrastructures, multidisciplinarity and creativity from which solutions can emerge. Cities can act as giant outdoor labs, experimental sites, research incubators and ideal environments for the implementation of interventions.”

Henry de Vries, Congress President

We would like to welcome you to:

24th STI & HIV 2021 World Congress
July 18 - 21

RAI Congress Centre
Amsterdam, The Netherlands

www.stihiv2021.org
IF YOU THINK IT’S CHLAMYDIA.

AND IT ACTS LIKE CHLAMYDIA.

IT MIGHT BE MYCOPLASMA GENITALIUM.

Many healthcare providers are unfamiliar with Mycoplasma genitalium—that’s why awareness is so important.

Visit HologicEd.com for diagnosis and treatment strategies.

References: